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Abstract 
The mammalian target of rapamycin (mTOR) regulates cell growth and proliferation 
in response to nutrients and growth factors. The role of mTOR in the biology of 
embryonic stem cells has not been extensively characterised.  
The principle aim of this research was to assess the feasibility of manipulating the 
mTOR pathway to provide bioprocessing improvements for the expansion and 
differentiation of embryonic stem cells. 
In order to achieve this aim, the cellular distribution and localisation of mTOR 
pathway phosphoproteins was assessed and the effect of pathway inhibition on ES 
cell proliferation and viability was characterised. 
The key findings of this study revealed that in mouse ES cells, mTOR pathway 
proteins were phosphorylated during mitosis. Secondly, inhibition of mTOR in 
growth factor-stimulated pluripotent stem cells impaired proliferation but not 
viability. Upon withdrawal of growth factors, cells lost their compact shape and 
exhibited a spread morphology. Under these conditions mTOR inhibition reduced 
the viability and proliferation of ‘compact’ cells but not ‘spread’ cells. 
Thus, during the expansion of ES cells the mTOR pathway may be stimulated. 
During early differentiation, inhibition of the pathway may improve the purity of the 
final cell preparation and reduce the prevalence of parent stem cells. 
In conclusion, the experimental findings discussed here show that temporal 
manipulation of the mTOR pathway in embryonic stem cells may provide 
bioprocessing advantages resulting in an increased yield of parent cell populations 
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during expansion and increased purity of differentiated cells. The sensitivity of the 
mTOR pathway to the bioavailability of nutrients may offer a cost-effective route to 
optimising cell production in an industrial scale process. 
Further work to elucidate the role of the mTOR complex 2 in ES cell proliferation 
may provide an additional level of control to independently modulate cell 
proliferation and growth during expansion and differentiation. 
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Chapter 1 
1.1  Aims of research. 
The principle aim of this research was to assess the feasibility of manipulating the 
mTOR intracellular signalling pathway to provide a bioprocess advantage in the 
expansion and differentiation of embryonic stem cells.  
1.2 Thesis structure. 
Chapter 1 provides background information pertinent to the study. This includes a 
historical perspective and the current understanding of the molecular mechanisms 
regulating embryonic stem cell biology, with a focus on the mouse embryonic stem 
cell self-renewal. The mammalian TOR signalling pathway is described in the 
context of molecular regulation, its role in development and pertinent pathway 
interactions. Finally, the current understanding of the impact of mTOR signalling on 
embryonic stem cell biology is reviewed.  
Chapter 2 provides details of the methodology utilised for experimental studies 
Proceeding chapters incorporate the analysis of experimental data and conclude with 
a summary of findings. Chapter 3 includes preliminary experimental findings 
relating to pluripotent cell culture conditions and biology. Chapter 4 details a 
microscopic investigation into distribution and localisation of mTOR 
phosphoproteins in mouse ES cells.  
Chapter 5 documents experimental findings relating to the assessment of mES cell 
viability and expansion under different in vitro growth conditions. 
23 
 
Chapter 6 incorporates a detailed discussion of research findings within a wider 
context of the current understanding of mTOR biology. This is followed by a 
conclusion and description of future studies. References are provided in Chapter 7, 
and the appendices in Chapter 8 include a methodological approach to develop and 
characterise image analysis techniques to assess stem cell expansion and morphology 
from phase contrast micrographs.  
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1.3   Introduction  
Embryonic stem cells (ES) are immortal progenitor cells isolated from the inner cell 
mass of a developing blastocyst
1
. These cells are pluripotent and can be propagated 
indefinitely in vitro whilst retaining this potential
2
. Pluripotency is defined by the 
ability to differentiate into cells of the three primary germ layers; endoderm, 
ectoderm and mesoderm
3
. Morphologically, ES cells are small and compact with a 
large nuclear to cytoplasmic ratio. In vitro, ES cells form compact colonies and 
express phenotypic markers associated with pluripotency
4
. 
Pluripotent cells have great potential as novel in vitro platforms for drug discovery 
and toxicology studies and for future cell-based therapies in clinical medicine
5,6
. 
Currently there is strong demand for cell-based assays to assist preclinical screening 
of candidate drug targets from small-molecule libraries. The use of these cell-based 
assays is desirable as it may facilitate the screening of potential cytotoxic effects of 
novel compounds.  
For the clinical application of cell therapies, material derived from embryonic stem 
cells must be devoid of pluripotent cells as injection of these cells into recipients can 
result in benign or malignant teratoma formation
7
. The robust and reliable expansion 
of stem cells and the generation of uniform populations of differentiated cells will be 
important for both industrial and clinical applications
8
. 
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1.4  Background 
1.4.1 A historical perspective on embryonic stem cell derivation. 
The inception of the field of stem cell biology followed the clinical observation that 
teratocarcinomas consisted of solid tumours containing malignant cells of diverse 
origins. During the 1950’s these malignancies were thought to occur following 
metastasis of a primary tumour. However, they are now understood to be a 
consequence of the malignant transformation of primary germ cells. In 1964, cells 
cloned from teratocarcinomas led to the hypothesis that the malignant cells may arise 
from progenitor cells with the capacity to differentiate into derivatives of the three 
primordial germ layers. Certainly this could explain the diverse tumour ontology 
observed in teratocarcinoma patients
9
.  
The first instance of the culture and retention of multipotency in teratocarcinoma 
cells in vitro occurred in 1967
10
, but it was not until 1972 that Martin Evans isolated 
these embryonal carcinoma cells (EC) from primary teratomas and showed that they 
had the ability to differentiate into non-malignant progeny
11
. It was hypothesised at 
the time that this transition was the converse of the malignant transformation of 
cancer cells. Therefore, these EC cells could serve as a model to investigate ontology 
and development in vitro and would also serve as a system for studying malignancy. 
Interestingly, the injection of embryonal carcinoma cells into experimental animals 
resulted in adoptive transfer of teratocarcinoma
12
. However, when these cells were 
injected into the mouse blastocyst they were incorporated, and normal development 
ensued
13
. That EC cells were integrated into the viable embryo yet exhibited 
malignant properties when injected into the adult suggested that they were highly 
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sensitive to their nutritional and structural microenvironment; and have the potential 
to be reprogrammed by the niche.  
The first reports of the derivation of immortal, pluripotent stem cells isolated from 
the mouse were published by two independent groups in 1981
1,2
. Evans and 
Kaufman isolated cells by immunosurgical dissection of the inner cell mass (ICM) of 
the developing blastocyst. Culture of these ICM cells generated clonal lines that 
could be maintained indefinitely in vitro. These cells were karyotypically normal and 
morphologically and phenotypically similar to the original EC cells. Injection of 
these ICM cells into control animals resulted in the formation of teratomas. These 
neoplasms contained derivatives of the three embryonic germ layers, thus it was 
confirmed that they were pluripotent. Reimplantation of pluripotent ICM cells into 
the developing blastocyst resulted in viable chimeric animals. Almost 
simultaneously, a similar protocol for the derivation of embryonic stem (ES) cells 
was published by Gail Martin. These ES cells were successfully maintained by co-
culture with inactivated fibroblasts and provision of conditioned medium from EC 
cell cultures. This protocol enabled the ES cells to be maintained in an 
undifferentiated, pluripotent state over extended passage. Parallels were then drawn 
between the metabolic requirements of cancer cells and these ES cells. It was this 
metabolic similarity that enabled the in vitro culture of mouse, and later human 
embryonic stem cells.  
The early work to optimise mouse ES cell (mES) expansion has since enabled these 
lines to be grown as without co-culture with feeder cells. It was found that direct 
supplementation of mES cells with the growth factor leukaemia inhibitory factor 
(LIF) maintained the pluripotent phenotype
16,15,16
. Mouse ES cells have since been 
adapted to passaging by enzymatic treatment. 
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A major development arising from mouse ES cell research was the ability to 
generate transgenic animals. This was achieved by the insertion or deletion of 
genetic elements in ES cells and re-implantation of the donor blastocyst into a 
pseudopregnant female. Successful incorporation of the modified ES cells into the 
blastocyst results in chimeric progeny. These chimeric animals are then bred with 
other heterozygous animals with the same deletion; offspring will then bear the 
homozygous mutation in accordance with Mendelian patterns of inheritance
17
. This 
technique has enabled the generation of animal models bearing disease specific 
modifications and has been invaluable to the study of molecular and cellular biology 
of disease.  
Human ES cells were first derived by JA Thompson in 1998 
18
. The first published 
hES lines are still in use today and have broadened the scope of cell-based therapies 
for regenerative medicine. Inactivated feeder cells were necessary to support 
derivation and the maintenance of pluripotency of hES over extended passage. 
Human ES cells have since been adapted to feeder-free culture using combinations 
of extracellular matrix proteins such as found in Matrigel®; which is produced by 
Kaposi’s sarcoma cells; and conditioned medium from mouse embryonic fibroblasts 
19,20
. However, the specific factors that can support and maintain the pluripotent 
phenotype in hES cells have not been fully characterised. Thus, the successful hES 
culture is still dependent upon using by-products from complex biological systems. 
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1.4.2. Leukaemia inhibitory factor signalling in mouse ES cells. 
The leukaemia inhibitory factor (LIF) is a pleiotropic cytokine of the interleukin-6 
(IL-6) family that binds to the gp-130 cell surface receptor
21
. Ligand binding induces 
gp-130 dimerisation with the IL-6 receptor (IL-6R) and stimulates signal 
transduction cascades
22
. The binding of LIF to gp-130 receptor complexes drives the 
phosphorylation of the membrane localised janus-associated kinase proteins (JAKs). 
These tyrosine kinases then directly phosphorylate members of the signal transducer 
and activator of transcription pathway (STAT). Phosphorylation of Stat1 or Stat3 
results in the formation of hetero- and homodimers that shuttle to the nucleus
26
. The 
binding of STAT dimers to DNA subsequently initiates gene transcription events
27
. 
Thus STAT pathway components transduce signals derived from extracellular 
factors to initiate cellular responses at the transcriptional level. The actions of LIF 
however are not limited to JAK/STAT pathway activation. It is widely accepted that 
LIF signalling also activates the phosphotidylinositide 3-kinase (PI3K) and mitogen 
activated kinase pathways (MAPK). 
1.4.3. The regulation of pluripotency in mouse ES cells by l eukaemia 
inhibitory factor.  
In mouse ES cells, LIF signalling promotes pluripotent self-renewal. Consequently, 
the downstream actions of LIF have been studied to identify factors that may 
regulate the pluripotent state. The ligation of gp-130/IL-6R induces the 
phosphorylation and dimerisation of Stat3, and nuclear localisation of phospho-Stat3 
dimers promotes mouse ES cell self renewal
25
. Consequently Stat3 was understood 
to be a core component of the pluripotency network in mES cells. Indeed, a fusion 
protein containing the coding region of Stat3 was demonstrated to maintain 
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pluripotency independently of LIF
26
.  However, mouse ES cell self-renewal is not 
exclusively dependent upon Stat3 activation as it has since been proven to be 
dispensable for the maintenance of pluripotency
27
. Although Stat3 was considered a 
major factor driving mouse ES cell self-renewal it is not the principle mediator of the 
pluripotent phenotype maintained by LIF. 
Figure 1.4.1 
LIF-mediated activation of JAK/STAT pathway in mouse ES cells 
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The c-myc proto-oncogene is induced downstream of Stat3. Removal of LIF from 
mES growth medium results in downregulation of c-myc protein and transcript 
levels. Expression of constitutively active c-myc supports pluripotent self-renewal 
independently of LIF/Stat3. Additionally, dominant negative c-myc mutant mES 
cells spontaneously differentiate in the presence of LIF
27
. Therefore c-myc supports 
self-renewal and inhibits the differentiation of mES cells and is the principle 
mediator of LIF-mediated pluripotency.  
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As LIF stimulates the PI3K pathway, the importance of this signal transduction 
cascade in mouse ES cell biology has been extensively studied. The PI3K pathway 
mediates an array of cellular responses including survival, cell cycle progression, 
motility and proliferation
29,30,31
. Ligation of cell surface receptors including receptor 
tyrosine kinases (RTK), G-protein coupled receptors (GPCR) by growth factors or 
insulin stimulates the phosphorylation of membrane phospholipids by PI3K. 
Membrane localised phosphoinositides are phosphorylated at the 3’OH ring by 
PI3K.  
Activation of PI3K signalling pathway initiates a signal transduction cascade 
involving the protein dependent kinase-1 (PDK1) mediated phosphorylation of 
protein kinase-B (AKT). The downstream biological effects of PI3K signalling is 
orchestrated by AKT. The plekstrin homology domain (PH) of AKT elicits 
recruitment to the plasma membrane where it is binds PIP3 and interacts with PDK1. 
This kinase then phosphorylates AKT at threonine residue 308 (th308).  The actions 
of PDK1 are inhibited by the tumour suppressor PTEN. Genetic mutations at the 
PTEN locus are implicated in the pathogenesis of numerous site-specific cancers and 
myeloproliferative diseases
31,32
. Conditional knockout of the PTEN gene results in 
embryonic lethality and mouse ES cells derived from PTEN 
-/+ 
blastocysts exhibit 
increased tumourogenic potential. This arises from the loss of anchorage-dependent 
growth inhibition, thus PTEN null (
-/-
) ES cells exhibit aberrant differentiation 
potential
33
. It was therefore concluded that PTEN is essential for normal 
development, and the impaired regulation of PI3K signalling upon loss of PTEN 
promotes the proliferative phenotype that is a hallmark of cancer.   
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Figure 1.4.2 
Activation of AKT and PI3K-mediated phosphorylation of PIP2. 
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Figure 1.4.2 documents the key interactions resulting in AKT phosphorylation at 
th308 by PDK1. The phosphorylation of AKT at the serine-473 residue (ser473) by 
the protein dependent kinase-2 (PDK2) will be discussed in later sections. Activation 
of AKT via the PI3K pathway promotes mES proliferation, survival and self-
renewal. In mouse ES cells the inhibition of AKT results in cellular differentiation. 
The pluripotent phenotype is rescued by expression of constitutively active 
myristolated AKT (myr-AKT). Thus myr-AKT-mES cells maintain pluripotent self 
renewal in the absence of LIF. This highlights the importance of the PI3K-AKT 
pathway in the LIF-dependent maintenance of pluripotency in mES cells
36
, however 
this pathway operates upstream of c-myc.  
In 2005, Takahashi, Murakami and Yamanaka documented the role of the PI3K 
pathway in the tumourogenic potential of mouse ES cells. Prior analysis of the 
mouse expression sequence tag database (EST) led to the identification of the ES 
cell-expressed Ras (ERas) in ES cells but not in differentiated cells. Near 
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constitutive activation of ERas was observed in pluripotent cells. The expression of 
ERas in NIH3T3 fibroblasts induced malignant transformation and led to tumour 
formation when injected into adult mice. Additionally, ERas expression induced the 
proliferation of mouse embryonic fibroblasts.  As ERas was a potent PI3K pathway 
agonist it was speculated that the tumourogenic properties of mES cells may be 
driven by the ERas-PI3K axis. However, injection of ERas-null ES cells into mouse 
blastocysts resulted in the generation of developmentally normal chimeric mice. 
While ERas did not therefore regulate pluripotency in mouse ES cells, it did appear 
to promote proliferation and tumorigenicity. While ERas-null ES cells retained their 
teratogenic potential, teratomas were smaller in size. Additional pathway interactions 
were speculated to regulate the ERas/PI3K mediated teratogenic potential of mouse 
ES cells
37
. It is now understood that this effect is mediated by downstream signalling 
via the mTOR pathway. 
Leukaemia inhibitory factor signalling also stimulates the mitogen activated kinase 
pathway (MAPK) pathway leading to phosphorylation of ERK1 and ERK2. 
Phospho-ERK promotes cell proliferation and has been strongly associated with the 
differentiation of mouse embryonic stem cells
38
. Inhibition of ERK phosphorylation 
or the upstream kinase promotes mouse ES cell self-renewal by potentiating the 
actions of Stat3
41
. It was postulated that the LIF/Stat3 pathway dominates cell fate in 
mouse ES cells, upon removal of LIF, the ERK pathway gains prominence and 
differentiation is induced
28
. The inclusion of serum in mES culture medium supports 
the LIF-mediated maintenance of pluripotency by inhibiting the downstream 
consequences of ERK phosphorylation. This has been shown to involve the actions 
of a class of compounds entitled the inhibitor of differentiation (Id) proteins arising 
from the bone-morphogenic protein (BMP) signalling pathway
40
. 
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1.4.4 The core network regulating pluripotency in mouse ES cells.  
The transcription factors octamer-binding transcription factor-4 (OCT4) and the 
homeobox protein Nanog have been implicated as major regulators of the pluripotent 
phenotype
41,42,43
. Constitutive expression of Nanog was considered to be a hallmark 
of stem cell pluripotency
46
, and genetic mutation of the Nanog gene results in 
lethality early in development
43
. Investigations into the levels of the Nanog in mouse 
ES cells revealed fluctuations in expression levels that may act as discrete windows 
whereby stem cells are prone to differentiate in response to environmental signals
47
. 
It has been postulated that Nanog acts as a negative regulator of differentiation 
especially toward the endodermal and mesodermal lineages by promoting pluripotent 
self renewal.  
The transcription factor OCT4 is first detected at the 4 cell stage of mouse 
development and has been shown to be closely associated with pluripotency both in 
vivo and in vitro 
42, 43
. The expression of OCT4 diminishes as cells differentiate, and 
somatic cells can be reprogrammed to display the pluripotent phenotype by 
transfection with OCT4 mRNA and at least one other transcription factor
46
. These 
findings provide the strongest case for the OCT4-mediated regulation of the 
pluripotency network. The observation that OCT4 is detected in some adult cancers 
may be support the ‘cancer stem cell’ hypothesis, whereby undifferentiated stem-like 
cells act as cellular drivers of neoplasia. 
The transcription factor Sox2 is key factor in the core network regulating 
pluripotency. Inhibition of Sox2 by RNA interference induces the differentiation of 
mouse ES cells
47
. Both OCT4 and Sox2 have been shown to bind to the Nanog 
promoter to enhance transcription
48
, and cooperate to maintain the pluripotent state. 
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1.4.5  The ground state of embryonic stem cell self-renewal. 
Austin Smith and colleagues have extensively documented the molecular regulation 
of mouse ES pluripotency in response to LIF stimulation. It was found that ERK 
inhibition is essential to maintain pluripotency in mouse ES cells. Additionally 
inhibition of the PI3K/AKT pathway results in accumulation of glycogen synthase 
kinase-3 (GSK3) in the nucleus. The kinase activity of AKT antagonises the function 
of GSK3 by phosphorylating specific threonine and serine residues. Phosphorylation 
of GSK3 by AKT is important for the maintenance of mouse ES cell pluripotency. 
Extrapolating these findings, Smith et al proved that mouse ES cell self-renewal 
could be maintained by the combined inhibition of GSK3 and ERK phosphorylation 
with small molecule inhibitors. Thus, pluripotent self renewal can be maintained by 
inhibiting intrinsic differentiation signals rather than providing extrinsic growth 
factors to promote pluripotency. That Stat3-null cells proliferate under these 
conditions implies that mouse ES cells have an innate capacity for self-renewal. It 
was postulated that it is this innate capacity that underpins tumorigenic potential. 
This concept was termed the ‘ground state of embryonic self renewal’49, 50.  
Figure 1.4.3 
The regulation of stem cell pluripotency in the mouse 51. 
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1.4.6   Cell cycle regulation in mouse ES cells.  
The mammalian cell cycle is regulated by proteins and protein kinases of the cyclin 
and cyclin-dependent kinase (cdk) family. In somatic cells and differentiated stem 
cells a series of interactions regulates progression from the G0/G1 phase to the DNA 
synthesis (S) phase, and G2 to mitosis (M) phase. A major checkpoint of the cell 
cycle occurs during G1-S transition. For progression through this checkpoint cyclin-
D is necessary to induce retinoblastoma protein (Rb) phosphorylation. This results in 
the release of the E2F transcription factor and subsequent cyclin-E activation. 
Cyclin-E then is free to induce the transcription of S-phase genes necessary for DNA 
synthesis.  
In pluripotent embryonic stem cells this G1 checkpoint is compromised as Rb protein 
is hyperphosphorylated and cells transit rapidly through the G1 phase. The length of 
the G1 phase is reported to be approximately 1 to 1.5 hrs in these ES cells
28
. 
Interestingly, it has been documented that mES cells are refractory to cell cycle 
inhibition upon deletion of regulatory proteins involved in G1-S transition. When 
cellular differentiation proceeds following LIF withdrawal, Rb checkpoint control is 
then acquired. The proto-oncogene c-myc appears to be directly involved in the 
production of S-phase genes via activation of cyclin-E, and Stat3 may also act 
directly upon cell cycle regulators to promote S-phase transition. Thus LIF-mediated 
induction of Stat3/c-myc may supersede the Rb checkpoint at G1 of the cell cycle. 
Activation of the PI3K pathway downstream of LIF also induces cyclin-D 
expression and activation, thereby promoting the transition through the G1 phase of 
the cell cycle in mES cells. 
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1.5  The mammalian target of rapamycin pathway.  
1.5.1 The discovery of metazoan and mammalian TOR. 
The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine 
protein kinase that links the availability of extracellular nutrients to key checkpoints 
of cell growth and proliferation, cytoskeletal commitment and autophagy. The 
discovery of rapamycin followed observations of the inhibitory effects of the soil 
bacterium Streptomyces hygroscopicus on the growth of Candida albicans and other 
fungi. Canadian researchers isolated the organism responsible and purified the active 
compound. It was termed rapamycin after Rapa Nui, the indigenous name for Easter 
Island where the samples were first obtained 
52
. 
Rapamycin binds to the highly conserved 12kb molecule FKBP12 and inhibits the 
action of an associated protein. The identification of two TOR genes was reported in 
1993 following drug resistance screening of the yeast Saccharomyces cerevisaie
53
. 
Disruption of the TOR2 gene was lethal, whereas rapamycin treatment induced cell 
cycle arrest at the G1 phase
54
. The mammalian orthologue of the yeast TOR gene 
was cloned a year later by three independent groups
55,56,57
. Mammalian TOR is 
transcribed from a single locus and is structurally similar to metazoan TOR. The 
mammalian TOR protein was observed to have close homology with PI3K.  
Upstream regulators of mTOR include amino acids, growth factors, insulin, energy 
availability, hypoxia and reactive oxygen species. Of note is the sensitivity of mTOR 
signalling to the bioavailability of the branched-chain amino acid leucine
58
.   
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1.5.2 The rapamycin sensitive mTOR complex (TORC1). 
 Mammalian TOR is a high molecular weight protein (290 kDa) and has a number of 
highly conserved domains with catalytic activity. The N-terminus contains tandem 
repeat domains that are implicated in protein interactions while the C-terminus 
retains the kinase activity. The structure of mTOR is represented below. 
Figure 1.5.1 
Functional structure of mammalian TOR protein 59 
 
 
 
Mammalian TOR forms two distinct heteromeric complexes, TORC1 and TORC2. 
The TORC1 complex consists of mTOR bound to the protein raptor
60
. Additional 
subunits of the complex include GβL (LST8) 61, and PRAS40 62. The activity of the 
TORC1-raptor complex is sensitive to nutrients and growth factors, kinase activity is 
dependent upon the formation of this stable complex
63
 
64
. 
The TORC1 kinase phosphorylates p70S6-kinase (p70S6K) and the eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1). These substrates regulate 
protein translation. The mechanisms of the regulation of protein translation 
downstream of mTOR have been relatively well characterised. Phosphorylation of 
the mRNA translation repressor 4EBP1 leads to its inactivation and liberates the 
eIF4E translation initiation factor from an inhibitory complex with 4EBP1. This 
promotes translation initiation and the production of new proteins. The detection of 
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phosphorylation of distinct sites on these two proteins acts as a reporter of the 
mTOR/raptor complex activity
65,66
. Of particular significance is the phosphorylation 
of the threonine 389 residue of p70S6K by TORC1
67
. 
1.5.3 The mTOR complex-1 in the regulation cell size. 
Rapamycin treatment results in a reduction in cell size in proliferating cells.  
Dividing cells must double their mass at each round of division, proliferation and 
cell growth are closely regulated to match metabolic processes to nutrient 
availability. Cell growth occurs predominantly in the G1 phase of the cell cycle, 
occurring after cell division, although protein translation is necessary in the G2 phase 
prior to mitosis. The TORC1 mediated effectors of cell growth are p70S6K and 
4EBP1, together they induce protein translation and ribosome biogenesis. Inhibition 
of TORC1 reduces cell size, and a rapamycin-resistant mutant of mTOR ablated this 
cell size defect, the S6K mutant only partially rescued this size-defective 
phenotype
68
. However, the rapamycin mediated effects on cell size and proliferation 
in yeast are separable. Changing nutrient provision from a nitrogen-rich to nitrogen-
poor source results in continued cell division at the expense of cell growth. 
Inhibition of cell proliferation does not affect cell size, whereas cells deprived of 
nutrients continue to progress through the cell cycle, progeny are of a smaller size
69
. 
Figure 1.5.2 
Key outputs of mTOR mediating cell growth
70 
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1.5.4 The rapamycin insensitive mTOR complex (mTORC2).  
The formation of the mTOR-raptor complex is inhibited by rapamycin; however 
mTOR also forms an additional heteromeric complex that competes for free mTOR 
protein. In budding yeast cells, two TOR genes form independent complexes 
transcribed from different genes Tor1 and Tor2 
64
. In the mammalian system, only 
one TOR homologue was identified. However, as mTOR was shown to exhibit 
rapamycin insensitive functions, it was postulated that two independent TOR 
complexes might exist in the mammalian system. Jacinto and colleagues 
demonstrated that mammalian TOR did indeed form two functional protein 
complexes
71
. A second binding partner was identified and termed ‘rapamycin 
insensitive companion of mTOR’ (rictor)72. It is now known that the mTOR 
complex-2 contains mTOR, rictor, sin1 
73
, protor
74
, PRR5
75
 and LST8
76
.  
The mTOR complex-2 exhibits discrete kinase activity from mTORC1. The first 
substrate for mTORC2 was identified as the serine-473 residue in the hydrophobic 
loop of AKT
77
. Other substrates have been identified, namely the serum- and 
glucocorticoid-dependent kinase-1 (SGK1) and Protein Kinase C-α (PKC-α)78,79. 
Reports indicate that TORC2 may signal to the cytoskeleton, inducing actin 
polymerization and cell spreading
71,72
.  Knockdown of rictor in mouse blastocysts 
results in growth arrest at E9.5 and death by E11.5. This is in contrast to the 
homozygous mTOR kinase-dead mutant whereby embryonic lethality occurs at E6.5 
80
. It appears that intact TORC2 signalling is necessary for midgestation whereas 
TORC1 is required for early development. Interestingly mTORC2 is necessary for 
the adoptive transfer of prostate cancer in PTEN null mice. This implies an 
unrecognised role for TORC2 in cellular proliferation
81
.   
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Figure 1.5.3                         
Kinase substrates of TORC2
82
. 
 The protein kinase A/G/C family proteins 
(AGC) share common mechanisms of 
activation involving phosphorylation at the 
T-loop motif by PDK1 and the hydrophobic 
motif (HM). Full activation of AGC 
kinases depends upon these two 
modifications. Phosphorylation of the turn 
motif (TM) by TORC2 may stabilise newly 
synthesised protein and prevent 
proteosomal degradation. 
 
 
1.5.5 Upstream regulation of mTOR signalling. 
The tuberous sclerosis complex (TSC) is a key regulator of mTOR activation. 
Benign tumours called harmatomas arise from mutations in the TSC genes
83
. These 
neoplasms result from the impaired negative regulation of mTOR signalling. Two 
TSC proteins form a complex that ultimately inhibits mTOR via the GTPase Rheb 
(ras enriched in the brain). Phosphorylation of TSC2 by PI3K or MAPK related 
kinases release Rheb, and activate mTOR
84,85,86
.  The TSC complex is known to 
regulate TORC2 activation as mutations in the TSC genes impairs the TORC2 
mediated phosphorylation of AKT in some cell types
87
. 
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1.5.6 Interactions between the mTOR and PI3K pathway. 
Mammalian TOR signalling is closely integrated with the phosphoinositide kinase 
(PI3K) pathway. The interaction between AKT and mTOR is complex and 
multifaceted involving both upstream and downstream regulation. A substrate of the 
AKT kinase includes the tuberous sclerosis complex molecule TSC2. The AKT 
mediated phosphorylation of TSC2 results in disruption of TSC1/TSC2 complex and 
releases the inhibition of TORC1 via the GDP exchange factor Rheb
62
. Thus 
PI3K/AKT potentiates mTOR signalling. Downstream interactions involve the 
mTOR complex-2. Phosphorylation of the serine-473 residue of AKT by TORC2 
results in full activation of AKT. It has been documented that the serine-473 
phosphorylation induces a conformational change exposing the PH-membrane 
localisation sequence. This brings AKT into contact with PDK1 at the plasma 
membrane and elicits phosphorylation of the threonine-308 residue
88
. Mammalian 
TOR also regulates its own activity through a feedback mechanism involving PI3K. 
High levels of phospho-p70S6K, resulting from TORC1 activation, inhibits PDK1-
mediated phosphorylation of AKT. This mechanism process occurs at the cell 
membrane via the insulin-response unit, IRS-1. This feedback inhibition may serve 
to prevent unregulated cell growth and proliferation in response to mTOR over-
activation
89
.  
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Figure 1.5.4 
Pathway map of key TORC1 interactions
90
. 
 
 
 
 
 
 
 
1.5.7 The mTOR/PI3K pathways regulate cellular metabolism in response 
to nutrient availability. 
The mammalian TOR pathway is known to regulate cellular survival under 
conditions of nutritional stress. Depletion of key nutrients such as branched-chain 
amino acids
91,92
, glucose and oxygen results in the inactivation of mTOR. The 
regulation of these processes may however depend upon cell type and 
microenvironmental conditions. 
 Branched-chain amino acids such as leucine are known agonists of mTOR 
activation and protein translation. It has been widely reported that amino acid 
availability stimulates protein production in skeletal muscle
93
, adipose tissue
58
 and 
myoblasts
94
. The effect of amino-acid availability on protein translation is not 
restricted only to these cells types.  Indeed the converse may be true and mTOR 
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signalling appears to provide a fundamental checkpoint in cell growth control in 
response to nutrient availability. This is exemplified by pathological nutrient 
restriction during development. During intrauterine growth restriction, the transport 
of amino-acids via the expression of A- and L-type amino acid receptors is impaired 
resulting in reduced placental nutrient transport. The mTOR pathway is implicated in 
the regulation of placental nutrient sensing as impaired mTOR signalling reduces 
foetal growth
95
. Insulin is increases growth via the upregulation of nutrient 
transporter expression, an effect that is impaired by AKT deletion
96
. The B0+ amino 
acid transporter system regulates the uptake of branched-chain amino acids and 
affects both blastocyst implantation and differentiation by an mTOR mediated 
mechanism
97, 98
. 
Energy stress is also a modulator of the mTOR pathway. The adenosine 
monophosphate kinase (AMPK) regulates cellular metabolism in response to glucose 
availability. This kinase becomes activated when cellular ATP is depleted and the 
ratio of AMP to ATP rises. The level of ATP correlates directly with glucose bio-
availability. Consequently, AMPK slows cell metabolism and inhibits proliferation 
by activating repressor proteins upstream of the mTOR pathway. Adenosine 
monophosphate protein kinase activity inhibits mTOR activation via the TSC 
complex
99
. And phosphorylation of raptor by AMPK impairs TORC1 complex 
formation and activity
100
. High levels of glucose have been documented to have a 
positive effect on embryonic stem cell proliferation via an increase in AKT 
signalling
101
. Therefore, high glucose stimulates proliferation through the PI3K and 
mTOR pathways whereas low glucose inhibits proliferation by inactivating the 
mTOR/raptor pathway.   
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Inhibition of mTOR also results in the stimulation autophagy, an intracellular 
catabolic process involving lysosomal degradation and recycling of cellular material. 
Recent research has shed light on the molecular mechanism of the mTOR-mediated 
induction of autophagy
102
. The restriction of nutrients inhibits mTOR activation 
which in turn induces autophagy. This mechanism enables cells to regulate their 
metabolism in dynamic equilibrium with the availability of nutrients.  
1.5.8 Substrates of AKT promote cell survival.  
Many substrates of the AKT serine/threonine kinase have been identified. These 
substrates are broadly categorised as type1 or type2. Type 1A substrates become 
activated following phosphorylation by AKT whereas type 1B phosphorylations are 
predominantly inhibitory. The type2 substrate interactions involve serine/threonine 
phosphorylations that promote binding to 14-3-3 proteins
103
.  Binding of intracellular 
proteins to 14-3-3 commonly results in degradation or dephosphorylation of the 
substrate and therefore represents a major regulatory system to limit signal 
transduction pathway activation. One such interaction involves the Bcl-2 mediated 
inhibition of apoptosis. The phosphorylation of the BAD protein by AKT promotes 
its binding to 14-3-3 and consequently inhibits this association with Bcl-2. Unbound 
Bcl-2 is anti-apoptotic and promotes cell survival following AKT activation
104
 .  
Figure 1.5.5   
Mechanisms of cell survival mediated by AKT
105
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1.5.9 The mammalian TOR pathway during development.  
The mammalian target of rapamycin (mTOR) signalling pathway has been 
implicated as a regulator of cell growth and proliferation in response to nutrient 
availability. In 2004, two publications independently assessed the effect of mTOR 
inactivation or depletion on embryonic development in the mouse
106
 
107
. The first 
study published by Murikami and colleagues documented the levels of mTOR 
protein in developing and adult mouse tissues. Relatively high levels of protein were 
identified in mouse ES cells compared with many adult tissues.  Genetic disruption 
of the kinase domain of mTOR by homozygous recombination impaired 
proliferation of both embryonic and extra-embryonic tissues and resulted in 
embryonic lethality. Embryonic stem cells derived from the inner cell mass of 
homozygous mutant blastocysts failed to proliferate in vitro. Utilising a conditional 
deletion approach to target mTOR, homozygous mutant ES clones (mTOR 
flox/flox
) 
were tested for their ability to proliferate in vitro. Interestingly, the severe reduction 
in the proliferative capacity of these ES mutant cells was not seen with rapamycin 
treatment alone. Although rapamycin did reduce cell proliferation it was clear that 
the role of mTOR in ES cell proliferation extended beyond the rapamycin sensitive 
effects. Additionally, the ERas-null phenotype described by Takahashi and 
colleagues resembles that of mTOR deficient ES cells. It was therefore speculated 
that the teratogenic potential of mouse ES cells may be driven by the mTOR 
pathway. 
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The second study by Gangloff et al demonstrated that heterozygous mutation of the 
mTOR gene resulted in reduced mTOR protein levels and phosphorylation of the 
mTORC1 substrate p70S6K in embryonic fibroblasts. However no phenotypic traits 
were observed and cell size and cell cycle transit were not affected. Homozygous 
mutation resulted in severe phenotypic abnormalities and embryonic lethality at 
E5.5. Embryonic stem cells could not be derived from these homozygous mTOR 
mutant blastocysts
107
. It has been postulated that developmental arrest at this time is 
due to impaired blastocyst implantation. This is consistent with the observations that 
rapamycin treatment impairs trophoblast outgrowth, which occurs at E4.5 in the 
mouse
98
, and that amino acid deprivation impairs blastocyst implantation and 
outgrowth in vivo
108
. Interestingly, Gangloff et al observed that cell cycle transit was 
not impaired in preimplantation blastocysts. This may relate to the low requirement 
for amino acid uptake at this stage of development, and the increase in amino acid 
dependency at implantation when embryo size begins to increase rapidly
109
. Loss-of 
function mutations in the mTOR gene inhibit proliferation and embryonic 
development in the mouse, however, cell size was not affected in these flat-top 
mutants
110
. 
In human ES cells, mTOR was found to be important for the maintenance of 
pluripotent self-renewal. Inhibition of mTOR resulted in loss of pluripotency and a 
tendency towards the formation of endoderm and mesoderm lineage specification. 
Interestingly, in mouse ES cells, this effect was not observed and mTOR inhibition 
had no effect on pluripotent marker expression or self-renewal. Colony size was 
reduced indicating that mTOR is important for mES cell proliferation but not 
pluirpotency. The compact morphology of pluripotent mES cells was also 
maintained
111
.      
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The mTOR/PI3K axis is strongly associated with cell proliferation and survival in 
mouse and human ES cells. Genetic mutations in components of the mTOR and 
PI3K pathways result in embryonic lethality. Excessive PI3K activation drives rapid 
cell cycling, and the loss of regulation of PI3K/AKT promotes cell survival. Of 
particular interest to this investigation is the finding that the depletion of serum 
results in PI3K/mTOR pathway activation, an effect that is postulated to provide a 
survival advantage under conditions of nutritional depletion
112
. The role of the 
mTOR complex-2 is not well understood in ES cells or somatic cells. There is 
evidence implicating TORC2 in cytoskeletal commitment and polarity, and there is a 
body of evidence to suggest that mTORC2 may play a role in the regulation of 
cellular proliferation.  
Table 1.1. Summary of key signalling events in mES cells. 
Agonist Target Downstream  Effector Outcome in mES cells  
LIF gp130/LIFR PI3K p-AKT (th308) Survival, proliferation 
    STAT3 p-STAT3 dimer  Self-renewal 
    MAPK p-ERK 1/2 Differentiation 
Leucine Unknown mTORC1 p-S6K (th389) Protein translation/cell growth 
      p-4EBP1 Translation initiation/cell growth 
Unknown  mTORC2 AKT p-AKT (ser473) Unknown 
 
In summary, mTOR is at a nexus of intracellular signalling pathways that regulate 
cell growth, cell cycle progression, survival and proliferation in response to the 
availability of nutrients and growth factors. The impact of the mTOR pathway on the 
behaviour of mES cells has not been fully characterised and the role of the mTORC2 
complex in mammalian cells is poorly understood. 
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1.5.10  Manipulation of the mTOR pathway as a bioprocessing tool for the enhanced 
expansion and differentiation of ES cells. 
Embryonic stem cells are currently attracting great interest as a potential source of 
cellular material for novel regenerative medicines. Currently the first ES cell based 
therapies are undergoing clinical trials for macular degeneration. Furthermore, 
industrial application of stem cell technologies is centred upon developing cell-based 
assay systems for toxicology testing in pre-clinical drug discovery and validation 
programmes. 
Critical to the success of ES cell therapies is the development of robust protocols to 
generated pure population of target cells. As the injection of pluripotent cells into 
recipients may result in teratoma formation it is critical to ensure that final cell 
preparations are devoid of contaminating parent cells. The use of ES cells in pre-
clinical screening programmes also necessitates high levels of purity and 
reproducibility. Consequently, there is demand for bioprocess improvements that are 
cost-effective at an industrial scale. Manipulation of the mTOR pathway has not 
been previously considered as a route to bioprocess optimisation however this 
pathway is an ideal candidate as it is central to the regulation of cellular growth and 
proliferation. Whereas cell proliferation rate is relevant to cell expansion, cell growth 
is an important biological process during cellular differentiation. Furthermore, the 
mTOR pathway is sensitive to the bioavailability of glucose and branched-chain 
amino acids such as leucine. As amino acids are relatively cheap to produce 
compared with recombinant proteins, the mTOR pathway offers a unique 
opportunity for the cost-effective manipulation of ES cell fate at an industrial scale.  
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1.6  Research question 
Does the mTOR pathway offer a route to bioprocess optimisation during the 
expansion and differentiation of embryonic stem cells? 
1.7 Objectives 
The principle objective of this research is to characterise mTOR pathway signalling 
in a model pluripotent stem cell system. 
Secondly to advance the understanding of the role of the two mTOR complexes in 
the proliferation of embryonic stem cells. 
Finally to assess the impact of manipulating the mTOR pathway on the expansion 
and early differentiation of embryonic stem cells. 
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Chapter 2 
Experimental Methods 
2.1 Expansion and culture of mouse embryonic fibroblasts.  
Primary mouse embryonic fibroblasts (MEF)  at passage 1 were thawed in a water 
bath and seeded into T-75 tissue-culture flasks (Nunc; Stafford, UK) with 
Dulbecco’s modified Eagle’s medium (DMEM), (4500mg/ml glucose; Lonza-Bio-
Whittaker; Wokingham, UK) supplemented with L-glutamine and 10% foetal calf 
serum (FCS), (both Gibco Invitrogen; Paisley, UK). Cells were cultured until 
confluence and split (1:10 ratio) by enzymatic detachment (0.25% trypsin/EDTA; 
Gibco-Invitrogen) and grown until passage 5. Every 2 weeks confluent MEFs were 
mitotically inactivated by treatment for 2hr with mitomycin-C (1mg/ml, Sigma-
Aldrich, Poole, UK). Flasks were washed with dPBS and cells detached with 0.1% 
(w/v) trypsin (both Sigma-Aldrich) at 37 ºC. After 5min incubation, enzyme was 
neutralised with growth medium (DMEM) containing 10% FCS,  detached cells 
were centrifuged for 3min at 280g and seeded at a density of 4000 cells/T-25 flask or 
1000 cells/IVF dish. Fresh inactivated feeders were then sustained for 2 weeks to 
support human embryonic stem cell growth. Inactivated feeders were also 
cryopreserved in 90% FCS containing 10% dimethylsulphoxide (DMSO; Sigma-
Aldrich) and stored at -80 ºC. When needed cryopreserved cells were thawed and 
seeded at a density of 7000 cells/T25 flask. 
 
  
51 
 
2.2 Culture of human embryonic stem cells  
Human Shef3 embryonic stem cells (UK Stem Cell Bank) were maintained on 
primary inactivated mouse embryonic fibroblasts (MEFs) and cultured upon 0.1% 
gelatin (Sigma-Aldrich) coated T-25 flasks or IVF culture dishes (Nunc) in a 
humidified atmosphere at 37 ºC, 5% CO2. Human Shef3 cultures were cut by 
surgical microdissection under a microscope with a heated glass element in the 
presence of collagenase (0.025mg/ml. Invitrogen) for 3 minutes at 37℃. Cell 
suspensions were collected in 2ml DMEM containing 100mM ß- mercaptoethanol, 
1mM L-glutamine, 1% (v/v) non-essential amino acids (all Sigma) and seeded into 
tissue culture flasks containing adherent inactivated MEFs. Colonies were passaged 
every 3-4 days during expansion. 
 
2.3 Culture of human embryonic carcinoma cells  
Cryopreserved embryonic carcinoma cells N-Tera2 were rapidly thawed at 37ºC and 
diluted with 9mls of warmed DMEM containing 10% foetal calf serum (FCS) and 
centrifuged for 3min at 280xg. The cell pellet was resuspended in 5mls of growth 
medium, placed into 25cm
2 
tissue culture treated flasks (T-25, Nunc) and cultured in 
a humidified environment containing 5% CO2 at 37°C. Confluence was determined 
by visual inspection under light microscopy. Cultures were manually passaged by 
mechanical dissociation using sterile 5mm glass beads.  The monolayer of cells was 
first washed with fresh growth medium and then broken into clumps by the addition 
of approximately 15-20 glass beads in 4mls of medium followed by a gentle shaking 
of the flask for 20-30 seconds. Detachment was assessed by microscopy and the cell 
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suspension removed and reseeded into tissue culture flasks at a ratio of 1:2 for 
confluence within 2 days or 1:3 for confluence within 3 days.  
 
2.4  Culture of mouse embryonic stem cells.  
Mouse embryonic stem cells clone E14-Tga2 were cultured at 37 ºC and 5% CO2 in 
a humidified atmosphere for 2 days with Glasgow modified eagle’s medium 
(GMEM) supplemented with  sodium pyruvate, 1mM L-glutamine, 100mM β-
mercaptoethanol (all Sigma), 10
3
 u/ml LIF (ESGRO; Millipore, Watford, UK)  and 
10% foetal bovine serum (Gibco-Invitrogen). Monolayers were passaged by 
enzymatic dissociation with 0.01% trypsin containing 0.2M EDTA and 5% chick 
serum (all Sigma) at 37ºC for 3 min. Cells were liberated by gently tapping flasks 
under phase-contrast microscope. Enzyme was then inactivated with growth medium 
containing 10% FCS and cell suspensions centrifuged at 300xG for 3min. Cell 
pellets were resuspended and seeded at a 1:6 ratio onto gelatin-coated (0.1%) tissue 
culture plastic (Iwaki™; Thermo-Fisher, Waltham, UK). Mouse E14 Tga2 cells were 
observed to exhibit monolayer growth when cultured on Iwaki™ tissue culture 
treated plastic with 10% serum and 10
3
u/ml LIF and passaged every 48h by the 
method described. 
 
2.5  Protein isolation and purification. 
Protein isolates were prepared from cellular material for gel electrophoresis and 
western blotting. Cells were washed with ice-cold dPBS, harvested by scraping in 
1ml dPBS and centrifuged at 300xG for 5min. Cell pellets were lysed for 30min on 
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ice with 100µL commercially available RIPA lysis buffer (Gibco; Invitrogen) 
containing phosphatase and protease inhibitors (Roche; Welwyn Garden City, UK). 
Lysates were collected and centrifuged at 13000 x g for 30min at 4°C, the 
supernatant was collected and transferred pre-cooled 1.2ml micro-centrifuge tubes 
(Eppendorf; Cambridge, UK). Protein lysates were then stored at -80°C. Protein 
concentrations were assessed by the Bradford method (Bio-Rad, Hemel Hempstead, 
UK) and quantified against a standard curve generated by serial dilution of bovine 
serum albumin (BSA; Sigma-Aldrich). Optical density was measured at 597nm and 
sample protein concentrations determined by linear regression from the standard 
curve. 
2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting. 
Each lane of a pre-cast 10% Tris-glycine/SDS gel (Invitrogen) was loaded with 30µg 
of protein in Laemlli sample buffer. Protein samples were run alongside Western 
Blotting ECL™ molecular weight markers and Full-Range Rainbow™ markers 
(both GE Medical) and loading controls (see Antibodies) at 145 V, 50 mA for 1hr in 
a X-Cell II Sure-Lock system™ (Invitrogen). Proteins were transferred onto Hy-
Bond-ECL™ nitrocellulose membranes (GE-Heatlhcare-Amersham; Lt Chalfont, 
UK) pre-activated with methanol (Sigma-Aldrich). Protein transfer using the X-Cell 
II™ blot module (Invitrogen) and standard transfer buffer was undertaken for 2hrs at 
20V/450mA. Membranes were equilibrated with wash buffer for 5mins prior to 
incubation with 5% milk blocking solution for1hr. Membranes were then washed 3 
times with tris-glycine buffer (15mls). Membranes were cut at specific positions 
according to the molecular weight band identified by the Full-Range Rainbow 
54 
 
marker lane relevant for the target protein. Subsequently, membranes were incubated  
overnight on a rotating shaker with a 1:500 dilution of primary antibodies at 4ºC (see 
Antibodies). Membranes were washed 3 times and incubated for a further1hr at room 
temperature with goat-anti rabbit secondary antibodies conjugated with horseradish 
peroxidase (HRP). Membranes were again washed 5 times with 5ml wash buffer and 
visualised by enhanced chemiluminescence. A 10ml solution of ECL+ (GE 
Healthcare-Amersham) was prepared (1:1 ECL A: ECL B) and applied to labelled 
membranes. Chemiluminescence was detected by exposing Hyperfilm™ x-ray 
sensitive photographic film for between 30sec and 5 min in a hyperfilm cassette 
(GE-Healthcare-Amersham).  
2.7 Immunostaining  
Cells were fixed with 1% paraformaldehyde (Sigma) for 10min and washed with 
dPBS at room temperature, cultures were cooled to 4°C, washed again with pre-
cooled dPBS and fixed with 70% Etoh at -20°C for 10 min at 4°C. Solution was 
removed and wells were washed with a 50% ratio of EtOH/dPBS, 25% EtOH/dPBS 
and then left at room temperature in dPBS alone to rehydrate. Cells were incubated 
for 30min in XT-image enhancer blocking solution (Invitrogen) and then incubated 
for 1-2h with isotype control or antigen-specific primary antibodies at room 
temperature on a rotating shaker, or overnight at 4°C for phosphospecific antibodies. 
Primary antibody solutions were removed and cells washed with dPBS 3x and 
incubated with AlexaFluor-conjugated secondary antibodies (Invitrogen) for 1h at 
room temperature. Wells were washed 3x for a minimum of 30min and treated with 
0.5µg/ml DAPI (Invitrogen). Solution was removed and cells washed 2x with dPBS 
and kept at 4°C in the dark. 
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2.8 Antibodies  
Primary antibodies were used at the manufacturer recommended concentrations or as 
specified. Anti-mTOR, phospho-p70S6K (th389/th412 human/mouse), phospho-
p70S6K (th421/ser424); rabbit monoclonal IgG (Upstate/Millipore). Primary 
monoclonal p70S6K, mTOR, phospho-mTOR (ser2448), phospho-mTOR (ser2481), 
raptor, rictor, AKT, phospho AKT (ser473), phospho-AKT (th308), p44/p42 ERK, 
phospho p44/p42 ERK, phospho-histone H3 (ser10), ß-actin (all rabbit monoclonal 
IgG; Cell Signaling Technology/New England Biolabs, Hichin, UK). Phospho-
specific antibodies were used at minimum dilution of 1:100 overnight at 4°C. 
Monoclonal mouse anti-Oct4,1:400 (Invitrogen). Secondary antibodies; AlexFluor 
488nm, 555nm, 597nm, 647nm; goat anti rabbit IgG or goat anti-mouse IgG used at 
manufacture recommended concentrations. 
 
2.9  Image capture and processing  
Wide-field microscopy was performed with a Nikon Eclipse TE-2000U fluorescence 
microscope with NIS Elements-BR™ capture software. Test samples were 
background corrected with secondary antibody and isotype specific controls except 
where specified. Confocal microscopy performed with Leica SP1-UV with LCS 
capture software. All post-processing and image analysis was undertaken with 
ImageJ (MacBiophotonics ImageJ package)  
  
56 
 
2.10 Live-cell imaging.  
Mouse ES cells were cultured into triplicate wells of a 6-well tissue culture plate 
(Iwaki) coated with 0.1% gelatin (Sigma-Aldrich).  Cells were seeded at a density of 
5x10
4 
cells/cm
2
 and placed into the incubated stage of the Cell-IQ™ automated 
image analysis platform with 5% CO2 at 37°C.. Phase contrast images were captured 
at 5 locations per well by an automated protocol with an enhanced depth of field 
function that ensured in-focus images were obtained. Image capture locations were 
manually specified by a grid matrix using the integrated image capture software.  
Images were captured sequentially over a period of 48h 
 
2.11 Flow cytometry 
All flow cytometry performed with a Guava-EasyCyte benchtop cytometer with 
EasyCyte Express™ (Guava.) or DAKO CyAN ADP, 3 laser analyser, (Beckman 
Coulter, High Wycombe, UK). Post-processing performed with Cytomation Summit 
v.4.3 (DAKO). Single cells were gated by their characteristic forward scatter (linear 
scale) and peak width profile. At least 10000 gated events were recorded on the FL-2 
channel with the voltage settings modified so that the primary peak fell within the 
specified range. Calibration performed daily using standard bead kits. Flow 
cytometry was not undertaken to quantify protein phosphorylation. Alternatively 
cellular distribution and sub-cellular localisation of phosphoproteins was 
documented by fluorescence and confocal microscopy relative to cell morphology 
and cytoskeletal protein expression. 
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2.12 Assessment of cell viability and proliferation 
Mouse ES cells were harvested by treatment with trypsin as described. Cells were 
liberated by gently tapping flasks on the stage of a phase contrast microscope. 
Trypsin was quenched with 10mls dPBS containing 10% FCS and centrifuged for 
5min at 300xG. Cell pellets were resuspended in 1ml dPBS containing 0.1% BSA 
(fractionV) (Sigma-Aldrich) and held on ice until analysis was complete. Cell counts 
were obtained manually by trypin blue exclusion with an Enhanced Neubauer™ 
haemocytometer by phase contrast microscopy. Automated analysis was performed 
using the Vi-Cell™ Cell Viability Analyzer (Beckman-Coulter). Cell suspensions 
were diluted 1:1 with 0.5ml dPBS for analysis.  
 
2.13 Assessment of apoptosis in mES cells.  
 Mouse E14 cells were cultured for 48h in complete growth medium supplemented 
with LIF (10
3
u/ml). At specified time-points cell cultures were washed with dPBS 
and supplied with fresh growth medium with or without LIF. Wells were then with 
1µl DMSO or small molecule inhibitors. The effect of mTORC1 kinase activity on 
apoptosis induction was determined by treatment with rapamycin (100nM) and 
mTORC1/mTORC2 kinase activity determined by treatment with the dual kinase 
inhibitor Ku-0063 (100nM).).To assess the effect of short-term inhibition cultures 
were washed after 45h and incubated for a further 3h with kinase inhibitors whereas 
for extended inhibition, cells were washed after 24h and incubated for a further 24h 
in growth medium containing inhibitors. After a total of 48h of incubation, all 
cultures were washed and cells harvested and processed for apoptosis assessment by 
flow cytometry or for viability assessment by trypin blue exclusion. All analysis was 
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performed within 1h of the end of the reaction. The percentages of viable, apoptotic 
and necrotic cells were assessed by immunostaining for cell membrane bound 
annexin IV and nuclear incorporation of the fluorescent dye 7-AAD. The 
percentages of viable cells (annexin negative, 7-AAD negative), early apoptotic cells 
(annexin positive, 7-AAD negative), late apoptotic cells (annexin positive, 7-AAD 
positive) and necrotic cells/nuclear debris (annexin negative, 7-AAD positive) were 
determined according to the standard protocol for apoptosis assessment using the 
Guava-Nexin™ kit.  
 
2.14 Hypothesis testing and statistical significance  
The assessment of differences between the mean values of data sets generated from 
biological assays was undertaken using standard statistical tests. Statistical 
significance was determined when the null hypothesis was rejected at an alpha level 
of p<0.05, differences between treatment groups in parametric data sets (normal 
frequency distribution) was determined by paired or unpaired t-test (Minitab 3.1 
statistical software). Differences between treatment groups in non-parametric data 
were assessed by the Mann-Whitney U test (Minitab 3.1). Multiple comparisons 
within single data sets were treated with post-hoc correction calculations for 
parametric or non-parametric data. The Pearson’s product moment correlation 
coefficient was used to identify statistical concordance between normally distributed 
data sets.  
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2.15 Determination of statistical significance in multivariate data sets. 
In certain biological assays, multivariate data was generated from a single data set. 
In order to limit the chance of generating type 1 errors resulting from multiple 
statistical comparisons within a single data set, post-hoc corrections were applied in 
accordance with the Bonferroni method for normally distributed data. Briefly, the 
alpha value (α) of p<0.05 was selected for determination of statistical significance. 
In order to correct for multiple testing, alpha was then divided by the number of 
independent statistical tests (n) performed within a single data set (α/n). 
Table 2.1 
Bonferroni adjustment for significance testing with multiple comparisons . 
number of tests 
(n) 
alpha level 
(α) 
alpha level 
(α) 
1 0.05 0.01 
2 0.0250 0.0050 
3 0.0167 0.0033 
4 0.0125 0.0025 
5 0.0102 0.0020 
6 0.0083 0.0017 
7 0.0071 0.0014 
8 0.0064 0.0013 
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2.16 Assessment of significance in multivariate data with multiple 
treatment groups.  
Multiple testing errors were negated by defining a primary outcome measure, 
hypothesis testing was then performed on the primary outcome data.  Additionally, 
within the same data sets, secondary outcome measures were defined and tested for 
significance. In some cases statistical significance was observed in the secondary 
outcome variables, these findings were classed as preliminary observations. In such 
cases, repeat experiments were performed and new primary outcome measures 
defined. Secondary outcome measures that were not subject to independent 
validation were defined as preliminary or exploratory. 
 
2.17 Biological replicates and n-values. 
Where stated, biological replicates are denoted by n=(value). In certain cases a single 
cell culture was split and assayed as parallel cultures/technical replicates, in such 
cases this is clearly stated in the figure legend and denoted by n=(value
tech
). 
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Chapter 3 
Introduction 
The experimental data presented in this chapter will primarily serve to detail the 
model system to be utilised throughout this investigation and secondly to assess the 
impact of inhibition of the mTOR pathway on the proliferation of pluripotent and 
multipotent cells in vitro. Additionally, substrates of the mTOR kinase will be 
assayed to define the experimental conditions for the manipulation of the mTOR 
pathway in later experiments. 
Three pluripotent cell types were assessed in preliminary experiments to define the 
culture system for further investigation. Human embryonic stem cells, human 
embryonal carcinoma cells and mouse embryonic stem cells were cultured and 
assayed for their sensitivity to rapamycin. The practicality of cell culture was also 
considered.  
3.1.  Characterisation of human embryonic stem cells in vitro. 
Preliminary experiments were undertaken to characterise the Shef3 line of human ES 
cells. These cells were a natural choice for further investigation as they have been 
used extensively in- house and are stable over extended passaging.  
Figure 3.1.1 displays the typical morphology of Shef3 colonies by phase contrast and 
fluorescence microscopy. These ES cells were manually dissected and seeded into 
tissue-culture flasks containing a low density monolayer of primary inactivated MEF 
feeder cells. After 3 days growth, cells were fixed and stained with primary 
monoclonal antibodies specific for OCT4 and Alexa Fluor-488 conjugated secondary 
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antibodies. Expression of OCT4 and nuclear counterstaining with DAPI was 
visualised by fluorescence microscopy with the corresponding excitation and 
emission filters. The typical morphology of these hES colonies can be observed (A) 
and is indicated by white triangles. Expression of OCT4 was associated with 
colonies containing densely packed cells (image C).   
To confirm that OCT4 was not expressed by the feeder cells, mouse embryonic 
fibroblasts were cultured alone and stained for OCT4 expression. No 
immunoreactivity was observed in MEF cells (Figure 3.1.2).  Data presented in 
Figure 3.1.3 confirmed that OCT immunoreactivity was restricted to densely packed 
cells within hES colonies (white triangles). Again, no staining for OCT4 was 
observed in individual feeder cells (yellow triangles).  
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Figure 3.1.1 
Human ES cell colonies exhibit distinct morphology and express OCT4.  
 
 
 
 
 
 
 
 
Fig. 3.1.1 
Morphology and expression of OCT4 in Shef3 human embryonic stem cell colonies. Human ES 
cells were cultured in vitro on a layer of inactivated mouse embryonic fibroblasts. Cells were 
fixed with PFA and OCT4 expression determined by staining with monoclonal primary and 
Alexa-488 conjugated secondary antibodies. Nuclear counterstaining was achieved by DAPI 
uptake. Cultures were visualised by phase-contrast and fluorescence microscopy with a Nikon-
Eclipse TE2000 microscope (4x magnification). Colony morphology and staining was visualised 
by phase-contrast (image A), DAPI fluorescence (image B), OCT4 fluorescence (image C). Image 
D represents a merged composite of the three channels. White triangles specify hES colonies. 
Representative images from 3 independent cultures.  
A          B 
 
 
 
C          D 
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Figure 3.1.2 
Mouse embryonic fibroblasts do not express OCT4.  
 
 
 
 
 
 
 
 
 
Fig 3.1.2 
Morphology and expression of OCT4 in inactivated mouse embryonic fibroblasts. Cells were 
fixed with PFA and OCT4 expression determined by staining with monoclonal primary and 
Alexa-488 conjugated secondary antibodies. Nuclear counterstaining was achieved by DAPI 
uptake. Cultures were visualised by phase-contrast and fluorescence microscopy with a Nikon-
Eclipse TE2000 microscope and Nikon Elements BR software. Images were captured at 10x 
magnification. Colony morphology and staining was visualised by phase-contrast (image A), 
DAPI fluorescence (image B), OCT4 fluorescence (image C). Image D represents a merged 
composite of the three channels. Representative images from 3 independent cultures.  
  
A          B 
 
 
 
C          D 
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Figure 3.1.3 
Expression of OCT4 in hES and MEF co-cultures. 
 
 
 
 
 
 
 
 
 
Fig.3.1.3 
Morphology and expression of OCT4 in Shef3 hES and MEF co-cultures by fluorescence 
microscopy. Images were captured at 10x magnification. Colony morphology and staining was 
visualised by phase-contrast (image A), DAPI fluorescence (image B), OCT4 fluorescence (image 
C). Image D represents a merged composite of the three channels. White triangles indicate 
OCT4+ve hES cells, yellow triangles specify OCT4-ve MEF cells. Representative images from 3 
independent cultures. 
 
  
A            B 
 
 
 
C            D 
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During the culture of hES cells, spontaneous differentiation often proceeds from the 
edge of the colony. Pluripotent marker expression is maintained within compact, 
high density areas in the centre. Cells within these compact areas are selected for 
sub-culture. These observations are made by visual inspection under by phase 
contrast microscopy. Therefore, the maintenance of pluripotency in these hES cells 
is supported by a subjective process at the passaging stage.  
 Figure 3.1.4.1 shows the relationship between the morphology of Shef3 colonies 
and OCT4 staining by phase-contrast and fluorescence microscopy. Three areas with 
distinct morphology can be observed in images A and B. White triangles indicate 
compact cells within the colony. The surrounding layer of less compact cells at the 
edge of the colony is indicated by red triangles (spread morphology) and the low 
density monolayer of feeder cells is indicated by yellow triangles (diffuse 
morphology).  
The mean fluorescence intensity of OCT4 in these defined areas is shown in Figure 
3.1.4.2. Areas of the images were selected using image analysis software, and the 
intensity of OCT4 staining was recorded. Areas containing cells with a compact 
morphology exhibited strong staining for OCT4. Cells with spread morphology 
exhibited reduced OCT4 staining and diffuse cells were devoid of OCT4 
immunoreactivity. Statistical analysis of the difference between OCT4 intensity in 
these groups was assessed by paired t-test. There was a significantly reduced level of 
OCT4 staining in the spread areas compared with compact areas (p=0.01) and 
diffuse areas (p<0.01). Additionally, OCT4 expression in the spread areas was 
significantly greater than in diffuse cell areas (p<0.05). 
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Figure 3.1.4.1 
Morphology and OCT4 expression in hES and MEF co-cultures. 
 
 
 
 
 
 
 
 
 
Fig. 3.1.4.1 
Morphology and expression of OCT4 in Shef3 hES and MEF co-cultures by fluorescence 
microscopy at 10x magnification. White triangles indicate dense, tightly packed cells within the 
colony (compact morphology). The surrounding layer of less compact cells at the edge of the 
colony is indicated by red triangles (spread morphology) and the low density monolayer of 
feeder cells indicated by yellow triangles (diffuse morphology). Representative images from 3 
independent cultures. 
 
  
A                 B 
 
 
 
C             D 
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Figure 3.1.4.2 
Mean fluorescence intensity of OCT4 in morphologically distinct cell areas.  
 
 
 
 
Fig. 3.1.4.2 
Mean fluorescence intensity of OCT4 from fluorescence micrographs. Human ES (Shef3) and 
MEF co-cultures were stained with OCT4-Alexa488 and DAPI. Morphologically distinct areas 
containing cells from four fields of view were sampled and the mean intensity of OCT4 
fluorescence was measured and presented in tabular form. Sampled areas were identified 
visually from phase-contrast micrographs and categorised as in Figure 3.1.4.1. Dense, tightly 
packed cells within the hES colony (i. compact morphology), areas of less compact cells at the 
edge of the colony (ii. spread morphology) and the low density monolayer of feeder cells (iii. 
diffuse morphology). Methodology and results of statistical analysis is described in the text.  
 
 
 
 
  
Colony morphology  Compact  Spread  Diffuse 
Mean fluorescence intensity (MFI) 25.15 9.75 6.15 
Standard deviation 5.24 2.41 3.44 
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Human ES cells were stained with OCT4 antibodies and DAPI after 4 days in 
culture. This was visualised by phase contrast and fluorescence microscopy (Figure 
3.1.5.i.). This figure shows that areas of high cell density indicated by bright DAPI 
staining (white triangles) exhibited high OCT4 expression whereas staining was 
lower in areas with low cell density (red triangle). The intensity of OCT4 expression 
was measured along a line drawn through the colony (Figure 3.1.5.ii.A). The 
intensity of OCT4 expression was high within areas containing a high density of 
cells (Figure 3.1.5.ii.B).  
To assess whether these differences arose from the increased density of cells or the 
elevated expression of OCT4 within individual cells; data was collected from two 
hES colonies (Colony 1, 2) (Figure 3.1.6.1.i).  Individual nuclei were selected from 
Colony 1 (n=50) and Colony 2 (n=100) and the mean intensity of OCT4 expression 
of each selected nucleus was measured (Figure 3.1.6.1.ii).  
The number of nuclei within 100µm
2
 of the selected nucleus were counted and 
plotted as a scatter graph of cell density versus nuclear OCT4 expression (Figure 
3.1.6.2). The Pearson’s correlation statistic was utilised to assess the relationship 
between local cell density and nuclear OCT4 expression in Colony 1 (i) and Colony 
2 (ii). There was no correlation between cell density and OCT4 expression in either 
colony.  
Scatter graphs of OCT4 expression and nuclear size were generated for both colonies 
assessed in the previous figure (Figure 3.1.6.3). No statistical concordance was 
observed in either Colony 1 (i) or Colony 2 (ii). These findings indicate that the high 
levels of OCT4 expression observed in compact cells did not correlate with the 
number of cells within the measured area or the size of sampled nuclei. 
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Figure 3.1.5 
Expression of OCT4 may relate to density of hES cells in a colony.  
i. 
 
 
 
 
 
 
ii. 
 
 
 
 
 
 
  
Fig. 3.1.5 
Human Shef3 ES cells were cultured 
for 96h and stained with DAPI and 
OCT4 antibodies (i). Micrographs of 
phase contrast (A), DAPI (B) and OCT4 
fluorescence (C) were merged to form 
a composite image (D). The intensity of 
OCT4 expression was measured across 
the colony (ii), along a line that crosses 
high density and low density areas (E). 
The mean fluorescence intensity of the 
line measurement is presented 
graphically (F). 
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Figure 3.1.6.1 
Relationship between OCT4 expression and cell density in single hES cells.  
i. 
 
 
 
 
 
 
 
ii. 
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Figure legend 
Fig. 3.1.6.1 
Human Shef3 ES cells were cultured for 48h and imaged by phase contrast (A) and 
fluorescence microscopy. Two colonies were selected; Colony1 is indicated by a white triangle 
and Colony 2 by a black triangle. Individual nuclei were selected (E) and a region of interest 
(ROI) was drawn around the nucleus (red triangle).  At least 50 nuclei were selected from each 
colony in a raster pattern and the nuclear OCT4 expression with each ROI was measured (F). 
Image analysis was performed using ImageJ analytical software. An area of 100µm
2
 was around 
each ROI and the number of nuclei within the area was counted and recorded by excluding 
nuclei at the edges on the right and lower sides. The size of each nuclear ROI was also 
recorded.  The images of OCT4 staining in hES colonies in this  figure kindly provided by Dae-
Kyeong Bae, Department of Biochemical Engineering, UCL. 
 
 
 
 
 
  
73 
 
Figure 3.1.6.2 
Relationship between OCT4 expression and cell density in hES colonies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
i. Colony 1 
ii. Colony 2 
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Figure 3.1.6.3 
Relationship between OCT4 expression and nuclear size in hES.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
i. Colony 1 
ii. Colony 2 
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Figure legends. 
Fig.3.1.6.2 
Data generated from Figure 3.1.6 presented as a scatter graph of mean OCT4 intensity within 
the selected nuclei versus the number of nuclei within 100µm
2
 of the selected cell. Data 
collected from 50 cells from Colony 1 (i) and 100 cells from Colony 2 (i i).  Statistical analysis 
was performed using the Pearson’s product moment correlation statistic to assess the 
relationship between OCT4 expression and cell density.  
 
Fig.3.1.6.3 
Data generated from Figure 3.1.6 was also presented as a scatter graph of mean nuclear OCT4 
intensity versus the area of the selected nucleus.  Individual nuclei were selected from 
micrographs by drawing a region of interest (ROI) from the DAPI channel using ImageJ .The 
mean intensity of OCT4 and area of DAPI staining were recorded for each ROI. Statistical 
analysis was performed using the Pearson’s product moment correlation statistic to assess 
concordance between nuclear OCT4 intensity and nuclear size.   
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The effect of the mTOR complex1 (TORC1) kinase inhibitor rapamycin on Shef3 
colony formation was assessed in a preliminary experiment. Figure 3.1.7 shows the 
effect of TORC1 inhibition on the number of hES colonies after 72h growth. The 
number of colonies was determined manually by counting under phase-contrast 
microscopy. Rapamycin treatment dramatically reduced the total number of colonies 
compared with DMSO treated controls. This preliminary experiment suggests that 
hES colony formation is rapamycin sensitive. 
In order to assess the impact of contaminating feeder material on the molecular 
analysis of protein expression in hES cultures, lysates of MEF and human ES cells 
co-cultured with MEFs. Lysates were also taken from a breast cancer cell line 
(MCF7) as a positive control. Proteins were separated by gel electrophoresis and 
probed with monoclonal antibodies for mTOR and p70S6K by western blotting. 
Figure 3.1.8 shows the expression of total mTOR protein and phospho-p70S6K in 
MEF cells, hES/MEF co-cultures and breast cancer cells. All three cell preparations 
exhibited immunopositive bands for both mTOR and phospho-p70S6K.  
Evaluation of mTOR pathway activation in hES would require an efficient 
purification step to remove contaminating material originating from the supporting 
feeder cells. The maintenance of pluirpotency in Shef3 cultures was at this time 
refractory to enzymatic passaging necessitating the mechanical dissociation of 
colonies under a dissecting microscope. Plating single cell suspensions of Shef3 hES 
was therefore not possible. This inability to precisely regulate colony size during 
mechanical dissociation was a major obstacle to quantifying cell seeding density and 
considered to be a major drawback to the use of Shef3 cells in this investigation.  
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Figure 3.1.7 
Effect of rapamycin on human embryonic stem cell colony formation. 
 
 
 
 
 
 
Fig.3.1.7 
Human embryonic stem cells were mechanically dissociated under a dissecting microscope and 
suspended in hES growth medium. Equal volumes of cell suspension were seeded into gelatin -
coated T25 flasks containing adherent MEF feeder cells. Cultures were treated with DMSO or 
rapamycin (20nM) and cultured under standard conditions for 72h. At the designated time -
point colonies were counted by phase-contrast microscopy. Preliminary data from a single 
experiment. 
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Figure 3.1.8 
Expression of mTOR and phospho-p70S6K in mouse embryonic fibroblasts, 
human embryonic stem cell co-cultures and human breast cancer cells. 
               
 
 
 
 
Fig.3.1.8 
Mouse embryonic fibroblasts (a), human embryonic stem cell co -cultures containing MEF cells 
(b) and human breast cancer cells BRCA2 (c) were lysed and equal quantity of protein were 
separated by gel electrophoresis and transferred onto PVDF membrane by western blotting. 
Levels of total mTOR protein and phosphorylated p70S6K were probed with primary anti-rabbit 
monoclonal antibodies and HRP-conjugated anti-mouse secondary antibodies visualised by ECL 
chemiluminescence detection. 
 
 
 
  
 
  A     B    C 
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3.2  Assessment of the effect of rapamycin on human embryonal 
carcinoma cell proliferation 
Embryonal carcinoma (EC) cells are pluripotent cells isolated from primary germ 
line tumours. The biology of mouse EC cells has been extensively studied since they 
were first identified in 1964 
9
 and propagated in vitro as permanent cell lines in the 
1970’s. Embryonal carcinoma cells share many similar properties with embryonic 
stem cells in that they are immortal and can be induced to differentiate into somatic 
cells of the three primary germ layers in vitro 
113,
 
114
. Human embryonic carcinoma 
cells (N-Tera2) can be grown in vitro without co-culture with feeder cells. Therefore 
the applicability of EC cells as a model system for this investigation was assessed.  
Figure 3.2.1 shows the effect of rapamycin treatment on EC cell proliferation over 
72h. Human N-Tera2 cells were seeded in triplicate into 6-well plates and cultured in 
a humidified atmosphere at 37°C containing 5% CO2. At each time point, cells were 
harvested by trypsinisation and manually counted in a haemocytometer by light 
microscopy. The proliferation of EC cells was inhibited by rapamycin treatment. 
Cell numbers were significantly reduced at all time points compared with DMSO 
treated control cultures and the inhibitory effect of rapamycin was exacerbated by 
prolonged treatment (72h).  
The utilisation of human EC cells as a model system for the investigation presented 
limitations. Practical concerns related to the passaging technique for expansion. Self-
renewal of N-Tera2 cells is refractory to repeated enzymatic treatment for 
propagation. Therefore, the long-term passage of EC cultures is achieved by 
mechanical dissociation of cell monolayers with sterile glass beads. This inability to 
plate N-Tera2 cells as suspensions of single cells presented complications in both 
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quantitative and qualitative assays. Seeding density could not be accurately 
controlled and mechanical dissociation resulted in variable colony size, the use of 
human EC cells for further study was discounted. 
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Figure 3.2.1 
Rapamycin mediated inhibits the proliferation of human embryonal carcinoma cells. 
Fig 3.2.1 
Human embryonic carcinoma cells (N-tera2) were seeded into 6-well plates and cultured for 
24, 48 or 72h under standard growth conditions. Cultures were treated with DMSO or 
rapamycin (20nM), fresh medium and inhibitor treatments were replaced daily. At the 
designated time-points cells were harvested by enzymatic detachment and counted by trypin 
blue exclusion in a haemocytometer counting chamber under light microscopy. Error bars 
represent standard deviation of the mean from three independent cultures (n=3). Statistical 
significance at an alpha level of p<0.01 (**) was assessed by students t -test.     
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3.3  The mTOR pathway in E14 mouse embryonic stem cells. 
The biology of mouse ES cells has been the subject of intense research since they 
were first isolated and cultured in vitro in 1981
1,2
. The use of mouse ES cells in this 
study offered practical advantages over both human ES and EC cells. Significant 
advances in the understanding of the nutritional and growth factor requirements of 
mES cells have enabled researchers to maintain the pluripotent phenotype in vitro 
indefinitely without the requirement for co-culture with feeder cells. Additionally 
mES cells will readily grow as monolayer colonies under certain conditions. Mouse 
ES cells have been adapted to enzymatic passaging and therefore can be seeded as 
single cells thus affording precise regulation of seeding density.  
The in vitro culture of mouse ES cells without co-culture with feeders was enabled 
by the discovery that supplementation with the cytokine leukaemia inhibitory factor 
(LIF) supported pluripotent self renewal. That human ES cells do not maintain 
pluripotency when supplemented with LIF suggests that the regulation of the 
pluripotency network exhibits key differences with the mouse system. It is now 
apparent that although both human and mouse ES cells share the same core 
components of the pluripotency network (OCT4, Nanog). Consequently, the 
extrapolation of data generated from mouse ES cells to the human system must be 
interpreted with caution.   
The typical morphology of mouse ES cells can be observed in the phase-contrast 
micrograph presented in Figure 3.3.1. Mouse E14 cells were imaged after 48h 
growth in complete growth medium containing LIF and serum. Under these 
conditions E14 cells form a densely packed monolayer colony. Individual cells are 
small and compact with a large nuclear to cytoplasmic ratio. During routine culture 
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the morphology and confluence of cells is monitored by visual inspection under 
phase-contrast illumination. Loss of the compact colony morphology observed in 
this image would be the first indicator of cellular differentiation arising from batch 
variations in growth medium components. 
The effect of rapamycin treatment on the proliferation of mouse embryonic stem 
cells (E14-TGA2) was assessed and shown in Figure 3.3.2. Incubation with 
rapamycin at a concentration of 10 or 100 nM resulted in a significant inhibition of 
total cell numbers after 24h. This observation was confirmed by treatment of mES 
cells for 48h with a serial dilution of rapamycin. In this assay, cell counts were 
performed with the Vi-Cell™ automated counting system. At the assay end-point, 
cells were harvested by trypsinisation, washed and then resuspended in dPBS 
containing 0.1% BSA. All analysis was performed within 1h. Figure 3.3.3 shows that 
rapamycin treatment significantly inhibited mES cell proliferation at all 
concentrations tested. Statistical differences were determined by parametric t-test. 
The concentration of 100 nM resulted in approximately 50% inhibition in total cell 
numbers after 48h. 
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Figure 3.3.1 
Typical morphology of E14 mouse embryonic stem cells in culture.  
 
 
 
 
 
 
 
 
 
 
Fig 3.3.1 
Typical morphology of mouse ES cells in vitro. Mouse E14-tga2 cells were cultured under 
standard culture conditions with complete growth medium (GMEM) containing 10% serum and 
10
3 
U/ml LIF. After 48h, cultures were imaged by phase-contrast microscopy at 10x 
magnification. Scale is represented by a red line (100µm). Mouse ES cells exhibit compact 
morphology and are densely packed within monolayer colonies.  
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Figure 3.3.2 
Treatment of mouse ES cells with rapamycin for 24h inhibits proliferation at 
high concentrations. 
 
Fig. 3.3.2 
Mouse embryonic stem cells (E14TGa2) were cultured in gelatin-coated T25 flasks with 
complete growth medium supplemented with 10
3
 U/ml LIF. After 24h, triplicate cultures were 
treated with DMSO or rapamycin at the designated concentration and incubated for a further 
24h. Cells were harvested and manually counted by trypin blue exclusion assay in 
haemocytometer counting chamber by phase contrast microscopy. Statistical differences from 
the DMSO treated control were determined by students T-test at an alpha level of p<0.05 (*) 
or p<0.01 (**), n=3.   
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Figure 3.3.3 
Rapamycin treatment for 48h inhibits mES cell proliferation in a dose -
dependent manner. 
 
 
 
 
 
 
Fig. 3.3.3 
Dose-dependent effect of rapamycin on mES cell proliferation. Single -cell suspensions of 
Mouse E14 tga2 cells were seeded into 6-well plates supplemented with complete growth 
medium containing 10
3
 U/ml LIF. After an initial seeding period, cells were treated with DMSO 
or rapamycin at the specified concentrations. Cells were harvested and counted by trypin 
exclusion with the Vi-Cell™ counting system. Data is presented as the mean and standard 
deviation of three independent experiments (n=3). Statistical significance was determined by 
t-test (p<0.05 *, p<0.01 **). 
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The effect of rapamycin treatment on OCT4 expression was assessed by flow 
cytometry. Figure 3.3.4.1 shows that 72h treatment with rapamycin had no effect the 
percentage of GFP positive cells at any concentrations tested. Cellular GFP is 
transcribed from the promoter region of the OCT4 gene in these cells, therefore, 
levels of GFP protein is related to the transcription of OCT4 mRNA. Consequently, 
the level cellular of GFP may not precisely correlate with OCT4 protein levels. 
Mouse E14 cells were incubated with rapamycin and OCT4 expression was also 
assessed by immunostaining. Figure 3.3.4.2.i also shows that concentration of 
rapamycin did not alter the percentage of OCT4+ve mES cells.  However, the mean 
intensity of cellular OCT4 expression increased in a dose-dependent manner. This is 
shown in Figure 3.3.4.2.ii.  
The effect of rapamycin of the size of mES cells was assessed by flow cytometry. It 
was observed that 48h treatment with rapamycin significantly reduced mES cell size 
in a dose-dependent manner. Analysis was performed by flow cytometry, 
measurements were taken from the forward scatter channel and data is expressed as 
the mean and standard deviation of cell size. Differences in mES cell size were 
assessed by parametric t-test at and significance determined at the alpha level of 
p<0.05 (*) and p<0.01 (**).  
Mouse E14 ES cells were selected for further investigation as the practicality of the 
culture system would afford greater precision and flexibility in the design and 
implementation of specific cellular and biochemical assays. Subsequently, mES cells 
were assayed for the levels and phosphorylation of mTOR and mTOR substrates 
under different culture conditions. 
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Figure 3.3.4.1 
Rapamycin treatment does not alter OCT4/GFP expression in mES cells.  
 
 
 
 
 
 
 
Fig 3.3.4.1 
Mouse ES cells (E14-OCT4/GFP) were cultured in complete growth medium supplemented with 
103u/ml LIF.  Cells were treated for 48h with DMSO or rapamycin at the specified 
concentrations. Expression of OCT4 GFP was determined by flow cytometry using the Guava 
EasyCyte™ system. Channel gating was determined with parent E14 control cells. Data is 
expressed as the percentage of OCT4/GFP cells in suspension from triplicate experiments 
(n=3). Statistical analysis by parametric t-test revealed no differences between treatment 
groups. 
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Figure 3.3.4.2 
Rapamycin increases the mean intensity of OCT4 expression in mES cells.  
 
Fig.3.3.4.2 
Flow cytometric analysis of OCT4 expression. Mouse E14 tga2 parental cells were cultured for 
48h with DMSO or increasing concentrations of rapamycin. Cells were harvested, fixed with 
PFA and permeabilised before staining with OCT4 monoclonal antibodies and alexa -488 
conjugated secondary antibodies. Percentage of OCT-4 +ve cells (i) and the mean intensity of 
OCT4 expression (ii) from triplicate cultures (n=3). Statistical analysis by paired-test (* p<0.05). 
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Figure 3.3.5   
Rapamycin reduces the size of mES cells under normal growth conditions. 
 
 
 
 
 
 
 
Fig 3.3.5 
Mouse ES cells (E14-Tg2a) were treated with DMSO or rapamycin at the specified 
concentrations for 48h. Cells were harvested by enzymatic detachment and re -suspended in 
1ml of dPBS containing 10% FCS. Triplicate cultures were analysed by flow cytometry and cell 
size determined from the linear forward scatter channel. Parametric t-test revealed statistical 
differences between DMSO and rapamycin treated cells  at a level of p<0.05(*) and p<0.01(*), 
(n=3). 
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3.4 The effect of rapamycin on TORC1substrate phosphorylation. 
This experiment was designed to assess the effect of rapamycin treatment on the 
levels of mTOR and the TORC1 substrate p70S6K in mES cell cultures.  Figures 
3.4.1.i and 3.4.1.ii show the effect of rapamycin treatment on total mTOR protein 
levels and TORC1 activity under normal culture conditions (lanes 1,2). Rapamycin 
treatment exerted no effect on total mTOR protein levels after 48h. The activity of 
the TORC1 kinase was assessed by levels of phosphorylation of p70S6K at the 
threonine-389 residue.  
Treatment with rapamycin for 48h inhibited the phosphorylation of p70S6K th389.  
The effect of medium supplementation and rapamycin treatment for 1h was also 
assessed after 48h of normal growth (lanes 3, 4). Supplementing cultures with fresh 
growth medium increased the phosphorylation of p70S6K and 1h rapamycin 
treatment inhibited this effect. Total levels of mTOR protein were unaffected. These 
findings confirm that in mES cells, rapamycin treatment inhibited the basal and 
induced phosphorylation of p70S6K. As rapamycin is known to be a specific 
inhibitor of the TORC1 complex it was inferred that the phosphorylation of p70S6K 
at th389 is mTOR dependent in mES cells and this phosphorylation is an effective 
read-out of TORC1 activity. 
 The mTOR complex 2 has been shown to directly phosphorylate the serine-473 
residue of the PI3K pathway protein AKT. Thus, the serine-473 phosphorylation of 
AKT is considered a reporter of TORC2 kinase activity. Figure 3.4.1.iii shows the 
effect of rapamycin treatment and medium supplementation on the phosphorylation 
of the AKT serine-473. Medium supplementation increased this phosphorylation 
independently of rapamycin treatment.   
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Figure 3.4.1 
Rapamycin inhibits the phosphorylation of the TORC1 substrate p70S6K. 
i.   
 
 
 
ii. 
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Figure Legend  
Fig.3.4.1 
Gel electrophoresis and western blot of mouse ES cell lysates probed for pan-mTOR (i) and 
phosphorylated p70S6K th389 (ii) with rabbit anti-mouse monoclonal antibodies and HRP-
conjugated anti-rabbit secondary antibodies. Immunoreactivity bands were visualised by 
enhanced chemiluminescence on x-ray sensitive film. Cells were cultured for 48h in complete 
growth medium containing DMSO or 100nM rapamycin (lanes 1,2) or 47h in complete growth 
medium followed by supplementation for 1h with fresh medium containing DMSO  or 100nMl  
rapamycin. Representative images from 2 independent experiments are displayed.  
 
 
 
 
 
 
 
 
 
 
 
  
94 
 
3.5.  The effect of rapamycin on TORC2 substrate phosphorylation. 
The relationship between the activity of the TORC1 and TORC2 kinases remains 
unclear. Reports indicate that inhibition of mTORC1 with rapamycin results in the 
compensatory phosphorylation of AKT at serine residue 473
72
. This implies that that 
the two TORC complexes may compete for free mTOR protein. However, extended 
rapamycin treatment does inhibit this serine-473 phosphorylation in some cell 
types
115,116
.  
To assess the effect of extended rapamycin treatment on AKT serine-473 
phosphorylation in mES cells, cultures were treated for 48h with medium containing 
or devoid of serum. At the designated time-point cells were harvested and protein 
lysates were separated by gel electrophoresis and subjected to immunoblotting for 
total mTOR protein and phospho-AKT ser473.  
Figure 3.5.1 shows the effect of rapamycin treatment on total mTOR protein levels 
and phospho-AKT ser473 in representative immunoblots. Quantification of band 
density was performed from triplicate data with the ImageJ gel analyser tool (Figure 
3.5.2). Optical density measurements of phospho-AKT levels were normalised with 
mean total-mTOR levels for each lane. Whereas rapamycin treatment marginally 
increased AKT ser473 phosphorylation (1-2 fold increase), this effect was 
exacerbated in serum-free conditions (3-4 fold increase). Thus, rapamycin treatment 
for 48h resulted in a dose-dependent increase in the phosphorylation of the TORC2 
substrate AKT ser473, an effect that is impaired by serum.  
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Figure 3.5.1 
The effect of rapamycin treatment on TORC2 kinase activity. 
i. 
 
 
 
 
ii. 
 
 
 
Fig.3.5.1 
Mouse ES cells were seeded into 6 well plates and cultured with complete growth medium 
containing LIF. After an initial attachment period, cultures were either starved of FCS (lanes 1 -
3) or supplemented with 10% FCS (lanes 4-6) for the duration of the incubation. Cells were 
treated with DMSO or rapamycin at a concentration of 10nM or 100nM. After 48h cells were 
harvested and lysed for protein extraction.  Proteins were separated by gel electrophoresis 
and specific protein bands identified by western blotting and immunostaining with monoclonal 
antibodies for pan-mTOR (A) or phospho-AKT ser473 (B). Representative immunoblots from 
three independent experiments are presented (n=3).  
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Figure 3.5.2 
Rapamycin treatment increases phospho-AKT ser473 during serum 
starvation and normal culture. 
i. Relative expression of total mTOR. 
 
 
 
 
 
 
ii. Relative expression of phospho-AKT ser 473. 
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Figure legend. 
Fig.3.5.2 
Immunopositive bands from triplicate blots were quantified with the ImageJ gel analyser tool 
and represented graphically as expression relative to DMSO control. Data is expressed as the 
mean and standard deviation from three independent experiments (n=3). The mean levels of 
total mTOR protein for each condition were utilised to normalise AKT serine473 levels. Data is 
presented as fold increase in optical density relative to the DMSO treated control.  
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3.6 Activation of the mTOR pathway during in vitro culture. 
The proliferation and pluripotency of mouse embryonic stem cells in vitro is 
maintained by regular passaging every 48h. Parental E14-Tg2a cells were grown on 
Iwaki brand tissue culture plastic with GMEM growth medium supplemented with 
10% FCS and 10
3 
u/ml LIF. It was observed that under these conditions regular 
passaging by enzymatic detachment maintained both cell expansion rate and colony 
morphology.  
It is not known what effect the passage cycle has on activity of the mTOR pathway. 
To explore this, mES cells were expanded in T-25 flasks under normal culture 
conditions for 48h and protein lysates were taken at specific time-points over 
following passage cycle (Fig 3.6). The first sample was taken prior to enzymatic 
detachment (A), remaining cultures were then detached and seeded into fresh 
gelatinised flasks and harvested after a further 2h (B), after 24h (C) and 48h. Protein 
was purified from cell lysates and equal quantities loaded into Tris-HCL gels and 
separated by electrophoresis. The total level of mTOR protein and phosphorylated 
mTOR ser2448, ser2481 or p70S6K th389 was determined by western blotting  
Figure 3.6 demonstrates that the total level of mTOR protein did not change over the 
course of the passage cycle (i). Phosphorylation of mTOR at serine 2448 (ii) and 
serine 2481 (iii) were also not altered by passaging. Levels of p70-S6K 
phosphorylation at th389 were low after 48h culture and directly before passaging 
(A). Phosphorylation of S6K then increased steadily at 2h (B), peaked at 24h (C) and 
then reduced by 48h (D). These findings demonstrate that the activity of mTORC1 
varies over the passage cycle.  
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3.7  The effect of rapamycin treatment on the PI3K and MAPK pathways. 
The mTOR pathway is closely integrated with PI3K signaling and AKT 
phosphorylation Figure 3.7 shows the impact of TORC1 inhibition on the 
phosphorylation of the th308 residue (T-loop) and the hydrophobic motif ser473 
(HM). PI3K mediated signalling at the cell membrane in response to growth factors 
such as LIF initiates the T-loop phosphorylation by PDK1. The HM phosphorylation 
is mediated by putative PDK2 enzymes such as TORC2. Data shown suggests that 
mTOR inhibition affects both AKT phosphorylation events.  Activation of the 
MAPK pathway is initiated by receptor tyrosine kinases at the cell membrane, 
culminating in the phosphorylation of extracellular signal-related kinase (ERK) 
proteins. The growth factor LIF is an agonist of ERK phosphorylation via this 
pathway. Figure 3.7 shows the impact of rapamycin treatment on ERK1/2 
phosphorylation from two independent cell culture experiments Rapamycin 
treatment induced the phosphorylation of both the p42 and p44 subunits of ERK1 
and ERK2 respectively (i). This effect was dependent upon the dose of rapamycin 
and was exacerbated by serum deprivation (ii). 
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Figure 3.6 
Levels of total and phosphorylated mTOR protein during in vitro culture . 
i. Total mTOR. 
 
 
 
ii. Phospho-mTOR ser 2448. 
 
 
 
iii. Phospho-mTOR ser2481. 
 
 
 
iv. Phospho-p70-S6K th389 
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Figure legend. 
Fig. 3.6 
The phosphorylation of mTOR pathway proteins in mouse E14 tga2 ES cells was assessed by 
western blotting over passage cycle. Cells were cultured in T25 flasks  for 48h and harvested for 
protein extraction (A), and 2h after enzymatic detachment (B), after 24h growth (lane C) and 
48h growth (D). Proteins were separated by gel electrophoresis; immunoblotting was 
performed to assess the levels of mTOR protein (i) and phosphorylation of mTOR a t serine 
2448 (ii), serine residue 2481 (iii) and p70S6K (iv) during the passaging cycle. Representative 
plots of 3 independent culture experiments (n=3). 
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Figure 3.7 
Rapamycin treatment increases ERK1/2 and reduces AKT th308 
phosphorylation in serum starved mES cells. 
i. 
 
 
 
ii. 
 
 
Fig.3.7 
Mouse ES cells were seeded into 6 well plates and cultured with complete growth medium 
containing 103 u/ml LIF. After an initial attachment period, cultures were either starved (i; 
lanes 1,2; ii; lanes 1-3 or supplemented with 10% FCS (lanes 4-6) for the duration of the 
incubation. Cells were treated with DMSO or rapamycin at a concentration of 10nM or 100nM. 
After 48h cells were harvested and lysed for protein extraction.  Proteins were separated by 
gel electrophoresis and specific protein bands identified by western blotting and 
immunostaining with monoclonal antibodies for AKT ser473 (i.a), AKT-th308 (i.b) or p42 ERK1 
or p44 ERK2 (i.c; ii). Representative immunoblots from three independent experiments are 
presented (n=3).  
serum    
rapamycin 
(100nM) 
    1     2       3      4      5     6 
       -      -       -      +    +     + 
       0     10   100   0   10  100 
p44 ERK2 
p42 ERK1 
 
     1       2      3      4       
103 
 
3.8 Summary of findings 
In this chapter, the practical applicability of the in vitro culture of three cell lines was 
assessed. The principle aim was to identify a suitable system to enable the 
investigation into the cellular distribution and localisation of mTOR pathway 
proteins. Human embryonic stem cells (hES), embryonal carcinoma cells (EC) and 
mouse ES cells (mES) were cultured according to established protocols and the 
limitations of each system was assessed. 
Human Shef3 embryonic stem cells were available within the laboratory. This cell 
line exhibited a stable phenotype over extended culture. Expansion and pluripotency 
of these cells was dependent upon co-culture with mitotically inactivated mouse 
embryonic fibroblasts. At the time of this investigation, these cells had not been 
adapted to culture without feeder cells and were refractory to enzymatic passaging. 
Consequently, sub-culture and expansion required manual passaging by mechanical 
microdissection. This method involved visual selection of stem cell colonies, which 
were then cut by hand under a dissection microscope. Suspensions containing 
irregular clumps of cells were then seeded into fresh culture flasks. Passaging by 
microdissection therefore does not control for variables such as colony size and so 
the seeding density of Shef3 hES cells could not be precisely regulated. Recently, 
Shef3 hES cells have been adapted to feeder-free culture with a combination of 
extracellular matrix proteins and a defined medium formulation
117
. However, this 
system was not available at the time of this study. Inactivated feeders secrete factors 
that support hES self-renewal
111
 but contamination of mEF derived growth factors in 
cell lysates from hES cultures was a concern as it may have obscured the molecular 
analysis of signal pathways.  
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It was noted that the pluripotency marker OCT4 was present in hES colonies, but not 
in feeder cells (MEF) alone or in co-culture with hES. Its expression related to 
colony morphology in that compact cells exhibited greater OCT4 expression than 
morphologically distinct spread cells present at the colony edges. This observation is 
consistent with expectations as OCT4 is central to the maintenance of the pluripotent 
phenotype
42,
 
119
, and the classical stem cell morphology is lost upon lineage-specific 
differentiation.  
In this study, the level of OCT4 staining in individual cells from hES colonies 
expressing OCT4. Expression of OCT4 in single cells did not correlate with local 
cell density or individual nuclear size. The morphology of hES colonies may serve as 
a preliminary indicator of pluripotency. This morphological assessment is widely 
used for the selection of colonies for sub-culture, thus, the maintenance of 
pluripotency during in vitro expansion is influenced by a subjective process during 
passaging. The relationship between spatial organisation of cells and pluripotent 
marker expression in mouse ES cells was studied by Zandstra et al
120
. It was found 
that mouse ES cells formed an autoregulatory niche whereby densely packed cells 
supported the maintenance of pluripotent marker expression independently of growth 
factor stimulation. Paracrine signalling from adjacent cells may also contribute to the 
maintenance of the stem cell phenotype.   
Although human embryonal carcinoma cells do not require co-culture with feeder 
cells, mechanical dissociation is necessary for sub-culture and expansion. This is 
performed by gently shaking sterile glass beads within the culture flask to detach the 
cells from the surface. This culture system has disadvantages as the sizes of 
individual clumps produced by this process cannot be regulated and mechanical 
detachment may damage the cells.  
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Another problem with EC cells arises from the heterogeneity in the differentiation 
capacity of clonal lines
9
. Human EC cells were documented to exhibit variability in 
their differentiation capacity
11
, and the N-Tera2 line investigated here, have been 
reported to exhibit restricted lineage specific differentiation in vitro
109
. Although 
these cells were found to be sensitive to mTOR inhibition, the analysis of embryonal 
carcinoma cells was not pursued further. 
The E14-Tga2 mES cell line proliferates rapidly in vitro and can be sub-cultured by 
enzymatic treatment. These cells were observed to form monolayers when cultured 
with growth medium supplemented with LIF and 10% serum and plated on Iwaki™ 
tissue culture plastic. Monolayer growth was a desirable characteristic as the 
homogeneous distribution of cells may restrict niche development and monolayer 
cells are useful for microscopic imaging. 
The current investigation documented that effect of rapamycin treatment exhibited a 
dose- and time- dependent inhibition of proliferation. Treatment with rapamycin for 
72h did not reduce OCT4-GFP levels. As this may have been due to the persistence 
of GFP in the cells after OCT4 levels had declined, levels of OCT4 were also 
assessed by immunostaining. It was found that rapamycin did not affect the number 
of OCT4 positive cells but did increase the mean fluorescence intensity of OCT4 
staining. In a report that showed concordance between OCT4 and GFP levels, it was 
noted that as the percentage of OCT4-positive cells increased, the standard deviation 
of the mean also increased
122
. This suggests that GFP is not an accurate indicator of 
OCT4 levels in pluripotent cells.  
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Treatment of mouse ES cells with rapamycin for 48h significantly reduced cell size. 
That rapamycin had this effect was anticipated as this has been demonstrated in other 
cell types
123
, and is consistent with the documented role of TORC1 in cell growth. 
Embryonic stem cells are typically characterised by their morphology as they are 
smaller than most somatic cells. Mouse ES cells also exhibit a large nuclear to 
cytoplasmic ratio and maintain a compact spherical morphology in dense colonies. 
These cells may therefore have less requirements for cell growth after each round of 
division than do many large somatic cells. It has been reported that the amount of 
total protein in mES cells increases upon differentiation
124
 as do mRNA transcript 
levels
125
. Cellular differentiation requires the expansion of the cytoplasmic 
compartment and production of new proteins that confers phenotype and function. It 
has previously been reported that rapamycin reduces the size of mES cells.  
When mES cells were stimulated with fresh growth medium containing LIF and 
serum, the phosphorylation of the TORC1 substrate p70S6K at the threonine 389 
residue increased. During normal culture, passaging and medium replacement is 
scheduled every 48h. By this time mTOR activation declined indicating that key 
nutrients or growth factors may be depleted. Given that TORC1 inhibition with 
rapamycin impaired the proliferation of mouse ES cells in this study and other 
published investigations
111
 it is possible that the expansion of mES cells may be 
enhanced by optimising mTOR activation. The conclusions drawn here are 
supported by the observation that the levels of phospho-S6K (th389) modulated over 
the course of the passage cycle. 
Medium supplementation also increased the phosphorylation of the mTORC2 
substrate AKT (ser473), an effect that was promoted by rapamycin and potentiated 
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by serum deprivation. The phosphorylation of ERK in response to rapamycin 
treatment was also potentiated by serum withdrawal. 
The primary aim of this aspect of the study was to characterise the pluripotent cell 
systems for further investigation of the mTOR pathway. The use of human ES cells 
was limited by their dependence upon co-culture with mouse embryonic fibroblasts. 
Furthermore, mechanical dissociation of cell clumps is required for sub-culture and 
expansion. The human ES cell line available at this time was refractory to enzymatic 
passaging and retained an inherent dependence on the stem cell niche to maintain 
self-renewal.  
Human embryonal carcinoma cells do not require co-culture to maintain their 
phenotype. They were found to be sensitive to the growth inhibitory effects of 
rapamycin, however, as they are also refractory to enzymatic passaging and require 
mechanical dissociation with glass beads for sub-culture. This process may damage 
cells and introduce undesirable variables into the system. Moreover, EC cells are by 
their nature cancer progenitor cells that exhibit a stem cell phenotype.  
The E14 line of mouse ES cells have been extensively characterised by others and 
exhibit three key features. They are pluripotent in nature, do not require co-culture 
with feeder cells and can be passaged by enzymatic dissociation and seeded as single 
cells. Preliminary experiments revealed that these mES cells were sensitive to the 
anti-proliferative effects of rapamycin. Treatment with rapamycin inhibited the 
phosphorylation of the TORC1 substrate and increased the phosphorylation of the 
TORC2 substrate AKT. These findings confirm that the basic regulation of the 
mTOR pathway in mES cells operates in a similar fashion to other mammalian cells.  
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The secondary aim of this chapter was to characterise the experimental conditions 
for the manipulation of the mTOR pathway in pluripotent cells in vitro. The use of 
rapamycin as an mTOR inhibitor in ES cells was confirmed and the effect 
concentration and incubation time on cell proliferation documented. It is clear from 
the data presented within this chapter that rapamycin is an effective inhibitor of ES 
cell proliferation in a concentration- and time-dependent manner. 
Additionally the activation of the mTOR pathway in mouse ES cells during the 
normal passage cycle was characterised. Results generated suggest that over the 48h 
passage cycle the activation of mTOR pathway is not uniform and exhibits maximal 
activation after 24h post-seeding and sub-maximal activation after 48h. Thus it is 
concluded that regular nutrient supplementation may be necessary to ensure that 
mTOR activity and consequently cellular proliferation is optimised. During the 
expansion of embryonic stem cells mTOR activation should be maintained to 
optimise cell expansion rate. 
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Chapter 4 
The principle objective of this chapter is to further characterise the mTOR pathway 
in mouse embryonic stem cells with an emphasis on the distribution and localisation 
of components and substrates of the two mTOR complexes, mTORC1 and 
mTORC2. Better understanding of the spatio-temporal regulation of the two mTOR 
complexes in ES cells may aid in selective targeting of the proliferative and cell 
growth-promoting effects of this pathway. This would be advantageous as 
pluripotent cells exhibit rapid proliferation with little requirement for cell growth 
whereas cell growth is increasing important for cell specification during 
differentiation. 
 
4.1 The cellular distribution of phosphorylated mTOR in mES cells.  
Mouse ES cells were cultured for 48h and then fixed, permeabilised and stained with 
monoclonal phosphospecific antibodies and AlexaFluor-conjugated secondary 
antibodies, nuclear counterstaining was visualised with DAPI. Analysis was 
performed by phase-contrast, fluorescence and confocal microscopy. Further details 
of the immunostaining and image capture protocols are documented in Experimental 
Methods.  
Figure 4.1.1 shows that mES cells expressed mTOR protein and distinct staining was 
observed in the nuclear compartment. Figure 4.1.2 shows that phospho-mTOR 
ser2448 was not uniformly distributed in these cells. Representative cropped images 
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are of single cells are presented in Figure 4.1.3. The level of phospho-mTOR in cells 
at interphase (i) appeared lower than during mitotic prophase (ii) and metaphase (iii).  
Similar analysis was performed to assess the distribution of the phospho- mTOR 
ser2481 (Figure 4.1.4). Staining was not uniform and some cells exhibited strong 
nuclear phosphorylation (red triangles). Cropped enlargements of individual cells 
highlight these staining patterns (Figure 4.1.5). Distinct phosphorylation patterns 
were observed in mitotic cells. Cropped enlargements of single cells at metaphase 
(iii; white triangles), anaphase (iv), and telophase (v). Phospho-mTOR ser2481 was 
localised to midbody of dividing cells (vi; red triangle). These observations show 
that the phosphorylation of mTOR protein is not uniformly distributed in mES cells 
in culture and phospho-mTOR ser2481 exhibits distinct patterning within cells at 
specific stages of mitosis.  
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Figure 4.1.1 
The cellular distribution of native mTOR in mES cells in vitro.  
 
 
  
Fig.4.1.1 
Representative micrographs of the 
cellular distribution of total mTOR 
protein. Merged composite (A) of 
DAPI (B) and pan-mTOR 
fluorescence (C) in mES cells under 
standard culture conditions. Mouse 
ES cells were cultured for 48h then 
fixed and permeabilised prior to 
staining with rabbit anti-mouse IgG 
monoclonal antibodies. Specific 
staining was visualised by anti-
rabbit Alexa-488 secondary 
antibodies by fluorescence 
microscopy. Non-specific staining 
was assessed with IgG isotype 
control antibodies (not shown). 
Representative images from at 
least 3 independent culture assays. 
(50µm scale bar) 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. total mTOR/alexa-488 
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Figure 4.1.2 
Cellular distribution of phospho-mTOR at serine residue 2448 in mES cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.1.2 
Representative micrographs of the 
cellular distribution of total mTOR 
protein in mES cells. Merged 
composite (A) of DAPI (B) and 
phospho-mTOR serine 2448 
fluorescence (C) in mES cells under 
standard culture conditions. Mouse 
ES cells were cultured for 48h then 
fixed and permeabilised prior to 
staining with rabbit anti-mouse IgG 
monoclonal antibodies. Specific 
staining was visualised by anti-rabbit 
Alexa-488 secondary antibodies by 
fluorescence microscopy. Non-
specific staining was assessed with 
IgG isotype control antibodies (not 
shown). Representative images from 
at least 3 independent culture 
assays. (50µm scale bar) 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. mTOR ser2448/alexa-488 
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Figure 4.1.3 
Mitotic phosphorylation of mTOR at serine 2448 in mES cells. 
 
 
Fig. 3.8.3 
Merged composite (A) of cropped images at 100% magnification from micrographs of fixed 
mES cells stained with DAPI (B) and anti-mTOR serine 2448 monoclonal antibodies(C). Cell 
cycle phase was determined by visual inspection of nuclear condensation from DAPI 
micrographs. Panels show cellular expression of phospho-mTOR at interphase (i), prophase (ii) 
and metaphase (iii). Representative images of single cells from micrographs from at least 3 
independent culture assays. 5µm scale bar. 
  
i. 
 
 
ii. 
 
iii. 
 
 
 
 
 
d) 
A. composite                 B. DAPI                    C. mTOR (2448) 
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Figure 4.1.4 
Non-uniform distribution of phospho-mTOR serine-2481 in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.8.2 
Representative micrographs of 
the cellular distribution of 
phospho-mTOR at ser2481. 
Merged composite (A) of DAPI 
(B) and mTOR ser2481 
fluorescence (C) in mES cells. 
Mouse ES cells were cultured 
for 48h and stained with rabbit 
anti-mouse IgG monoclonal 
antibodies. Specific staining 
was visualised by anti-rabbit 
Alexa-488 secondary antibodies 
imaging by fluorescence 
microscopy. Non-specific 
staining was assessed with IgG 
isotype control antibodies (not 
shown). Representative images 
from at least 3 independent 
culture assays. (50µm scale bar) 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. mTOR ser2481/alexa-488 
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Figure 4.1.5 
Nuclear localisation and mitotic phospho-mTOR serine-2481 in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. composite           B. DAPI        C. mTOR ser2481 i. 
 
ii. 
 
 
 
iii. 
 
iv. 
 
v. 
 
vi. 
 
 
 
A            B                      C 
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Figure legend. 
Fig. 4.1.5 
Cropped enlargements of single cells from micrographs of mES cells. Merged composite (A) of  
DAPI (B) and phospho-mTOR ser2481 (C). Distribution of mTOR ser2481 is not uniform in 
equivalent cells (i, ii). Intracellular localisation of phospho-mTOR at metaphase (iii, white 
triangle), anaphase (iv), telophase (v) and cytokinesis (vi, red triangle). Representative images 
of single cells from at least 3 independent culture assays. white line represents scale (50µm). 
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To document the cellular distribution and localisation of phospho-mTOR ser2481 in 
mES-derived cells during early differentiation, mES cells were cultured without LIF 
for 48h. Cultures were then fixed and stained with DAPI and phosphospecific 
antibodies. Withdrawal of LIF induces the spontaneous differentiation of mES cells 
but many cells retain their stem cell phenotype as paracrine signaling may support 
pluripotency. Therefore, compact colonies were present alongside spread, 
differentiated cells 
Figure 4.1.6 shows a representative micrograph of mES cells stained with phospho-
mTOR ser2481 monoclonal antibodies. Examination of this image revealed that 
compact colony morphology was retained in some areas (white triangle). Large cells 
with spread morphology were also present (red triangle). These morphologically 
distinct cells are identified by an increased cell area and reduced nuclear to 
cytoplasmic ratio. There were differences in the intracellular localisation of 
phospho-mTOR ser2481 in cells exhibiting this spread morphology with 
localisation at cell borders. This staining pattern is indicated by yellow triangles. 
Spread cells undergoing mitosis also exhibited increased staining for phospho-
mTOR, consistent with the observations made in compact mES cells. 
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Figure 4.1.6 
Localisation of phospho-mTOR serine 2481 in cells during early 
differentiation. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.6 
Representative micrographs of the cellular distribution of phospho-mTOR ser2481. Merged 
composite (A) of DAPI (B) and phospho-mTOR serine-2481 fluorescence (C) in mES-derived 
cells following LIF deprivation. Mouse ES cells were cultured for 48h then fixed and 
permeabilised prior to staining with rabbit anti-mouse IgG monoclonal antibodies. Specific 
staining was visualised by anti-rabbit Alexa-488 secondary antibodies by fluorescence 
microscopy. Non-specific staining was assessed with IgG isotype control antibodies (not 
shown). Representative images from at least 3 independent culture assays. (50 µm scale bar) 
Merged composite of DAPI (blue), mTOR ser2481 (green) 
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Figure 4.1.7 
Relationship between OCT4 staining and mTOR ser2481 in compact and 
spread mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. phase                     B. DAPI                          
 
 
 
C. mTOR ser2481/alexa-488          D. OCT4/alexa-555 
 
 
 
E. merged composite 
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Figure legend 
Fig.4.1.7 
Intracellular localisation of phospho-mTOR in OCT4 negative cells. Cell spreading was induced 
by 48h LIF deprivation and cells were stained with DAPI, phospho-mTOR ser2481 and OCT4 
monoclonal antibodies. Cultures were imaged by phase contrast (A) and fluorescence 
microscopy. Image panel shows DAPI (B), phospho-mTOR ser2481/Alexa-488 (C) and 
OCT4/alexa-555 (D) fluorescence. Merged composite of three fluorescence channels (E), white 
triangles indicate localisation of phospho-mTOR ser2481 at cell borders in OCT4-ve spread 
cells. 50µm scale bar. 
 
 
 
 
 
 
 
 
 
 
 
121 
 
Figure 4.1.8 
Phospho-mTOR ser2481 is present at the midbody of dividing cells.  
 
 
 
 
 
 
 
 
 
Fig.4.1.8 
Localisation of phospho-mTOR ser2481 at centrosomal and midbody regions of dividing cells. 
Cropped enlargements of single cells Representative images of merged composite (A) of DAPI 
(B) phospho-mTOR ser2481 (C) and OCT4 (D )in mES cells during differentiation. 
 
  
A. composite        B. DAPI                C. mTOR ser248    D. OCT4 i. 
 
 
ii. 
 
iii. 
 
iii. 
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4.2 The cellular distribution and localisation of phosphorylated p70S6K 
in mES cells. 
The ribosomal S6 protein regulates protein translation and is activated by 
phosphorylation by the S6 kinases. The phosphorylation of p70S6K is mediated by 
TORC1. The threonine-389, residue is the substrate for this kinase and the activity of 
p70S6K is closely correlated with this phosphorylation event
70
. Additional 
serine/threonine specific sites are present on p70S6K, including the threonine-421 
residue which is located within the autoinhibitory domain
126
. Other phosphorylation 
sites present on p70S6K were not investigated in this study. 
In the proceeding assays, the cellular distribution and localisation of total p70S6K, 
phospho-th389 and phospho-th421 were assessed in pluripotent mES cells after 48h 
in culture. This was achieved by fluorescence microscopy according to the protocols 
as described previously. The staining of total p70S6K protein is represented in 
Figure 4.2.1. Expression was ubiquitous and was present in nuclear and cytoplasmic 
compartments. Phospho-p70S6K th389 staining was also repeatedly observed in all 
cultures, representative image of this staining is shown in (Figure 4.2.2). Whereas 
distribution was uniform in mES colonies, high expression was observed in the 
nuclear compartment of individual cells. 
A different pattern was observed when cells were stained with phosphospecific 
antibodies to the threonine-421 residue of p70S6K (Figure 4.2.3). Expression of 
phospho-th421 was almost undetectable in most cells, however strong and distinct 
staining was observed in a small number. Individual cells exhibiting this staining 
pattern were examined to identify shared morphological features. Detailed inspection 
revealed that these cells exhibited nuclear condensation that was indicative of 
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mitosis. Individual cells were selected and cropped from composite micrographs to 
highlight the association with specific stages of mitosis (Figure 4.2.4). High 
expression was prevalent in all cells from prometaphase to anaphase. During 
cytokinesis, expression had reduced to basal levels, this can be seen in Figure 4.4.5. 
Strong staining for phospho-th421 can be seen in two cells during anaphase (red 
triangles) whereas the three cells at telophase/cytokines did not express phospho-
th421 (yellow triangles). Non-mitotic cells did not exhibit strong staining. In 
summary, p70S6K is phosphorylated at the threonine-412 residue during mitosis. 
This phosphorylation persists until late mitosis after which staining levels are 
reduced. 
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Figure 4.2.1 
Cellular distribution of total p70S6K protein in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2.1 
Representative micrographs of 
the cellular distribution total 
p70S6K. Merged composite (A) of 
DAPI (B) and total-p70S6K 
fluorescence (C) in mES cells 
under standard conditions. 
Mouse ES cells were cultured for 
48h then fixed and permeabilised 
prior to staining with rabbit anti-
mouse IgG monoclonal 
antibodies. Specific staining was 
visualised by anti-rabbit Alexa-
488 secondary antibodies by 
fluorescence microscopy. Non-
specific staining was assessed 
with IgG isotype control 
antibodies (not shown). 
Representative images from at 
least 3 independent culture 
assays n=3. (50µm scale bar) 
 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. total p70S6K/alexa-488 
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Figure 4.2.2 
Cellular distribution of phospho-p70S6K th389 in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. p70S6K th389/alexa-488 
Fig. 4.2.2 
Representative micrographs of 
the cellular distribution 
phospho-th389 p70S6K. 
Merged composite (A) of DAPI 
(B) and phsopho-th389 
fluorescence (C) in mES cells 
under standard conditions. 
Mouse ES cells were cultured 
for 48h then fixed and 
permeabilised prior to staining 
with rabbit anti-mouse IgG 
monoclonal antibodies. 
Specific staining was visualised 
by anti-rabbit Alexa-488 
secondary antibodies by 
fluorescence microscopy. Non-
specific staining was assessed 
with IgG isotype control 
antibodies (not shown). 
Representative images from at 
least 3 independent culture 
assays n=3. (50µm scale bar) 
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Figure 4.2.3 
Cellular distribution of phospho-p70S6K th421 in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2.3 
Representative micrographs of 
the cellular distribution 
phospho-th421 p70S6K. 
Merged composite (A) of DAPI 
(B) and phospho-th421 
fluorescence (C) in mES cells 
under standard conditions. 
Mouse ES cells were cultured 
for 48h then fixed and 
permeabilised prior to staining 
with rabbit anti-mouse IgG 
monoclonal antibodies. 
Specific staining was visualised 
by anti-rabbit Alexa-488 
secondary antibodies by 
fluorescence microscopy. Non-
specific staining was assessed 
with IgG isotype control 
antibodies (not shown). 
Representative images from at 
least 3 independent culture 
assays. (50µm scale bar) 
 
A. composite 
 
 
   
 
B. DAPI 
 
 
 
 
C. p70S6K th421/alexa-488 
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Figure 4.2.4 
Phosphorylation of p70S6K th421 during mES mitosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.2.4 
Cropped images of single mES cells during mitosis. Image panel A is a composite of DAPI (B) 
and p70S6K th421 fluorescence. A cell at early prophase (i) was identified by nuclear 
condensation. At early prophase nuclear condensation is apparent and phospho-th421 staining 
is increased (ii). Staining is distinct at prometaphase (iii) and metaphase (iv). At mitotic 
anaphase phsopho-p70S6K appears localised with DAPI staining (v). At the stage of cytokinesis 
strong staining is no longer observed. White line represents 10µm scale. 
i.        EARLY PROPHASE 
 
ii.        PROPHASE 
 
iii.        PROMETAPHASE 
 
iv.        METAPHASE 
 
v.        ANAPHASE 
 
vi.        CYTOKINESIS 
 
 
 
A. composite   B. DAPI C. th 421 
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Figure 4.2.5 
Phosphorylation p70S6K th421 is downregulated during late mitosis. 
 
4.3 AKT 473 phosphorylation  
intro paragraph here  
 
 
 
 
 
 
 
Fig.4.2.5 
Panel of images of p70S6K th421 phosphorylation in non-mitotic and mitotic mES cells. Merged 
composite (A) of DAPI (B) and p70S6K th421 fluorescence (C). Composite image D represents 
image A repeated and enlarged to highlight nuclear morphology. White triangle indicates a 
typical non-mitotic mES cells. Two cells at mitotic anaphase exhibiting strong p70S6K 
phosphorylation are indicated by red triangles and three cells at late telophase/cytokinesis are 
indicated by yellow triangles. White line represents 20 µm scale. 
 
A. composite           B. DAPI          C. p70S6K th421  
 
 
  
 D. Enlarged composite 
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4.3  The cellular distribution and localisation of the mTORC2 complex 
substrate AKT ser473 in mES cells. 
Protein kinase B (AKT) is a serine/threonine kinase that mediates an array of cellular 
processes including survival, proliferation, and motility. The activity and stability of 
AKT is regulated by specific phosphorylation events. It is widely accepted that the 
phosphorylation of the th308 residue is mediated by PDK1 at the cell membrane in 
response to insulin and growth factor stimilation
144
. The kinase responsible for the 
phosphorylation of the ser473 residue was termed the PDK2. A number of putative 
PDK2 candidates have been identified. Enzymes responsible for this 
phosphorylation include, the mTOR complex-2 (TORC2), the integrin linked kinase 
(ILK) and DNA-protein kinase (DNA-PK). In the previous chapter it was 
demonstrated that inhibition of TORC1 by rapamycin increases the phosphorylation 
of AKT ser473. This effect has been widely reported and may arise from a dynamic 
equilibrium between TORC1 and TORC2 activity.  
The cellular distribution of phospho-AKT ser473 in mES cells was documented by 
fluorescence microscopy. Mouse ES cells were cultured for 48h with complete 
growth medium, serum and LIF according to the previously established protocol. 
Cells were fixed with paraformaldehyde and ethanol and stained with 
phosphospecific antibodies. Images were captured and examined for the distribution 
and localisation of phospho-specific protein.   
Data presented in figure 4.3.1 shows the distribution of phospho-AKT (ser473) in 
mES cells. The distribution of phospho-AKT was not uniform in mES cells in 
culture.  The majority of cells did not express high levels of AKT (ser473), however 
strong staining was observed in some cells. Close examination of individual cells 
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exhibiting AKT phosphorylation revealed distinctive patterning (Figure 4.3.2).  
Cropped images of AKT (ser473) positive nuclei were presented as a composite 
image (A) of DAPI (B) and phospho-AKT fluorescence. Clear patterning of AKT 
phosphorylation can be observed in these images. 
To assess whether AKT (ser473) phosphorylation was associated with mitosis, 
mouse ES cells were cultured for 48h under standard conditions and stained for AKT 
(ser473) as described. Additionally, microtubules were visualised by 
immunostaining for α-tubulin and alexa-555 (red). Micrographs of DAPI, alexa-488 
and alexa-555 fluorescence were captured and merged into a composite image. 
Mitotic nuclei were identified by characteristic nuclear morphology and tubulin 
patterning. Individual cells were selected and cropped from these composite images 
(Figure 4.3.3) and displayed according to the stage of mitosis. AKT serine-473 
phosphorylation appeared to be strongly expressed from prometaphase (Image iii) 
until anaphase (Image v.).  The staining patterns observed in these representative 
images were observed repeatedly in independent culture assays.  
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Figure 4.3.1  
Non-uniform distribution of phospho-AKT (ser473) in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.3.1 
Mouse E14-Tga2 cultures were 
stained with DAPI and phospho-
AKT (ser473) monoclonal 
antibodies visualised with alexa-
488 secondary antibodies by 
fluorescence microscopy. Non-
uniform distribution of phospho-
AKT (ser47) can be observed in 
mES cells with colonies. Composite 
image (A) of DAPI fluorescence (B) 
overlayed with phospho-AKT 
(ser473) fluorescence (C). 
Representative images from at 
least three independent culture 
experiments. White line represents 
scale (100µm).  
 
A. composite   
 
 
 
 
 B. DAPI             
 
 
 
 
C. Phospho-AKT (ser473)/alexa-488 
 
 
  
 D. 
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Figure 4.3.2 
Nuclear localisation and patterned phosphorylation of AKT at serine -473 in 
mES cells. 
 
 
 
Fig.4.3.2 
Distinct patterning of phospho-AKT can be observed in cropped images of single mES nuclei 
from fluorescence micrographs. Composite images of DAPI fluorescence ( greyscale) overlayed 
with phospho-AKT ser473 fluorescence (green). Representative images from at least three 
independent culture experiments. White line represents scale (7.5µm).  
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Figure 4.3.3  
Phosphorylation of AKT at serine-473 during mitosis in mES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. composite           B. DAPI            C. α-tubulin         D. AKT (ser473) 
i.              INTERPHASE 
 
ii.            PROPHASE  
 
iii.            PROMETAPHSE 
 
iv.            METAPHASE 
 
v.            ANAPHASE 
 
vi.            TELOPHASE 
 
vii.             CYTOKINESIS 
 
134 
 
Figure legend 
Fig.4.3.3 
Mouse ES cells exhibit distinct AKT (ser473) phosphorylation during mitosis. mES cells were 
seeded in into 6 well plates and cultured for 48h in complete growth medium without LIF. 
Wells were washed and fixed as described in Experimental Methods. Samples were stained 
with monoclonal antibodies specific for mouse α-tubulin. rabbit anti–phospho-AKT ser473 or 
isotype control antibodies. Specific staining was visualized with anti -mouse alexa 488 and anti-
rabbit alexa 555 secondary antibodies, nuclear counterstaining with DAPI. Triplicate wells were 
imaged with 20x objective lens using a Nikon TE2000U fluorescence microscope with the 
corresponding filter blocks for UV, 488 nm and 555 nm excitation. Cropped images of 
composite and single channel fluorescence of single mES cells at different Stages of mitosis  
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In order to assess whether there was concordance between the strong nuclear AKT 
(ser473) staining and mitosis in mES cells, fluorescent micrographs of DAPI and 
tubulin staining were analysed. Numbers of total nuclei (DAPI) and mitotic nuclei 
(DAPI + α-tubulin) were counted and compared with AKT ser473 positive staining 
to generate data for significance testing. The results of this analysis are presented in 
Figure 4.3.4. It was found that there was a strong concordance between mitotic 
nuclei and AKT (ser473) positive nuclei that was statistically significant by the 
Fisher’s exact test. This statistic was selected in preference to the typical chi-square 
analysis as sample numbers within some of the groups were low.    
Mouse ES cells were deprived of LIF for 48h to allow cells to begin to differentiate. 
The justification for this was to assess AKT staining patterns in cells that had lost the 
typical compact morphology of pluripotent ES cells. Figure 4.3.5 shows that 
colonies of compact mES cells persist but are surrounded by areas of cells with a 
developed cytoskeleton, large nucleus and extensive cytoplasmic compartment. 
These cells are consistent with the ‘spread’ cells documented throughout this 
investigation. Mitotic cells were identified from three areas, the compact densely 
packed area (compact morphology), intermediate area (spread morphology adjacent 
to compact cells) and spread area. It was observed that AKT serine-473 
phosphorylation was maintained in these mitotic cells. 
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Figure 4.3.4 
Concordance between phospho-AKT (ser473) and mitosis in mES cells. 
 
 
 
 
 
Fig. 4.3.4 
Concordance between the number of mitotic cells and AKT (ser473) positive cells in mE S cell 
cultures. Fluorescence micrographs of mES cells stained with DAPI, α -tubulin and AKT (ser473). 
Total nuclei were counted from micrographs (10x magnification) of DAPI fluorescence (blue 
channel) and corresponding numbers of mitotic nuclei and AKT+ve nuclei were counted from 
the α-tubulin (red) and AKT (green) channels respectively. Data expressed as mean number of 
total nuclei in 4 fields of view from triplicate culture assays .The positive association between 
AKT (ser473) and mitosis was statistically relevant (p<0.001, Fisher’s exact test).  
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Figure 4.3.5 
Mitotic localisation of AKT (ser473) in mES cells with compact and 
compact and spread morphologies.  
 
 
 
 
 
 
 
 
 
 
 
 
  
i. 
 
 
 
 
 
 
 
 
ii. 
 
iii. 
 
iv 
A. composite          B. DAPI                C. α-tubulin        D. AKT (ser473) 
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Figure legend. 
Fig. 4.3.5 
The mitotic localisation of AKT ser473 in can be observed in compact and spread cells upon LIF 
deprivation. Mouse ES cells were seeded in into 6 well plates and cultured for 48h in complete 
growth medium without LIF. Wells were washed and fixed as described. Samples were stained 
with monoclonal antibodies specific for mouse α-tubulin, rabbit anti–phospho-AKT ser473 or 
isotype control antibodies. Specific staining was visualized with anti -mouse alexa-488 and anti-
rabbit alexa-555 secondary antibodies, nuclear counterstaining with DAPI. Triplicate wells 
were imaged with 20x objective lens using a Nikon TE2000U fluorescence microscope with the 
corresponding filter blocks for UV, 488nm and 555nm excitation. Ten fields of view were 
captured for each sample under identical exposure conditions. A representative fluores cence 
micrograph of the composite RGB image generated by merging the 3 fluorescence channels 
(image i). Cropped enlargements are presented as a merged composite image (A) and the 
corresponding greyscale images from the DAPI (B), α-tubulin (C) and phospho-AKT (C) 
channels. Mitotic cells were identified by the distinctive microtubular structures visualized by 
α-tubulin staining. A mitotic cell within the compact colony area (Image panel ii), a mitotic cel l 
at within the intermediated area (image pane iii) and a mitotic cell within the spread cell area 
(image panel iv) exhibit AKT ser473 phosphorylation. Representative image from two 
independent culture experiments (n=2). 
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4.4.  Colocalisation of AKT serine-473 with α-tubulin in mitotic mES cells. 
The assessment of colocalisation between proteins is performed by confocal 
microscopy. There are numerous methods for this type of analysis that are subject to 
drawbacks and limitations that have been widely discussed and reviewed in the 
literature
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. Interpretation of colocalisation data can be either qualitative or 
quantitative. A simple qualitative approach involves merging the colour channels of 
interest (e.g. red and green) and observing the areas of overlap (yellow pixels). 
Quantitative approaches require more complex statistical analysis of the relationship 
between pixel intensities at specific positions in the x, y and z-planes. Furthermore, 
background intensity levels must be normalised and correlation statistics generated 
from single slices of a z-stack. These methods are also prone to interpretation errors 
as thresholds are defined subjectively. At the image capture stage it is important to 
ensure that is no bleed-through of signal occurs between the channels of interest and 
that the z-planes of each frame are aligned.  
Colocalisation provides a description of the correlation of pixel intensities in the x, y 
and z-planes but it does not provide proof of a direct association between two 
proteins as the resolution limit of a standard confocal microscope is around 0.2µm.  
Therefore, in this study, a combined approach was undertaken. Firstly, confocal z-
stacks were capture at the maximum resolution possible and intensity level 
thresholding colocalisation analysis was performed. This is the presented visually as 
a merged image of the colour channels displaying colocalisation above the threshold 
at designated levels. Secondly, microtubular polymerising and depolymerising 
agents were used to disrupt microtubular organisation to assess the effect on the 
localisation and patterning of the molecule of interest, phospho-AKT (ser473). The 
techniques used in this study are detailed in Experimental Methods. Briefly, staining 
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for α-tubulin was visualised with anti-mouse, alexa-488 conjugated secondary 
antibodies and phospho-AKT (ser473) visualised with anti-rabbit, alexa-597 
conjugated antibodies. Nuclear counterstaining was performed with DAPI and 
images were captured ‘between-frames’ to ensure z-plane alignment. Isotype 
controls and single staining controls were performed; single-slice images were taken 
but not shown.  
Confocal microscopy and the ImageJ analytical software was utilised to assess the 
colocalisation between phospho-AKT (ser473) and mitotic microtubules in mouse 
ES cells. The proceeding figures demonstrate that phospho-AKT (ser473) is 
associated with α-tubulin during mitotic metaphase. Figure 4.4.1 shows that similar 
patterning of AKT and tubulin was observed when the image stack was combined 
into a sum-projection of the individual z-slices. This supports the hypothesis that 
there is a close association between the two proteins during mitosis.  
The assay was repeated and an image stack of a whole colony was captured. Figure 
4.4.2.1A shows that phospho-AKT (ser473) was restricted to the cells undergoing 
division as the majority of cells did not exhibit strong staining.  Image B is a cropped 
enlargement of a metaphase cell. This image represents a projection of the individual 
slices of the z-stack showing DAPI (blue), α-tubulin (green) and phospho-AKT 
(red). The areas of colocalisation where equivalent staining intensity was greater 
than the 85% threshold level are indicated by white pixels in image C. This figure is 
a sum projection of α-tubulin (green pixels) and AKT serine-473 (red pixels) with 
the colocalised points. The individual z-step slices of this projection are presented in 
Figure 4.4.2.2A. Enlargements of two individual slices of the metaphase cell 
showing colocalisation with intensity level thresholding at the 95% level are shown 
in Figure 4.4.2.2.B and 4.4.2.2.C. Examination of these images reveals that at the 
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highest level of threshold discrimination, colocalised points (white pixels) are in 
close proximity to kinetochore microtubules. Colocalisation is also seen during mES 
cell anaphase and telophase (Figure 4.4.2.3. Low levels of phospho-AKT (ser473) 
are seen during telophase; however, colocalisation can be observed at the polar 
microtubules between the dividing cells (Figure 4.4.2.3.C) 
Treatment of mouse ES cells with nocodazole impaired the association of phospho-
AKT (ser473) with α-tubulin in metaphase cells (Figure 4.4.3). Is was hypothesised 
that if phospho-AKT (ser473) was in direct association with microtubules during 
mitosis that treatment with the microtubule depolymerising agent nocodazole would 
impair the AKT patterning that was observed in mitotic cells. This was found to be 
true, a sum projection of z-stack cropped images of single cells at metaphase (B) and 
interphase (C) show that the organisation of α-tubulin is lost and cells do not exhibit 
a structured cytoskeleton. In the metaphase cell, the    distinctive AKT patterning is 
lost. The z-plane slices of these projections are presented in Figure 4.3.4.A 
(metaphase) and B (interphase).  
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Figure 4.4.1  
Distribution of AKT (ser473) and α-tubulin in a metaphase mES cell. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4.1 
Nuclear localisation of phospho-AKT (ser473) in mouse ES cell during metaphase. Mouse E14-
Tga2 cells were cultured for 48h in Iwaki™ tissue culture plates under standard growth 
conditions and fixed with PFA/EtOH as previously described. Cells were stained with DAPI and 
primary rabbit anti-mouse IgG monoclonal antibodies and fluorochrome-conjugated secondary 
antibodies. Composite image of DAPI, α-tubulin/alexa-488 and AKT phospho-ser473/alexa-597 
(image A). Single channel images of DAPI (B), tubulin (C) and AKT ser473 (D) are shown.  
Projection of sum slices from confocal microscopy image stack (63x objective, 2.81x zoom).    
 
A. composite             B. DAPI               
 
 
 
 C. α-tubulin                 D. AKT (ser473) 
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Figure 4.4.2.1 
Colocalisation of AKT (ser473) with α-tubulin in a metaphase mES cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. composite (DAPI/ α-tubulin/ AKT (ser473)    
 
 
 
 
 
 
 
B. composite enlargement   C. co-localisation (white pixels) 
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Figure legends 
Fig.4.4.2.1 
Sum projection of colocalisation of phospho-AKT (ser473) with α-tubulin in a metaphase mES 
cell. Composite image of DAPI, α-tubulin/alexa-488 and AKT phospho-ser473/alexa-597 (image 
A). Cropped enlargement of metaphase cell (image B) showing DAPI (blue), α-tubulin (green) 
and AKT ser473 (red). Colocalisation of tubulin (green) with AKT (red) (image C) at  threshold 
level of 85% indicated by white pixels. Projection of sum slices from confocal microscopy 
image stack, analysis performed with ImageJ colocalisation tool (63x objective, 2.81x zoom, 
resolution x/y= 216.9nm, z=625nm) 
 
Fig. 4.4.2.2 (overleaf) 
Co-localisation of AKT (ser473) with α-tubulin in cropped z-stack of image presented in Figure 
4.4.3.C. DAPI channel (blue) and α-tubulin (green) overlayed with white pixels representing co-
localisation at 85% threshold (image panel A). White triangle indicates point of colocalisation 
at kinetochore microtubules. Enlargement of individual z-plane slices showing colocalisation at 
95% threshold, images B and C.  Image series at 63x objective, 2.81x zoom.    
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Figure 4.4.2.2  
Co-localisation of AKT (ser473) with α-tubulin in a metaphase mES cell 
from confocal z-series image stack. 
 
 
 
 
 
 
 
  
A.     
 
 
 
 
 
 
B. image slice enlargement           C.  image slice enlargement  
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Figure 4.4.2.3 
Colocalisation of phospho-AKT (ser473) with α-tubulin in mES cells during 
mid and late mitosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A. Max projection of DAPI (blue), α-tubulin (green) , phospho-AKT (red) 
 
 
 
 
 
 
 
 
 
B. colocalised points (85%)         C. co-localised points (85%) 
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Fig. 4.4.2.3 
Maximum projection of mouse E14 ES cells stained with DAPI, α -tubulin/alexa-488, phospho-
AKT (ser473)/alexa-543 by confocal microscopy. Colocalisation of proteins by intensity level 
thresholding at 85% in cropped enlargements of a cell at anaphase (B) and cytokinesis (C). 
White pixels represent colocalised points at 85% threshold. Colocalisation determined in x/y 
plane single slices and displayed as maximum projections of the z-stack. Imaging undertaken 
with Leica SPE2 confocal with HCX APO 63x objective lens (0.9 NA), 2.81x zoom, resolution 
x/y= 216.9nm, z=625nm. DAPI excitation at 405nm; detector range 415-510nm Green 
fluorescence excitation at 488nm; detector range 500--560nm. Red fluorescence excitation at 
543nm; detector range 583-640nm. images captured with between frames, raster scan.  
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Figure 4.4.3.1 
Nocodazole treatment disrupts both tubulin and AKT (ser473) organisation 
in metaphase mES cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  mES colony   
 
 
 
 
 
 
 
B. metaphase                         C.  interphase  
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Figure 4.4.3.2 
Confocal z-stacks of individual mES cells treated with nocodazole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.metaphase   
 
B.interphase       
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Figure legends 
Fig.4.4.3.1 
Nocodazole treatment disrupts microtubular organisation and AKT (ser473) patterning at 
metaphase. Projection of sum slices from confocal microscopy z-stack of mES cells stained with 
DAPI (blue), α-tubulin (green), phospho-AKT serine-473 (red). Mouse ES cells were cultured for 
48h in complete growth medium containing 103u/ml LIF and 10% FCS and treated with 50nM 
nocodazole for 1h. Composite image of DAPI, α-tubulin/alexa-488 and phospho-AKT 
ser473/alexa-597 (image A). Cropped enlargement of a single cell at metaphase (image B). Co-
localisation of tubulin (green) with AKT (red) (image C) at the 85% level indicated by white 
pixels. Image analysis and colocalisation performed with ImageJ co-localisation tool (63x 
objective, 2.81x zoom; resolution x/y= 216.9nm, z=625nm) 
Fig.4.4.3.2 
Individual confocal slices of the z-stack presented in Fig.4.4.3.1 displaying a mES cell at 
interphase (image series A) and metaphase (image series B) following treatment with 
nocodazole. 
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4.5  Colocalisation of phospho-AKT (ser473) with α-tubulin in mouse 
embryonic fibroblasts.  
The association between phospho-AKT (ser473) and α-tubulin during mitosis was 
then investigated in MEF cells by confocal microscopy. Figure 4.5.1 shows a sum 
projection of a z-stack of a single metaphase MEF cell stained with DAPI and the 
two proteins of interest (A). It is clear from this image that both proteins are in close 
association. Colocalisation by the intensity thresholding method is shown in image 
B; white pixels represent coexpression of the two proteins above the 85% threshold. 
Quantitative colocalisation was inferred from the Pearson’s product moment and 
Mander’s correlation coefficients. Image C shows the PDM values (product of the 
differences between the means) for each pixel from a single z-slice image. The 
Pearson’s correlation statistic returned a value of 0.937 indicating that there is close 
concordance between the localisation and intensities of the two proteins. Mander’s 
correlation coefficeint values for AKT phospho-serine 473 show close concordance 
with green fluorescence (0.97) whereas coefficient for α-tubulin is lower (0.878). 
The implication of this finding is that phospho-AKT is associated with α-tubulin 
staining. However, α-tubulin staining is observed independently of phospho-AKT. 
This is indicated by white triangles in image B and image C. Negative PDM values 
(blue pixels) are seen at the location of astral microtubules during metaphase. 
Figure 4.5.2 shows the effect of short-term paclitaxel treatment on the organisation 
of phospho-AKT (ser473) in MEF cells. Image panels represent individual cells 
stained for DAPI, α-tubulin and phospho-AKT (ser473). Paclitaxel stabilises 
microtubules and disrupts spindle formation during polymerisation. This can be seen 
in panel D where abnormal spindle formation is observed in a single cell. Phospho-
AKT patterning is consistent with this abnormal spindle structure. This supports the 
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notion that phospho-AKT is physically associated with microtubules during mitosis 
in embryonic stage cells in the mouse. Phosphorylation patterns during anaphase and 
cytokinesis are consistent with observations made in mouse ES cells. 
4.6 Effect of mTOR inhibition on mitosis in mouse embryonic stem cells. 
In order to assess the effect of mTOR kinase inhibition on the percentages of mitotic 
cells in mES cultures, an immunostaining assay was developed to visualise mitotic 
cells by the expression of phospho-histone H3 (ser10). The relationship between H3 
phosphorylation and the stages of mitosis can be observed in Figure 4.6.1. Histone 
H3 phosphorylation is commonly used to generate mitotic index data as it is not 
phosphorylated during interphase. Sequential phosphorylation of histone H3 residues 
culminates in ser10 phosphorylation at early prophase. This phosphorylation is 
maintained throughout mitosis until late telophase when it is dephosphorylated by 
mitotic proteinases
146,147
. This can be seen in Figure 5.6.1, phospho H3 staining 
shown in red with α-tubulin (green) and nuclear DAPI staining (blue).  
Mouse ES cell cultures were treated with mTOR kinase inhibitors for 3h or 24h 
before fixation and staining for phospho-histone H3 and DAPI. Images were 
captured by fluorescence microscopy and total nuclei and phospho-H3 positive 
nuclei were counted. A mitotic index statistic was generated by dividing the number 
of H3 positive nuclei by the total number of DAPI nuclei.  The effect of mTORC1 
inhibition was determined by rapamycin treatment. Also investigated was the effect 
of the dual mTOR complex kinase inhibitor Ku-0063. The concentration of 
inhibitors was determined by the titration assays shown in Figures 3.3.3 and 6.3.1. 
Concentrations were selected that inhibited mES cell proliferation by 50% after 48h. 
Short-term treatment (3h) of mES cells with rapamycin or Ku-0063 had no effect on 
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the numbers of cells in mitosis; this can be seen in Figure 4.6.2.i. Treatment of mES 
cells for 24h with rapamycin significantly reduced the numbers of mitotic cells, and 
treatment with Ku-0063 resulted in a greater reduction in the mitotic index. These 
findings were statistically significant and are shown in Figure 4.6.2.ii. 
 
 
 
 
 
 
 
 
 
 
  
154 
 
Figure 4.5.1 
Co-localisation of AKT ser473 with α-tubulin in a proliferating mouse 
embryonic fibroblasts. 
 
 
 
 
 
 
 
 
 
 
Fig.4.5.1 
Mouse embryonic fibroblasts (MEF) were fixed and stained on glass coverslips for analysis by 
confocal microscopy as previously described. Single slice from z-series image stack. Composite 
image (A) of nuclear staining with DAPI (blue), α-tubulin/alexa-488 (green) and AKT 
ser473/alexa-597 (red) of a single metaphase MEF cell. Image B represents merged composite 
of α-tubulin (green), AKT ser473 (red) colocalised points at 85% threshold. Image C is a 
graphical representation of PDM values (Product of the Differences from the Mean = (red 
intensity-mean red intensity) × (green intensity - mean green intensity)). Pearson’s correlation 
value = 0.937. Mander’s correlation coefficient M1 = 0.97 (red); M2 = 0.878 (green).   
A.  composite image              B. co-localisation   
 
 
C. co-localisation correlation  
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Figure 4.5.2 
Short-term paclitaxel treatment does not impair the association of phospho-
AKT (ser473) with α-tubulin in MEF cells. 
 
 
 
 
 
 
 
 
 
 
 
 
  
A.  phase-contrast     B. composite   
 
 
 
C.i. composite   ii.  DAPI              iii. α-tubulin        iv. AKT(ser473) 
 
D. 
 
E. 
 
F. 
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Fig.4.5.2  
Proliferating mouse embryonic fibroblasts were treated with paclitaxel (5nM) for 4min then 
fixed and stained to generate composite fluorescence micrographs (image panel i) of DAPI (ii), 
α-tubulin/alexa-488 (iii) and AKT (ser473)/alexa-555 staining (iv). Selected cells from the 
phase-contrast image (A) and composite image (B) were identified according to cell cycle 
phase. Cropped images of cells at interphase (image panel C), prophase/metaphase (image 
panel D), anaphase (image pane E) and cytokinesis (image panel F) are displayed. The staining 
of AKT (ser 473) was maintained in paclitaxel treated MEF cells and was associated with 
mitosis. 
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Figure 4.6.1 
Assessment of mitotic index by phospho-histone H3(ser10) staining.  
 
 
 
 
 
 
 
 
 
 
 
Fig.4.6.1 
Mouse E14 Tga2 cells were cultured under standard growth conditions for 48h and fixed for 
immunostaining according to a pre-established protocol Cells were stained with DAPI and 
phospho-histone H3 (ser10) and imaged by fluorescence microscopy at 10x magnification. 
Individual cells at interphase (i) and successive stages of mitosis were identified by nuclear 
morphology and α-tubulin patterning. The corresponding expression of phospho-histone-H3 
was assessed at each stage of mitosis to enable the use of this antibody to generate mitotic 
index data from fluorescence micrographs.  
i        composite       DAPI            α-tubulin        H3(ser10)    INTERPHASE 
 
ii.       PROPHASE  
 
iii.       PROMETAPHSE 
 
iv.       METAPHASE 
 
v.       ANAPHASE 
 
vi.       TELOPHASE 
 
vii.        CYTOKINESIS 
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Figure 4.6.2 
Treatment of mES cells for 24h with TORC1 and TORC2 inhibitors reduces 
the number of cells in mitosis. 
 
 
 
 
 
 
Fig.4.6.2 
Mouse E14 Tga2 cells were cultured under standard growth conditions for 48h and fixed for 
immunostaining according to a pre-established protocol. Triplicate cultures (n=3) were treated 
with mTORC1 kinase inhibitor rapamycin (100nM) or the dual mTO RC1/mTORC2 kinase 
inhibitor Ku-0063 (5μM) for the final 24h or 3h of the assay. Cells were stained with DAPI and 
phospho-histone H3 (ser10) and imaged by fluorescence microscopy. Total numbers of DAPI 
nuclei and histone-H3+ve nuclei were counted from single channel micrographs from 5 fields 
of view at 10x magnification. Data presented as the mean percentage of histone -H3+ve nuclei 
(mitotic index) and standard deviation of the mean. Statistical  analysis by parametric t-test, 
alpha level of p<0.05 (*) or p<0.01 (**).  
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4.7 Summary of findings.  
The aims of this study were to document the cellular distribution and localisation of 
mTOR pathway phosphoproteins in mES cells. The methods used here involved the 
culture E14 cells under standard conditions that had been defined in the previous 
chapter. Immunostaining protocols were developed to enable the visualisation of 
phosphoproteins by fluorescence and confocal microscopy. 
It was shown that mTOR protein was present in both the nuclear and cytoplasmic 
compartments. Phosphorylated mTOR was not homogenously distributed or 
localised within mES cells. Phospho-mTOR serine-2448 was found to be 
upregulated in some cells. Upon examination it was noted that mitotic cells exhibited 
increased expression of this phosphospecific form of mTOR. Similar findings were 
documented with the phospho-serine (2481) specific mTOR as high expression was 
observed in the nuclei of some cells and mitotic cells exhibited enhanced staining. 
Examination of these mitotic cells revealed staining patterns that were consistent 
with localisation to the centrosome and spindle during metaphase. During late 
mitosis mTOR ser2481 was localised to the midbody between dividing cells. When 
mES cells were induced to differentiate, they acquired spread morphology and 
phospho-serine2481 was distributed at cell borders. This was not seen in compact 
cells that maintained stem cell marker expression. The localisation patterns of 
phosphospecific mTOR during mitosis were also observed in these spread cells.  
The cellular distribution of the TORC1 substrate S6K threonine-389 was 
homogenous throughout cells in mES cell colonies. However, staining patterns of a 
different phosphospecific residue of S6K (threonine-412) exhibited dramatic 
upregulation in some cells. These cells were observed to be in the mitotic phase of 
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the cell cycle as staining was increased in all cells at prophase and was evident until 
late anaphase. Cells at telophase or cytokinesis exhibited a marked downregulation 
of phospho-S6K th412.  
Findings revealed that the TORC2 substrate phospho-AKT serine-473 exhibited 
similar patterns of staining.  All cells exhibiting high AKT expression were found to 
be undergoing mitosis. It was noted that the pattern of staining was distinct at each 
stage of mitosis and appeared to localise with spindle microtubules. This association 
was confirmed by confocal microscopy as phospho-AKT colocalised with α-tubulin.  
Disruption of the microtubular network with nocodazole inhibited the AKT 
patterning in mitotic cells. This mitotic AKT localisation was maintained in early 
differentiated mES-derived cells that exhibited a spread morphology following LIF 
deprivation. Mouse embryonic fibroblasts also exhibited this expression pattern, 
colocalisation was maintained when the spindle organisation but not microtubular 
polymerisation was disrupted. Extended treatment with inhibitors of mTOR activity 
reduced the mitotic index of mES cells. This effect was observed following 
inhibition of TORC1 alone and was potentiated by dual inhibition of TORC1 and 
TORC2.  
In conclusion it was documented that mTOR proteins are phosphorylated during 
mitosis and exhibit discrete spatio-temporal localisation. During differentiation, mES 
cells acquired a spread morphology, in these cells mTOR proteins localised at cell 
borders. This suggests that the mTOR pathway may be regulated differently in 
compact, pluripotent cells compared with spread, differentiated cells. The 
implication of this finding is that pluripotent stem cells may exhibit discrete 
sensitivity to mTOR inhibition and this may enable selective targeting of ES cell 
proliferation in mixed cell preparations.  
161 
 
Chapter 5 
The principle aims of this chapter are to assess the impact of inhibition of the two 
mTOR complexes and related pathways on the proliferation and viability of mES 
cells during early differentiation. These experiments follow on from previous 
findings that show that mTOR pathway proteins may be differentially regulated in 
compact, pluripotent stem cells and spread, differentiated cells. Furthermore 
previous experimental finding indicate that components and substrates of the mTOR 
complex-2 are activated in spatio-temporal manner during cell division. The use of 
dual-TORC inhibitors in this part of the study will aim to dissect the mTORC1 and 
mTORC2 mediated effects and strengthen the hypothesis that the timely 
manipulation of the mTOR pathway in ES cells may provide a bioprocessing tool for 
industrial scale expansion and differentiation of stem cells. Data presented in this 
chapter will draw upon image analysis tools that have been developed for this study. 
Details of the development and validation of these image analysis tools are presented 
in Appendix 1. Pertinent to this series of experiments is the impact of mTOR 
inhibition during early differentiation. It is anticipated that development of image 
analysis tools will enable quantification of the expansion of morphologically distinct 
pluripotent (compact) and differentiated (spread) cells in mixed cell populations. 
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The mammalian TOR pathway in the proliferation and viability of mouse 
embryonic stem cells. 
Mammalian TOR sits at a nexus of signal transduction cascades that regulate cellular 
proliferation and survival. In mouse ES cells, LIF stimulation of the gp-130 receptor 
activates AKT via the PI3K pathway and promotes TORC1 activation. The TORC2 
kinase phosphorylates AKT serine-473, therefore the PI3K pathway interacts both 
up-stream and down-stream of mTOR. Comparing the inhibition of the PI3K 
pathway with mTORC1 inhibition alone and dual-TORC inhibition will serve to 
dissociate the mTOR complex specific effects from global pathway activation.  
5.1 Assessment of the effect of the PI3K inhibitor LY294002 on mES cell 
proliferation and viability. 
 The inhibitor LY294002 inhibits the PI3K mediated activation of AKT. The effect 
of LY294002 on the inhibition of mES cell proliferation was assessed. The working 
concentration range of inhibitor was determined by titration in the nanomolar 
(Fig.5.1.1) and micromolar ranges (Fig.5.1.2). These findings demonstrate that 
LY294002 exerts a dose-dependent inhibition of mES cell proliferation. The 
concentration of 10µM inhibited mES cell proliferation by approximately 50%. 
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Figure 5.1.1 
Dose-dependent effect of LY294002 on mES cell proliferation.  
 
 
 
 
 
 
Fig.5.1.1 
Dose-dependent effect of LY294002 on mES cell proliferation. Mouse ES cells were seeded into 
6 well plates and cultured for 48h with complete growth medium containing  10
3
 u/ml LIF and 
with a nanomolar concentration range of LY294002. At the designated time point, cells were 
harvested and counted by trypin blue exclusion assay using the Vi-Cell™ automated cell 
counter. Numbers of total cells and viable cells from a representative assay are presented.    
 
 
  
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
0 0.1 1 10 100 
ce
ll 
n
u
m
b
er
 (
1
0
5 /
cm
2 )
 
LY-293 concentration (nM) 
Total cells 
Viable cells 
164 
 
Figure 5.1.2 
Dose dependent effect of LY294002 on mES cell proliferation.  
 
Fig.5.1.2 
Dose-dependent effect of LY-290043 on mES cell proliferation. Mouse ES cells were seeded 
into 6 well plates and cultured for 48h with standard growth medium containing 10
3
u/ml LIF 
and treated with a micromolar concentration range of LY294002 inhibi tor. Control wells were 
treated with DMSO. At the designated time point, cells were harvested and counted by trypin 
blue exclusion assay using the Vi-Cell™ automated cell counter. Numbers of total cells from 
three independent culture assays are presented (n=3).   Statistical analysis by parametric t-test 
revealed significant differences at an alpha level of p<0.01 (**) and p<0.001( ᶲ).    
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5.2  Combined inhibition of mTOR complex 1 and the PI3K pathway on 
mES cell viability. 
This series of experiments were designed to assess the effect of combined inhibition 
of mTORC1 and PI3K activity on mES cell viability. Mouse E14 cells were seeded 
into 6-well plates and incubated for 48h in the presence of sub-optimal doses of 
rapamycin and LY294002 (10 nM rapamycin; 0.1µM LY294002) or combined 
treatment with both inhibitors at equivalent concentrations. Figure 5.2.1 shows the 
effect of single and combined inhibitor treatment on cell proliferation assessed by 
trypin-blue exclusion. Whereas treatment of mES cells with single inhibitors induced 
a marginal and non-significant inhibition of total cell numbers, the combined 
inhibitors produced a statistically significant reduction in cell numbers compared 
with the DMSO treated control and single inhibitors alone (p<0.01). This data 
demonstrates that the combined inhibition of mTORC1 and PI3K pathways 
synergistically inhibits mES cell proliferation. Treatment of mES cells with 
inhibitors alone or combined at low concentrations did not reduce mES cell viability 
(Figure 5.2.2). 
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Figure 5.2.1 
Comparison between the effects of rapamycin, LY-294003 and combined 
inhibition on mES cell proliferation. 
 
 
Fig. 5.2.1 
Mouse embryonic stem cells were seeded into 6-well plates allowed to attach for 2h in 
complete growth medium containing LIF. Wells were then treated with sub-optimal doses of 
rapamycin (10 nM) and LY294002 (0.1µM) for the duration of the experiment. At the 
designated time-point cells were harvested and manually counted by trypin blue exclusion.  
Data presented from three independent experiments (n=3) and statistical significance was 
determined by one-tailed t-test (p<0.01 **). 
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Figure 5.2.2 
Low dose rapamycin and LY294002 does not reduce mES cell viability. 
 
Fig. 5.2.2 
Mouse embryonic stem cells were seeded into 6-well plates allowed to attach for 2h in 
complete growth medium containing LIF. Wells were then treated with sub -optimal doses of 
rapamycin (10 nM) and LY294002 (0.1µM) for the duration of the experiment. At the 
designated time-point cells were harvested and viability assessed by trypin blue exclusion. 
Data presented from three independent experiments (n=3). 
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5.3 The effect of the dual mTOR kinase inhibitor Ku-0063 on mES cell 
proliferation. 
Rapamycin has great promise in cancer therapy as inhibitor of cellular proliferation. 
The efficacy of rapamycin treatments in vivo has not met the expectations of the in 
vitro studies. Consequently rapamycin analogues have been developed through drug 
screening programs in industry and academia. Recently, a number of dual TORC 
kinase inhibitors have been developed. One such inhibitor Ku-0063 has been shown 
to inhibit both TORC1 and TORC2 kinase activity without inhibiting 76 other 
kinases
134
. The effects of dual TORC kinase inhibitors have not been assessed on 
mouse embryonic stem cells. 
The effect of this inhibitor on mES cell proliferation was assessed in Figure 5.3.1. 
Mouse ES cells were treated for 48h at the specified concentrations. The numbers of 
total cells were assessed by an automated trypin blue exclusion assay. The highest 
concentration used in this assay resulted in crystalisation of the inhibitor and ablation 
of cell proliferation was observed. Treatment of mES cells with Ku-0063 for 48h 
significantly inhibited proliferation at all concentrations tested with the concentration 
of 3μM producing a 50% inhibition of cell numbers. 
. 
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Figure  5.3.1 
Dose-dependent effect of Ku-0063 treatment on mES cell proliferation.  
 
 
 
 
 
 
 
Fig 5.3.1 
Dose-dependent effect of Ku-0063 inhibitor on mES cell proliferation. Mouse ES cells were 
cultured for 48h with complete growth medium supplemented with 103u/ml LIF and 10% FCS 
and treated with DMSO or a 5-fold titration of Ku-0063. At the assay end-point cells were 
harvested and counted by trypin blue exclusion with the Vi-Cell™ automated cell counter. 
Mean and standard deviation of triplicate culture assays (n=3). Statistical differences by 
parametric t-test (p<0.05*, p<0.01**). Dose of 1000nm resulted in crystallisation of inhibitor. 
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5.4 The effect of mTOR and PI3K inhibitors on mES cell viabili ty. 
To assess the effect of mTOR and PI3K inhibitors on mES cell viability, cultures 
were treated with inhibitors at a concentration that were shown to produce a 50% 
inhibition in cell proliferation after 48h. Mouse ES cells were cultured with complete 
growth medium containing serum supplemented with or devoid of LIF and treated 
with the inhibitors for 48h before harvesting for viability assessment. Treatment of 
mES cells with these inhibitors did not affect viability in LIF stimulated growth 
medium (Figure 5.4.1). Similar effects were observed when inhibitors were applied 
in growth medium devoid of LIF (Fig 5.4.2)  
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Figure 5.4.1 
Inhibitors of the mTOR and PI3K pathways inhibit the proliferation but not 
viability of LIF stimulated mES cells.  
i. 
  
 
 
 
ii.  
 
 
 
 
 
Fig. 5.4.1 
Mouse E14 ES cells were cultured with complete growth medium supplemented with 10
3
u/ml 
LIF and 10% serum and treated for 48h with DMSO (1µl), rapamycin (100nM), Ku-0063 (3µM) 
or LY-294 for 48h. Cells were harvested and analysed by trypin b lue exclusion assay with the 
Vi-Cell™ automated cell counting system. Data presented as mean cell number (i) and viability 
(ii) from 3 parallel culture assays (n=3
tech
) Statistical analysis was performed by parametric t -
test adjusted for multiple comparisons p<0.016 (**).  
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Figure 5.4.2 
Inhibitors of the mTOR and PI3K pathways inhibit  the proliferation but not 
viability mES cells deprived of LIF. 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.2 
Mouse E14 ES cells were cultured with complete growth medium supplemented with 10
3
u/ml 
LIF and 10% serum and treated for 48h with DMSO (1µl), rapamycin (100nM), Ku-0063 (3µM) 
or LY-294002 for 48h. Cells were harvested and analysed by trypin blue exclusion assay with 
the Vi-Cell™ automated cell counting system. Data presented as mean cell number (i) and 
viability (ii) from 3 parallel culture assays (n=3
tech
). Differences were deemed significant at the 
alpha level of p<0.016 (**) adjusted for multiple comparisons. No significant differences in cell 
viability were observed.  
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Figure 5.4.3 
Inhibitors of the mTOR and PI3K pathways increase the numbers of 
detached mES cells when deprived of LIF.  
 
 
 
 
 
 
Fig. 5.4.3 
Mouse E14 ES cells were cultured with complete growth medium supplemented with 10
3
u/ml 
LIF and 10% serum and treated for 48h with DMSO (1µl), rapamycin (100nM), Ku-0063 (3µM) 
or LY-294 for 48h. Cells were harvested from spent medium and counted by automated trypin 
blue exclusion. The percentage of detached cell was calculated by dividing number of cells in 
suspension by the total number of adherent cells. Data presented as mean and stand ard error 
of three parallel cultures (n=3
tech
). Statistical analysis was performed by parametric t-test 
adjusted for multiple comparisons p<0.016 (**). LIF deprivation increased cell detachment, an 
effect that was exacerbated by inhibitor treatment.  
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5.5  The effect of serum deprivation on mES colony formation .   
This experiment was designed to assess the impact of mTOR inhibition on mES cell 
colony formation and integrity after 24h of serum deprivation. Cultures were imaged 
by phase contrast microscopy and assessed with the image analysis tool Method 2 
(see Appendix 1). Representative examples of the phase-contrast and results images 
are shown (Figure 5.5.1). 
Figure 5.5.2 shows that LIF supported colony expansion in serum deprived 
conditions as deprivation of LIF reduced the total cell area (p<0.01). Rapamycin 
inhibited colony expansion in serum deprived only in the presence of LIF. Viability 
was determined by dividing the non-viable cell area by the total area. It was 
observed that rapamycin but not Ku-0063 promoted viability during serum 
deprivation in the presence and absence of LIF (p<0.01)  
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Figure 5.5.1 
Representative phase contrast and results images of mES cells following 
serum deprivation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.5.1 
Mouse E14 Es cells were cultured in growth medium and starved of serum for 24h. Cells were 
either provided with 10
3
u/ml LIF or deprived of LIF and treated with the mTOR kinase 
inhibitors rapamycin (100nM) or Ku-0063 (3µM) for 24h before analysis. Data is presented as 
phase contrast images (A) and results images generated by Method 2 image analysis tool.   
A 
B 
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Figure 5.5.2 
Mouse ES cell colony expansion is impaired by LIF withdrawal during 
serum starvation. 
 
 
 
 
 
 
 
Fig.5.5.2 
Data generated by Method 2 shows that LIF withdrawal impairs mES colony expansion during 
serum deprivation. Mouse ES cells were cultured for 24h without serum and LIF or 
supplemented with 10
3
u/ml LIF. Total cell area was calculated from phase contrast 
micrographs. Data is expressed as the percentage of cell area relative to total measured area. 
Statistical differences were determined by parametric t-test adjusted for multiple comparisons 
(p<0.01). 
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Figure 5.5.3 
Rapamycin treatment promotes mES viability independently of LIF during 
serum starvation. 
 
 
 
 
 
 
Fig. 6.5.3 
Fig.5.5.3 
Data generated by Method 2 analysis shows that rapamycin treatment promotes viability 
independently of LIF during serum deprivation. Mouse ES cells were cultured for 24h without 
serum and LIF or supplemented with 10
3
u/ml LIF. Cell area and phase (viable, non-viable cell 
area) was calculated from phase contrast micrographs. Data is expressed as the ratio of viable 
cell area relative to the total cell area. Statistical differences assessed by parametric t-test 
(p<0.05; *) 
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5.6  The effect of mTOR inhibition on mES colony expansion during 
differentiation. 
Mouse ES cells were deprived of LIF for 96h to initiate differentiation. After 48h 
cells were detached and seeded into fresh flasks with growth medium containing or 
devoid of LIF. The mTOR inhibitors, rapamycin and Ku-0063 were applied for the 
final 48h of the assay. Total cell confluence and the percentage area containing 
compact and spread was assessed by the Method 2 image analysis technique. Figure 
5.6.1 shows that both inhibitors reduced the total cell area in medium LIF-
supplemented growth medium (p<0.01). Both inhibitors also reduced the area 
covered by compact cells but not spread cells (P<0.01). Similar findings were 
observed in LIF-deficient growth medium (Figure 5.6.2). Total confluence was 
decreased in each case and inhibitor treatment impaired the compact cell area but not 
the spread cell area (rapamycin p<0.01; Ku-0063 p<0.05); however, the effect of 
KU-0063 was not significant when the alpha level was reduced for multiple 
comparison errors to (α/number of tests). Representative images of the results 
returned from images of mES cells in LIF-deficient growth medium are shown in 
Figure 5.6.3. 
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Figure 5.6.1 
Mammalian TOR complex inhibitors reduce the expansion of cells with 
compact but not spread morphology. 
 
 
 
 
 
 
 
Fig.5.6.1 
Mouse ES cells (E14) were seeded into parallel T25 flasks and cultured for 48h in complete 
growth medium devoid of LIF. After seeding, cultures were treated with 1ul DMSO (control), 
100nM rapamycin or 3µM Ku-0063. Cells were then detached and seeded into 6-well plates at 
a density of 10
5
cells/cm
2
. Wells were treated with Inhibitors and growth medium containing 
10
3
u/ml LIF for a further 48h. After a total of 4 days in culture triplicate wells were imaged by 
phase contrast microscopy at 10x magnification (10x FOV)  
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Figure 5.6.2 
Mammalian TOR complexes inhibitors reduce the expansion of cells with 
compact but not spread morphology during differentiation.  
 
 
 
 
 
 
 
Fig.5.6.2 
Mouse ES cells (E14) were seeded into parallel T25 flasks and cultured for 48h in complete 
growth medium devoid of LIF. After seeding, cultures were treated with 1ul DMSO (control), 
100nM rapamycin or 3µM Ku-0063. Cells were then detached and seeded into 6-well plates at 
a density of 10
5
cells/cm
2
. Wells were treated with Inhibitors and growth medium containing 
10
3
u/ml LIF for a further 48h. After a total of 4 days in culture triplicate wells were imaged by 
phase contrast microscopy at 10x magnification (10x FOV)  
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Figure 5.6.3 
Representative phase contrast and results images from Method 2 analysis of 
expansion of compact and spread cells during differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.6.3 
Representative images of analysis of mES cell morphology after 4 days LIF deprivation. Phase 
contrast (A) and results images (B) by Method 2 analysis of compact cells (blue pixels) and 
spread cells (green pixels). Details of the validation of the MEthod 2 image analysis tool are 
documented in Appendix 1. 
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5.7 The effect of mTOR inhibition on mES cell apoptosis  
Inhibition of mTOR complex signalling has been shown to reduce the proliferation 
of many cell types. It was demonstrated that mouse ES cell proliferation was 
impaired by treatment with mTOR inhibitors rapamycin and Ku-0063. In some cell 
types rapamycin treatment has been observed to promote cell death
135
. In this study, 
a series of experiments was designed to test the effect of mTOR inhibitors on mES 
cell viability and apoptosis under different growth conditions.  
The assessment of apoptosis was undertaken using by flow cytometry using a 
commercially available apoptosis detection kit. Cells were harvested and processed 
for analysis within 1h. Apoptosis was determined by immunostaining for annexin IV 
and nuclear incorporation of the fluorescent dye 7-AAD using the Guava-Nexin™ 
kit. All analysis was performed with the Guava-EasyCyte™ flow cytometer. Details 
of the immunostaining protocol are found in Experimental Methods.  
To assess the effect of mTOR inhibition on apoptosis levels, mouse E14-Tga2 cells 
were cultured in 6-well tissue culture dishes with complete growth medium 
supplemented with LIF (10
3
 u/ml). After 45h, wells were washed to remove non-
viable cells and then treated with 1µl DMSO, 100nM rapamycin or 3µM Ku-0063.  
After 3h treatment, cells were harvested for analysis. 
The primary outcome measure for this assay was to determine whether rapamycin 
and Ku-0063 increased the levels of apoptosis in mES cells. Figure 5.7.1 shows that 
rapamycin did not have an effect on cell viability and did not modify the percentages 
of early and late apoptotic cells. However, treatment with Ku-0063 increased mES 
cell viability (DMSO = 79.2% +/- 1.4%; Ku-0063 = 84.5% +/- 0.9%; p = 0.01). This was 
complemented by a small reduction in the proportion of cells in late apoptosis (DMSO 
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= 13.5% +/- 1.0%; KU = 10.5% +/- 0.4%; p=0.01). Thus mTOR inhibitors do not appear to 
induce apoptosis in mES cells. Moreover, these findings suggest that Ku-0063 
treatment may increase viability under normal growth conditions. 
Leukaemia inhibitory factor (LIF) is known to activate cell survival pathways via 
activation of the PI3 kinase pathway and mitogenic pathways. Consequently the 
potential cytotoxic effects of the short-term application of mTOR inhibitors to mES 
cells may not seen when LIF is present. So to assess whether mTOR inhibition 
reduced the viability of E14 cells when LIF was absent the experiment was repeated 
without LIF supplementation. 
Figure 5.7.2 shows the effect of 3h inhibitor treatment on mES viability and 
apoptosis in LIF deficient growth medium. Once again treatment with rapamycin did 
not reduce viability. Furthermore there was a small reduction in the percentage of 
cells entering apoptosis with Ku-0063 treatment (DMSO = 4.1 +/- 0.9%; KU = 1.6 +/- 0.2%; 
p<0.01). These findings confirm that short-term application of mTOR inhibitors does 
not induce impair viability, conversely dual inhibition of the two mTOR complexes 
appears to promote survival. The absence of LIF did not the affect the viability 
response of mES cells to the dual kinase inhibitor Ku-0063. 
The effects of extended inhibition of the mTOR complex 1 with rapamycin and 
mTOR complexes 1 and 2 with Ku-0063on apoptosis was assessed in mES cells. 
Mouse E14 cultures were grown for 48h with complete growth medium without LIF 
or medium supplemented with 10
3
u/ml LIF. Inhibitors were added after 24h, 
thereafter cells were incubated for a further 24h until the experiment was halted at 
48h. Cultures were washed and adherent cells were collected for apoptosis 
assessment by flow cytometry.  
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Figure 5.7.1 
Short term treatment of pluripotent mES cells with mTOR inhibitors does not 
induce apoptosis. 
 
 
 
 
 
 
 
Fig.5.7.1  
Short-term treatment with mTOR inhibitors does not increase mES cell apoptosis. Mouse E14 
cells were treated for 3h with mTOR inhibitors rapamycin (100nM) or Ku -0063 (100nM) in the 
presence of LIF (103u/ml). The percentage of cells undergoing early and late apoptosis was 
assessed by flow cytometric assessment of 7-AAD incorporation and annexin V binding. Results 
presented from 3 experiments (n =3), statistical significance was determined by parametric t -
test, single asterix denotes significance at alpha level of p<0.05 (*).  Viability determined as the 
primary outcome measure in multiparameter apoptosis assays, other findings were designated 
as secondary outcome measures (Experimental methods 2.16).  
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Figure 5.7.2 
Short-term mTOR inhibition (3h) does not induce apoptosis in mES cells in 
LIF deficient growth medium. 
 
Fig.5.7.2 
Short-term treatment of mES cells with mTOR inhibitors does not induce apoptosis. 
Treatment of E14 mES cells with 100nM rapamycin or Ku-0063 for 3h had no effect 
on viability. Ku-0063 reduced the percentage of cells entering apoptosis. Statistical 
analysis was performed with the two-tailed unpaired t-test and significance was 
determined at α = 0.01 (*).  Data is presented as mean plus standard deviation from 3 
experiments (n=3). 
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Figure 5.7.3 shows the effect of 24h inhibition of mTOR on mES cell viability and 
apoptosis in LIF supplemented growth medium. Inhibition of the TORC1 kinase 
with rapamycin resulted in a significant increase in the proportion of viable cells 
relative to the DMSO treated control (p<0.05). Increased viability was associated 
with a decrease in the mean percentage of cells in early apoptosis. However, 
extended inhibition of TORC1 and TORC2 with Ku-0063 reduced viability (p<0.05) 
and increased levels of late apoptotic E14 cells after 24h.   
Figure 5.7.4 shows the impact of 24h treatment with mTOR inhibitors on mES cell 
viability and apoptosis in LIF deficient growth medium. It was found that rapamycin 
treatment increased mES cell viability (p<0.05), and reduced the percentage of cells 
in early apoptosis.  
The spent growth medium from the previous assay was collected and levels of 
apoptosis were assessed by flow cytometry. The primary outcome measure was 
defined as the effect of inhibitor treatment on the viability of detached cells in spent 
growth medium. A secondary outcome measure was defined as the impact of LIF on 
the mTOR mediated effect on inhibition on viability. 
Figure 5.7.5 shows the effect of mTOR inhibition on the viability and apoptosis of 
detached mES cells in LIF-deficient growth medium. Rapamycin treatment increased 
the viability of detached cells (DMSO = 27.9% +/- 9.2%; rapamycin = 71.3% +/- 14.8%; 
p=0.04). Treatment with Ku-0063 also increased the mean percentage of viable cells 
(Ku-0063 = 60.1% +/- 3.8%; p=0.04) and decreased the percentage of late apoptotic cells. 
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Figure 5.7.3 
Extended mTOR inhibition affects the viability and apoptosis of E14 mES 
cells cultured with LIF. 
 
 
 
 
 
 
 
Fig.5.7.3 
Treatment of mES cells with mTOR inhibitors for 24h under normal growth conditions. 
Rapamycin (100nM) and Ku-0063 (100nM) treatment generated significant alterations in the 
levels of viability and apoptosis of E14 cells. Data is presented as the mean and standard 
deviation of 3 parallel culture experiments (n=3
tech
).Statistical significance was determined by 
two-tailed t-test at α <0.05 (*) and p<0.01 (**). 
 
 
  
 
* 
* 
188 
 
Figure 5.7.4 
Extended mTOR inhibition affects the viability of E14 mES cells cultured in 
LIF deficient growth medium. 
 
 
 
 
 
 
 
Fig.5.7.4 
Treatment of mES cells with mTOR inhibitors for 24h under normal growth condition s. 
Rapamycin (100nM) and Ku-0063 (100nM) treatment generated significant alterations in the 
levels of viability and apoptosis of E14 cells. Data is presented as the mean and standard 
deviation of 3 parallel culture experiments (n=3
tech
).Statistical significance was determined by 
two-tailed t-test at α <0.05 (*) and p<0.01 (**).  
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Figure 5.7.5 
Inhibition of mTOR treatment increases the viability of detached cells in 
LIF-deficient growth medium. 
 
 
Fig.5.7.5 
Treatment of mES cells with mTOR inhibitors for 24h under normal growth conditions. 
Rapamycin (100nM) and Ku-0063 (100nM) treatment generated significant alterations in the 
levels of viability and apoptosis of E14 cells. Data is presented as the mean and standard 
deviation of 3 parallel culture experiments (n=3
tech
). Statistical significance was determined by 
two-tailed t-test at α <0.05 (*) and p<0.01 (**).  
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To assess the effect of mTOR inhibition on viability and apoptosis in differentiating 
mouse ES cells, cultures were deprived of LIF and expanded for 96h. Cells were pre-
treated for the first 48h (D0-D2) with DMSO (control), 100nM rapamycin or Ku-
0063 (5µM). Alternatively, cells were treated with mTOR inhibitors for 96h (D0-
D4).  After 48h, cultures were supplied with fresh growth medium and grown for a 
further 48hrs before harvesting for apoptosis analysis.   
The effect of long-term mTOR inhibition on the viability of differentiating mES cells 
is shown in Figure 5.7.6.  Rapamycin treatment reduced the percentage of viable 
cells, and increased the percentage of cells in early apoptosis; these findings were 
statistically significant by parametric t-test (p<0.05). Treatment of cultures with the 
dual TORC kinase inhibitor Ku-0063 resulted in a significant inhibition in cell 
viability and increased the percentage of cells in late apoptosis (p<0.01). These 
effects were not observed when cultures were pre-treated with inhibitors for the first 
48h. Therefore, extended inhibition of TORC1 kinase activity impaired the viability 
of differentiating mES cells. Furthermore, dual inhibition of TORC1 and TORC2 
exacerbates this effect and results in increased apoptosis.  
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Figure 5.7.6 
Treatment but not pretreatment of differentiating mES cells with mTOR 
kinase inhibitors reduces cell viability. 
i. 
 
 
 
 
 
 
ii. 
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Figure legend 
Fig, 5.7.6 
Treatment of differentiating mES cells for 96h with mTOR inhibitors reduces viability  and 
increases apoptosis. Mouse E14 cells were cultured for a total of 96h without LIF 
supplementation. Triplicate cultures (n=3) were pretreated for 48h or treated for 96h with the 
mTOR inhibitors rapamycin (100nM) or Ku-0063 (5µM). Assessment of apoptosis undertaken 
by flow cytometry after a total of 96h in culture; statistical differences determined by 
parametric t-test (p<0.05*; p<0.01**). 
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5.8 Summary of findings. 
The aim of this study was to assess effects of mTOR inhibitors on the expansion of 
and viability of mES cells during normal culture and spontaneous differentiation. 
Initially, the working concentration of the PI3K inhibitor LY294002 was established 
by a dose-response assay. Sub-optimal doses of rapamycin and LY294002 were 
applied to mES cells in culture. It was observed that single inhibitors alone did not 
reduce proliferation; however, combined treatment produced a synergistic inhibitory 
effect.  
Mouse ES cells were then treated with a concentration of inhibitors that generated a 
50% reduction in proliferation (Ic50). Rapamycin, Ku-0063 (dual TORC inhibitor) 
and LY294002 alone did not reduce viability either in the presence or absence of 
LIF. However, when LIF was absent, the percentage of detached cells in the spent 
medium increased. This effect was notable upon rapamycin treatment, greater with 
Ku-0063 treatment and was exacerbated with LY294002 treatment. These findings 
suggest that the activity of AKT may underlie the effects seen here as rapamycin, 
Ku-0063 and LY294002 are AKT inhibitors with increasing specificity. 
Serum deprivation impaired mES colony formation, this effect was more apparent 
upon LIF deprivation. Rapamycin treatment inhibited colony formation in LIF-
supplemented but not LIF-deprived conditions. Interestingly, rapamycin promoted 
viability in both treatment groups; this effect was not seen with Ku-0063 treatment. 
It can be deduced from this that TORC1 inhibition promotes the survival of serum-
starved mES cells whereas additional TORC2 inhibition negates the survival 
advantage of TORC1 inhibition. As mTOR is known to regulate autophagy, this 
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process may explain these observations as recycling intracellular proteins may 
provide a survival advantage in serum deprived conditions. 
Mouse ES cells were induced to differentiate by withdrawal of LIF for 48h, after 
passaging and re-plating, cells were then provided with mTOR inhibitors and growth 
medium containing or devoid of LIF for a further 48h. The effects of LIF and mTOR 
inhibitors on cell expansion were then assessed. The objective was to induce cell 
spreading upon early differentiation and then test the impact of mTOR inhibitors on 
the expansion of morphologically distinct cells. The image analysis tool, Method 2 
(see Appendix 1) was used to assess cell confluence and morphology. It was 
observed that both rapamycin and KU-0063 inhibited the expansion of compact but 
not spread cells in LIF-containing medium. In medium devoid of LIF similar effects 
were observed. This finding is key to the overarching hypothesis of this study, the 
implication of this data is that during early differentiation, inhibition of the mTOR 
pathway may selectively inhibit the expansion of pluripotent stem cells but not 
differentiated cells. Consequently it may be possible to achieve both a greater purity 
of differentiated cells and eliminate contaminating parent cells from mixed cell 
cultures. Interestingly these observed effects were independent of LIF stimulation 
and may therefore be applied to stem cells that are not dependent upon LIF to 
maintain pluripotency. 
The effects of mTOR inhibitors on viability and apoptosis were also assessed. Short 
term treatment did not mediate a biological effect. However extended treatment with 
rapamycin increased viability whereas extended Ku-0063 treatment impaired 
viability, similar effects were observed in both medium containing and devoid of 
LIF. Inhibition of the mTOR pathway increased the percentage of cells in suspension 
when cultures were deprived of LIF, interestingly the viability of these detached 
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cells was enhanced by rapamycin and Ku-0063. This supports the notion that 
inhibition of mTOR/PI3K signalling impairs cell attachment, an effect that is 
apparent when LIF stimulation of the PI3K pathway is removed and cells are 
allowed to differentiate. Putting these findings into the context of a bioprocess, it 
would be necessary to remove suspended cells by the addition of a washing step to 
ensure that viable pluripotent cells do not persist in the culture vessel. 
Extending the differentiation period to 4 days, it was observed that mTOR inhibition 
impaired cell viability whereas pre-treatment with inhibitors had no effect on 
viability. Rapamycin treatment mediated a significant effect and Ku-0063 treatment 
exacerbated the effect on cell viability.  
In conclusion, mTOR inhibition appears to promote the viability of pluripotent mES 
cells. When deprived of LIF, mES cells were prone to detach from the growth 
surface upon mTOR inhibition, as these detached cells were predominantly viable, 
apoptosis was not deemed to be responsible. This effect was enhanced by additional 
inhibition of TORC2 whereas LY294002 inhibition of the PI3K pathway further 
increased detachment. As differentiation proceeded during extended LIF deprivation, 
dual mTOR kinase inhibition but not TORC1 inhibition alone reduced viability. That 
these effects were observed when LIF was not present, it can be concluded that the 
activity and inhibition of AKT is likely to be a causal factor in this effect.  
Finally, during differentiation, mTOR inhibition impaired the expansion of cells with 
compact but not spread morphology. The implication of this finding is that targeting 
the mTOR pathway during early differentiation may be an effective intervention to 
improve the purity of differentiated cells and reduce the prevalence of pluripotent 
cells in cultures.  As the persistence of pluripotent cells in preparations for cellular 
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therapies may have serious safety implications, this intervention may be useful in the 
context of industrial production of ES cell based therapies. That mTOR inhibition 
also increases cell detachment and promotes the viability of these detached cells, an 
additional washing step must be incorporated to remove pluripotent cells from the 
culture vessels.  
In conclusion, mTOR inhibition during the early differentiation of embryonic stem 
cells may provide a bioprocessing advantage that both increases the purity of 
differentiated cells and removes potentially hazardous pluripotent cells from 
cultures. Further work will be necessary to find out if deprivation of branched-chain 
amino acids promotes similar effects to the inhibition of the mTOR pathway with 
small molecule inhibitors.  
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Chapter 6 
Discussion 
The primary objective of this study was to assess the principle that manipulation of 
the mTOR pathway during the expansion and differentiation of embryonic stem cells 
may provide a bioprocessing advantage that may be utilised at an industrial scale. 
The justification for this hypothesis stems from the fact that the mTOR pathway is 
central to the regulation of cell growth and proliferation, is highly conserved and is 
sensitive to the bioavailability of amino acids and glucose. Consequently the mTOR 
pathway may be modulated in a cost-effective manner by the provision and depletion 
of key nutrients. Pluripotent stem cells and somatic cells have different requirements 
regarding cell growth and proliferation, whereas embryonic stem cells proliferate 
rapidly and have little requirement for cell growth, differentiated somatic cells have 
a greater dependence upon cell growth and less requirement for proliferation. By 
targeting the mTOR pathway it may be possible to take advantage of these features 
for bioprocess improvements. However, the regulation of the mTOR pathway in ES 
cells is poorly understood. Consequently the experimental work presented in this 
study served to define the model system to be utlised, to characterise the mTOR 
pathway in the model system and finally to assess the effects of manipulating the 
mTOR pathway under different culture conditions. When this experimental data is 
taken together, conclusions are drawn to assess the validity of the central hypothesis. 
Furthermore, recommendations are made regarding the nature of intervention and 
caveats to mTOR modulation in the context of ES cell expansion and differentiation. 
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6.1  Preliminary observations. 
Preliminary observations indicated that during the routine culture of mES cells, 
mTOR complex 1 activity was not maximal after 48h. It was observed that growth 
medium supplementation potentiated the phosphorylation of p70S6K th389. The 
relative level of phospho-S6K was assayed throughout the course of the passage 
cycle and twenty four hours after seeding, phosphorylation of S6K was at the highest 
observed level. Levels of S6K phosphorylation were then observed to decline after 
48h. Interestingly, the pattern of S6K phosphorylation in mES cells over the 48h 
passage cycle was reflected in the growth rate curves presented in Appendix 1.2.2 
and Appendix 1.4.2. This data demonstrates that after 30-35 hrs in culture the rate of 
colony expansion declines. Therefore there is an association between mTORC1 
activity and colony expansion. This supports the notion that during the expansion of 
ES cells in vitro potentiating mTOR activation may provide a bioprocessing 
advantage. In this context, mTOR activity may be maintained by supplementing 
cultures with glucose and branched-chain amino acids. Whereas glucose will prevent 
mTOR deactivation via the AMPK-TSC complex in negative feedback loop, amino 
acids such as leucine act in a positive feedback system to promote mTOR activity. 
As both  glucose and leucine are relatively cheap to produce compared with 
recombinant proteins it is therefore recommended that in the context of industrial 
production of ES cells, levels should be maintained to prevent mTOR pathway 
deactivation. 
6.2 Subcellular localisation of mTOR phosphoproteins  
In order to further characterise the activation of the mTOR pathway in mES cells 
under standard culture conditions, the cellular distribution of phospho-mTOR 
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proteins were assessed by fluorescence microscopy. It has been documented that the 
cellular localisation of phospho-mTOR proteins is associated with the proliferative 
potential of cells. One such study documented a negative association between 
cytoplasmic localisation of mTOR and survival in gastric cancer patients
136
. In 
another study it was observed that both high levels of phospho-mTOR, and nuclear 
localisation were associated with tumour progression poor outcome in endometrial 
cancer
137
. Thus in the clinical context, mTOR activation and localisation is 
associated with neoplastic potential. It was not clear from these studies whether the 
differential activity and localisation of the two mTOR complexes related to the 
proliferation of cancerous cells or whether there was a relationship between discrete 
mTOR phosphorylation sites and proliferative potential. 
 In this study the total mTOR protein was stained and observed to reside in both 
nuclear and cytoplasmic compartments.  However it was documented that the 
distribution of phospho-mTOR at serine residue 2448 was not uniform in mES cells. 
It was observed that phospho-ser2448 was marginally increased in cells undergoing 
mitosis. This finding is supported by reports documenting an increase in the 
phosphorylation of the mTOR ser2448 residue during the M-phase in ovarian 
granulosa cells
138,139
. Thus there may indeed be a relationship between phospho-
specific mTOR localisation and proliferation. 
The immunostaining pattern of phospho-mTOR serine-2481 exhibited marked 
nuclear localisation in mouse ES cell, and distinct phosphorylation patterns were 
observed in cells undergoing mitosis. The mitotic phosphorylation of mTOR at 
serine 2481 has been previously reported
140,
 
149
. In the first study by Vasquez-Martin 
et al in 2009, the intracellular localisation of phospho-mTOR ser2481 was 
documented in cancer cells. It was observed that some interphase cells exhibited 
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punctate nuclear localisation and this was associated with proliferative capacity. As 
mitosis progressed through telophase, mTOR was localised at the midzone and 
midbody regions. Vasquez-Martin et al also reported that during late mitosis mTOR 
ser2481 formed a ring-like structure surrounded by microtubular bundles. They 
concluded that phospho-specific mTOR may be involved in the completion of 
mitosis, this hypothesis had not been previously considered.  
A second study by the same group concurred with these findings, similar localisation 
patterns were observed in dividing cells in breast cancer tissue biopsies. It was also 
noted that phospho-mTOR ser2481 was an accurate marker of mitotic cells. 
However this technique appeared to identify mitotic cells from prophase until late 
anaphase. The localisation of mTOR phosphoprotein in dividing breast cancer cells 
revealed a close association with condensed chromatin in prophase, localisation with 
the mitotic spindle at anaphase and the midbody and intercellular bridge during 
telophase and cytokinesis. These published observations support the findings of this 
study where very similar if not identical expression patterns were documented. 
It was observed in this investigation that there was an accumulation of phospho-
mTOR ser2481 at the spindle pole in dividing mES cells. However, this association 
was not confirmed by co-staining for microtubular or centrosomal proteins. The 
pattern of phosphoprotein activation observed in prophase and prometaphase can 
also be seen with related phosphoproteins. In one such study by Vasquez-Martin, 
phospho-AMPK was shown to exhibit identical staining patterns to that seen here 
with mTOR ser2481
150
. Phospho-AMPK was colocalised with α-tubulin and 
significantly, centrosomal γ-tubulin. These localisation patterns were confirmed by 
co-staining for Aurora-A, a mitosis marker and a member of the chromosomal 
passenger complex
151
. Phosphoproteins within this complex have a role in the 
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stabilisation of microtubules during spindle assembly, chromosome alignment and 
the completion of cytokinesis
152, 153
.  
Data presented in this study shows that mitotic phosphorylation of mTOR ser2481 
was present in differentiated mES cells that exhibited a spread morphology. In these 
cells, phospho-mTOR ser2481 was distributed at the borders between adjacent cells. 
It was not clear if mTOR ser2481 was also localised at the cell membrane in ES cells 
with compact morphology. There is strong evidence to support the notion that 
mTOR activity occurs at lipid membranes
146
. It was reported that mTOR is 
membrane anchored, however active mTOR complexes are predominantly found at 
endomembranes. This is supported by the finding that the activity of Rheb, the 
upstream regulator of mTORC1 complex is localised at these endomembranes
147
.  In 
yeast, it was reported that both TORC1 and TORC2 were associated with detergent 
resistant membrane fractions that were independent of lipid rafts. Proteins isolated 
from these preparations were associated with the plasma membrane, endocytic 
processes and the actin cytoskeleton.   
Here, mouse ES cells exhibited uniform distribution of both total and phospho-th389 
p70S6K. However, phsopho-th421 S6K was upregulated in a small percentage of 
cells. Upon examination of these images, it was apparent that the strong staining was 
restricted to cells in mitosis. This upregulation began at prophase and was 
maintained until late telophase. Cells undergoing cytokinesis did not exhibit high 
staining for this phosphoprotein.  
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Interestingly, similar findings were reported by Schmidt et al in 2007 
148
. Phospho-
th421 S6K was visualised in cells from rat kidney sections. They observed an 
increase in phospho-th421 expression at early prophase that persisted throughout 
mitosis. In that investigation, localisation at specific intracellular organelles or 
structures was not observed. Findings presented here, showed high expression in 
mitotic mES cells, but not the distinct patterning seen with mTOR phosphoproteins. 
Prior to this work, it was documented that phospho-ser421 was associated with 
mitosis in HeLa cells
149
. Phosphorylation of this S6K residue was correlated with the 
activity of the cell cycle regulatory protein cdc-2. Interestingly, p70S6K proteins that 
were phosphorylated at residues within the autoregualtory domain (eg: th421) were 
all elevated during mitosis. Interestingly, the converse was true for the th389 
phosphorylation site. It was found that th389 phosphorylation was lost during 
mitosis. Furthermore, in cells arrested by nocodazole treatment, the kinase activity of 
S6K was absent. Thus, Shah et al demonstrated that the functional activity of S6K is 
lost during mitosis, an effect that is associated with increased phosphorylation of 
th421 and reduced phosphorylation of th389. They postulated that regulation of S6K 
activity differs in mitosis than in mitogen or nutrient stimulated cells.  
In support of this hypothesis, Le et al demonstrated that paclitaxel treatment induced 
the upregulation of th421 phosphorylation and the concurrent inhibition of S6K 
activity
159
. Paclitaxel inhibits microtubule depolymerisation and arrests the cell cycle 
at G2/M when tubulin polymerisation is necessary to form the mitotic spindle. It was 
observed that the paclitaxel mediated phosphorylation of th421 was impaired by an 
inhibition of the ACG kinase protein kinase-C (PKC) or the MAPK enzyme ERK. 
The mitotic phosphorylation of th421 may also be dependent upon other kinases that 
are active specifically during mitosis. Importantly, it was observed that paclitaxel 
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treatment did not induce th389 phosphorylation and p70S6K activity was inhibited 
during mitosis.  
The TORC2 kinase is known to directly phosphorylate AKT at serine residue 473 
77
. 
In mES cells, evidence shown here demonstrated that the intracellular localisation of 
AKT ser473 was restricted to mitosis. In these cells, AKT ser473 exhibited distinct 
patterning. Co-staining between α-tubulin and AKT ser473 was undertaken to 
determine if this patterning was associated with the microtubular network. This was 
found to be true and AKT expression mirrored the microtubular structure throughout 
the stages of mitosis. The percentage of AKT-positive and mitotic cells was 
concordant, this confirmed that the distinct AKT expression was a mitosis specific 
event. 
Colocalisation between AKT ser473 staining and α-tubulin was confirmed by 
confocal microscopy. When tubulin polymerisation was disrupted with nocodazole, 
both the microtubular structure and AKT patterning were lost. This relationship was 
also observed in mouse embryonic fibroblasts, there was a significant correlation 
between α-tubulin and AKT ser473 in the x, y and z planes. Colocalisation was 
maintained after microtubules were disrupted with paclitaxel. Spindle formation was 
aberrant, however colocalisation was maintained. Thus, these findings showed that 
phospho-AKT ser473 is associated with polymerised microtubules. 
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To date, the mitotic association between AKT ser473 phosphorylation and spindle 
microtubules has not been shown. However, similar findings have been reported in 
mouse oocytes during meiosis. In these published studies, it was noted that AKT 
ser473 was localised with microtubules, and inhibition of PI3K activation impaired 
oocyte maturation. Meiosis involves asynchronous division resulting in the 
formation of a polar body after metaphase-1 (M1) and then spindle realignment. 
Following metaphase-2, emission of a second polar body completes meiosis. 
Inhibition of AKT phosphorylation with LY294002 impaired polar body formation 
at M1 and resulted in loss of the AKT ser473 distribution pattern
163
.  
Additionally, injection of an AKT ser473 binding antibody resulted in shortened, 
abnormal spindles. The actions of this AKT ser473 peptide in oocytes resulted in the 
failure of second polar body emission
164
. These findings were supported by a 
subsequent study undertaken by Kalous et al in 2006 who observed that AKT ser473 
appeared localised ‘in the area of the condensed chromosomes’ and co-stained with 
pericentrin, a centrosomal protein
153
. These reports are the only published 
observations of phospho-AKT ser473 localisation with microtubules during cell 
division. Therefore, the data presented here represent the novel observation that 
AKT ser473 localised with spindle microtubules during mitosis in embryonic stem 
cells and embryonic fibroblasts. 
Finally, it was observed that acute treatment of mES cells with mTOR inhibitors did 
not reduce the number of cells in mitosis. However, extended treatment with either 
rapamycin or the dual TORC inhibitor did inhibit mitotic cell numbers. This effect 
was enhanced with the dual kinase inhibitor. Consequently, these findings show that 
in response to TORC1 inhibition, cells continue to transit through mitosis, although 
in reduced numbers.  
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Dual inhibitors of the mTOR complexes also reduced the numbers of mitotic cells 
but did not arrest the cell cycle completely. Analysis of AKT ser473 staining in these 
cells was performed but not shown (Appendix 1), phospho-AKT persisted in mitotic 
cells under these conditions. It was documented that Ku-0063 treatment did not 
arrest mES cells at mitosis and at the high concentrations, proliferation was not 
abrogated. When cells were treated with 10µM Ku-0063, cell numbers were 
dramatically reduced and viability was very low. However, at this concentration of 
inhibitor, insoluble crystals formed in the aqueous culture medium. Consequently, 
whether AKT ser473 is essential for mitosis in mES cells could not be determined 
from these studies. Additional kinases have been reported to mediate AKT ser473 
phosphorylation in other cells and may provide an alternative pathway to AKT 
phosphorylation during mitosis. 
 It has been reported that the serine-473 phosphorylation in the hydrophobic motif 
(HM) of AKT is a prerequisite for full activation. This mechanism has been 
postulated to involve a conformation change in the pleckstrin (PH) domain, 
facilitating membrane localisation. At the cell membrane, AKT is exposed to the 
Protein-Dependent Kinase-1 (PDK1) leading to phosphorylation at the threonine-308 
residue
88
. 
In this study it was observed that the localisation of phospho-AKT ser473 in mitotic 
cells was also present in mouse embryonic fibroblasts. This suggests that mitotic 
association of AKT ser473 persists during embryonic development. It is curious that 
these observations have not been noted in cells other than oocytes, and here, 
embryonic stem cells and embryonic fibroblasts. It is possible that this AKT 
association is tissue specific or restricted during development. There are three AKT 
genes that transcribe similar molecules, AKT1, AKT2 and AKT3. Knockout studies 
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have identified that these isoforms are tissue restricted during development. 
Expression of AKT1 and AKT2 is ubiquitous whereas AKT3 expression is restricted 
to neural, cardiac and renal tissues
154
. The AKT2 isoform confers glucose sensitivity 
and is abundant in adipose tissue
155
 whereas AKT1 has been implicated in the 
growth of the organism. Knockout of all isoforms of AKT confers embryonic 
lethality and deletion of AKT1 and AKT2 results in lethality at the neonatal stage. 
However, these studies are complicated by functional redundancy between isoforms 
as just a single allele of one isoform can rescue observed defects
156
. Whether the 
mitotic AKT seen here can be attributed to a single isoform of AKT is not clear, 
however it has been suggested that AKT1 or AKT3 are likely candidates as AKT2 
clearly mediates glucose and insulin sensitivity
153
. It has also been documented 
however, that AKT2 levels increase during mitosis and mediates cell cycle 
progression and importantly, tumorigenicity. It was concluded that AKT2 may 
promote aberrant cellular proliferation
157
. 
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6.3   The viability of differentiating stem cells in response to mTOR 
inhibition. 
The aim of this aspect of the study was to assess the effects of mTOR inhibitors on 
the expansion of and viability of mES cells during normal culture and spontaneous 
differentiation. Initially, the working concentrations of a PI3K inhibitor, and dual 
mTOR kinase inhibitor were established by a dose-response assay and the effect on 
mouse ES cell proliferation after 48h was determined. This data was the used to 
select concentrations that generated a 50% reduction in proliferation after 48h. 
Mouse ES cell cultures were then treated with rapamycin (TORC1 inhibitor), 
LY294002 (PI3K inhibitor) and KU-0063 (dual TORC1/TORC2 inhibitor). It was 
shown that in growth medium containing LIF, viability was unaffected after 48h. 
Similar findings were observed with LIF-deprived growth medium and it was 
concluded that mTOR and PI3K inhibition impaired proliferation but not viability.  
It was observed that an increased percentage of detached cells were present in the 
spent culture medium without LIF and upon treatment with rapamycin, Ku-0063 and 
LY294002. This showed that cell attachment is negatively affected by inhibitors 
when LIF is not present. Rapamycin had less effect than both Ku-0063 and 
LY294002, with the greatest effect seen with the PI3K inhibitor. These findings 
suggest that AKT inhibition may underlie this effect.  Rapamycin marginally reduces 
the T-loop phosphorylation (Fig.3.7), Ku-0063 inhibits the HM-motif 
phosphorylation (required for full activation) and has a weak effect on the T-loop 
phosphorylation
136
; and the LY294002 compound is a potent inhibitor of AKT 
activation. Interestingly these effects were only observed in the absence of LIF, a 
potent inducer of PI3K activation. Taken together these findings suggest that AKT 
activation may mediate this loss of attachment upon mTOR inhibition. 
208 
 
The role of PI3K activation upon cell adhesion molecule binding to extracellular 
matrix proteins is well documented. The adhesion of cell surface integrins to ECM 
proteins activates AKT in a PI3K-dependent manner
156
, and focal adhesion kinase 
(FAK) molecules within focal adhesion complexes mediate survival and 
proliferation signals
157
. Focal adhesion complexes provide a direct link between cell 
surface molecules and the actin cytoskeleton and regulate processes such as 
migration and mitosis. The PI3K pathway also mediates the stabilisation of the 
microtubular cytoskeleton during migration, in one study it was found that 
stimulation of PI3K with platelet derived growth factor (PDGF) increased 
microtubule polymerisation, an effect that was prevented by PI3K inhibitors. 
Enforced expression of active AKT increased the amount of polymerised 
microtubules and a dominant negative form impaired microtubule stabilisation and 
cell migration in a wound healing assay
161
. Both AKT and TORC2 are recruited to 
the leading edge of migrating cells, whereas AKT is important for cell polarisation in 
response to chemoattractants
162
, and TORC2 is known to regulate the actin 
cytoskeleton in budding yeast and somatic mammalian cells
73
. In yeast, rapamycin 
treatment inhibits microtubule assembly, elongation and stability
163
.  
Embryonic stem cells that exhibited a round, compact shape have been shown to be 
sensitive to mechanical forces. Application of the tip of an atomic force microscope 
to individual cells generated membrane protrusions called blebs. This effect was not 
observed in flat, spread cells that also had a complex, committed cytoskeleton
135
. It 
was concluded that as mouse ES cell begin to differentiate, the cytoskeleton 
develops and gives the cell rigidity. As ES cells spread, they gain complexity and 
structure at the interface between cytoskeleton and cell membrane. Thus, when ES 
cells commit to differentiation and develop a defined cytoskeleton, spatial and 
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structural regulation of signalling pathways may be acquired. This supports the 
notion that in ES cells, differentiation and the acquisition of cytoskeletal rigidity may 
involve redistribution of signalling proteins to the cell membrane. Thus, in the 
spread cells observed in this study, the presence of mTOR serine2481 at the cell 
membrane may result in differential regulation of mTOR mediated processes. 
Consequently, the alterations in the survival and attachment response following 
mTOR inhibition may reflect this process. 
6.4  Wider implications of mTOR signalling in mES cells.  
Mammalian TOR is itself phosphorylated at a number of serine and threonine 
residues.  In this study, the levels of phospho-specific mTOR proteins were assessed 
over the course of the passage cycle, however no changes were observed. To date it 
is known that mTOR is phosphorylated at serine residues 2448 and 2481 and 
threonine residue-2446. It has been shown that insulin promotes threonine-2446 and 
serine-2448 phosphorylation via AKT
163
. However, substitution of these domains 
with alanine does not impair the mTOR mediated phosphorylation of p70S6K. 
Deletion of the region containing amino acids 2430-2450 increases mTOR kinase 
activity suggesting that this region is important for the repression of mTOR activity. 
Indeed these amino acid residues lie within the NRD regulatory domain of mTOR 
and may therefore not potentiate kinase activity
59
. The AMP-kinase also 
phosphorylates threonine residue-2446 and inhibits mTORC1 kinase activity
164
. It 
has been demonstrated that p70S6K mediates the phosphorylation of the serine-2448 
residue of mTOR as RNA interference inhibited serine-2448 phosphorylation. 
Furthermore, impairment of mTOR kinase activity by nutrient depletion reduced 
subsequent phosphorylation of ser2448 
165
. In a different study it was observed that 
both insulin and amino acid provision promoted this phosphorylation by independent 
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mechanisms. Glucagon was also shown to increase ser2448 phosphorylation without 
activating AKT, leading to a reduction in mTOR kinase activity
166
.  In summary, the 
serine-2448 phosphorylation appears to negatively regulate mTORC1 kinase activity 
and may operate as a self-regulating feedback mechanism to prevent excessive 
activation of mTOR. 
The functional significance of the serine-2481 residue of mTOR is not clear.  Recent 
studies have improved the understanding of the role this phosphorylation has on 
mTOR activity. It has been reported that the serine-2481 residue is an auto-
phosphorylation site that is present in both TORC1 and TORC2 complexes. It has 
also been documented that rapamycin inhibits serine-2481 phosphorylation in 
mTOR1 complexes but not mTOR2 complexes
167
. It is now thought that the serine-
2481 phosphorylation of mTOR is dependent upon the intact mTORC2 complex and 
is mTOR is rapamycin insensitive, whereas mTORC1 is found in association with 
phospho-serine-2448 
168
.  In conclusion, mTOR serine 2481 is considered to be a 
marker of active TORC2 complexes whereas the 2448 phosphorylation is associated 
TORC1 but may represent a marker of inactivation. Drawing on these conclusions, it 
appears that the mitotic phosphorylation events observed in this study are TORC2 
related events. 
 It has been well documented that the mTOR pathway interacts with other cell 
signalling pathways, including the mitogen activated protein kinase pathway 
(MAPK).  In mouse ES cells LIF promotes MAPK pathway activation resulting in 
ERK1/2 phosphorylation
169
 . The activation of ERK1/2 has a negative effect on 
pluripotency in mES cells
38
 and promotes endoderm and mesoderm lineage 
specification 
50
. This effect is negated by serum dependent signalling via ID proteins 
40
. It is not currently known what impact rapamycin treatment has on ERK1/2 
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phosphorylation in mES cells under normal growth conditions and serum 
deprivation. Data presented here shows that in LIF-stimulated mES cells, rapamycin 
treatment results in the phosphorylation of ERK1 (p42) and ERK2 (p44).  This effect 
is potentiated by serum deprivation. This is in concordance with the reported effect 
of serum on the inhibition of downstream ERK signalling in mES cells.  
The mechanism of rapamycin mediated ERK phosphorylation cannot be inferred 
from data presented here. Published studies suggest that ERK interacts with mTOR 
pathway via multiple mechanisms. Inhibition of the upstream kinase of ERK, the 
mitogen-activated protein kinase kinase (MEK), also impairs PI3K activation and 
negatively regulates AKT phosphorylation in response to growth factor 
stimulation
170
. In embryonic stem cell-derived neural progenitor cells, insulin 
signaling promotes cell survival during hypoxia by activating the PI3K/AKT 
pathway. It was observed that this response was accompanied by an inhibition of 
ERK phosphorylation
171
. Activated ERK potentiates endoderm and mesoderm 
lineage commitment and inhibits neuroectoderm differentiation in the mouse. This 
suggests that there may be a dynamic equilibrium between the PI3K/AKT and the 
MAPK/ERK pathways that regulates cell survival and differentiation. However, as 
this study incorporated oxygen depletion, multiple factors may have influenced the 
cross-talk between the two pathways. 
Other reported interactions between mTOR and ERK include the phosphorylation of 
raptor protein leading to TORC1 activation, and the phosphorylation of the S6-
kinase-2 (S6K2) isoform by phospho-ERK 
172,173
. Cross-talk between mTOR and 
ERK has also been implicated in self-renewal and tumorigenicity of glioblastoma 
stem-like cells
174
.Of particular interest to this study is the documented role of ERK 
in the phosphorylation of p70S6K th421 
170
. 
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It has been documented that ‘full’ activation of AKT is dependent upon 
phosphorylation at serine-473
176
. The search for a putative kinase (PDK2) identified 
a number of candidates including the mTOR complex 2 (TORC2)
77
, integrin-linked 
kinase (ILK)
177
 and DNA-protein kinase (DNA-PK)
178
. In this study the 
phosphorylation of AKT at serine-473 was found to be sensitive to rapamycin 
treatment. This is in accordance with published findings and supports the hypothesis 
that TORC2 mediates AKT serine-473 phosphorylation. Whereas the classical 
activation of AKT occurs at the plasma membrane, it is unclear in which cellular 
compartment the phosphorylation of serine-473 residue takes place. Upon activation 
AKT is known to exert its actions in the cytoplasm and nucleus where 
phosphorylation events induce the activation and repression of kinase substrates and 
gene transcription events
179,180
.  
Evidence for the membrane-activation of AKT ser473 suggests that this occurs at the 
in conjunction with the PDK1 phosphorylation of threonine-308 
154
. This is 
supported by investigations into novel PH-domain inhibitors which suppressed the 
Insulin-Like Growth Factor-1 (IGF-1) mediated phosphorylation of AKT at serine-
473. However, levels of phospho-p70S6K also reduced, this implies that the PDK1-
mediated regulation of mTORC1 activity may be involved. As PDK1 promotes 
TORC1 kinase activity indirectly through inhibiting the TSC complex; reducing 
AKT phosphorylation at the cell membrane may also relieve the inhibitory 
phosphorylation of TSC2. As the inhibition of TSC2 is necessary for mTOR 
complex-2 formation and kinase activity
87,181
, the reduced serine-473 
phosphorylation seen in response to the PH inhibitors may be due to TORC2 
inhibition by the TSC complex. These studies do not provide convincing evidence 
that the phosphorylation of serine-473 AKT occurs at the cell membrane. 
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The activation of AKT is also regulated by additional phosphorylation events that are 
independent of nutrient and growth factor stimulation. It has been documented that 
TORC2 mediates the phosphorylation of a residue in the turn motif (TM) of AKT
146
, 
and this phosphorylation, at threonine residue-450 stabilises native AKT protein 
from degradation. The TM phosphorylation was found to be dependent upon the 
functional TORC2 complex as this phosphorylation was lost in Sin1
-/- 
cells. Enforced 
membrane localisation of AKT by myristolation (myr-AKT) induced constitutive 
phosphorylation of the threonie-308 residue by PDK1. The impaired TM 
phosphorylation observed in Sin
-/- 
cells was not rescued by myristolated AKT. 
However, partial rescue of the HM (ser473) phosphorylation was observed
182
. This 
strongly suggests that the phosphorylation of AKT serine-473 can occur without 
active TORC2 and is a membrane localised event. It was hypothesised that the 
partial rescue was due to autophosphorylation, however, the evidence for this is not 
conclusive and additional membrane localised kinases may also been involved. 
One such kinase is the integrin linked kinase (ILK), localised predominantly at the 
cell membrane, ILK transduces signals arising from integrin adhesion molecule 
binding, to stimulate cellular processes such as survival and proliferation
183
. The HM 
motif of AKT is a kinase substrate of ILK
177
, and over-expression induces a dramatic 
upregulation in cellular proliferation, whereas inhibition impairs AKT ser473 
phosphorylation and causes cell cycle arrest and apoptosis in PTEN-deficient PC-3 
cells
184
. Interestingly, recent work has shown that ILK is also localised at 
centrosomes during mitosis, regulates the organisation of the mitotic spindle and 
colocalises with Aurora proteins
185
. This pattern of activity is similar to the 
observations documented here whereby TORC2 components localise at centrosomal 
areas and are upregulated during mitosis. Interestingly, the TORC2 associated 
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protein rictor also interacts with ILK to mediate the phosphorylation of AKT ser473 
and promotes the survival of cancer cells
186
. Both rictor and ILK were localised at 
the cell membrane and when mTOR protein was depleted, rictor, in cooperation with 
ILK mediated AKT ser473 phosphorylation and survival. 
Recent findings show that the mTOR mediated phosphorylation of the TM residues 
of ACG kinases prevents protein degradation. The AGC kinase, AKT is known to 
drive cell survival and transit through the cell cycle. It has been show here, and by 
others that rapamycin treatment increases TORC2 activity resulting in the 
phosphorylation of AKT at the hydrophobic motif. This is understood to be mediated 
by feedback inhibition via IRS-1 and PI3K
176
. It was shown in this study that 
inhibition of TORC1 with rapamycin did not completely abrogate cell proliferation. 
Feedback between the two mTOR complexes may therefore provide a mechanism to 
enable cells to complete the current cell cycle upon the depletion of nutrient and 
growth factor stimulation. This theory is supported by the observation that in cancer 
cells with the PTEN deletion, proliferation continues independently of environmental 
cues. In MCF7 and PC3 tumour cells it was found that the mTOR complex-2 was 
essential for cell cycle progression and anchorage-independent growth
83
. This 
observation is interesting as the HM phosphorylation of AKT is also mediated by 
ILK. Thus, when signalling from adhesion complexes is ablated, TORC2 activation 
of AKT ser473 may drive proliferation. That the anchorage-independent 
proliferation of these cells is dependent upon TORC2 provides strong evidence for 
the dynamic balance between cell attachment signals via ILK, and nutrient mediated 
signalling via mTOR in mediating AKT ser473 phosphorylation and resulting in cell 
survival and proliferation. 
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6.5 Conclusion 
The experimental data presented in chapter 3 defined the model pluripotent stem 
cells system utilised for further studies. The impact of mTOR activity on the 
proliferation of three cell systems was characterised. In mouse ES cells under 
standard growth conditions it was documented that mTOR activity modulates 
throughout the passage cycle and is sub-maximal after initial stimulation with 
growth medium. Supplementation of ES cells with factors that promote mTOR 
signalling is suggested in order to optimise cell proliferation rate during expansion of 
stem cells in a bioprocess.   
Experimental data presented in Chapter 4 served to further characterise mTOR 
signalling in ES cells. Conclusions drawn from these findings are that mTOR 
phosphoproteins are spatially and temporally regulated in embryonic stem cells. 
Furthermore, phosphoproteins associated with the mTOR complex-2 were associated 
with cytoskeletal structures involved in cell division. As mouse ES cells 
differentiated they spread and lost their distinctive compact shape. These cells 
expressed a developed cytoskeleton and mTOR phosphoproteins appeared to localise 
to the plasma membrane. The implication of these findings is that the mTOR 
pathway may be differentially regulated in pluripotent stem cells and differentiated 
cells. Consequently, targeting the mTOR complexes independently may afford 
additional levels of control to manipulate cell proliferation and cell growth to 
achieve bioprocess improvements. 
Observations documented in Chapter 5 build upon earlier findings by characterising 
the effect of mTOR pathway modulation on the expansion and viability of 
pluripotent and differentiated cells. Morphologically distinct ‘spread’ cells with a 
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developed cytoskeleton were less susceptible than compact stem cells, to 
proliferation inhibition and apoptosis by mTOR inhibitors upon the withdrawal of 
growth factor signalling. Additionally it was observed that during differentiation 
mTOR inhibition resulted in increased cell detachment. These effects may be utilised 
to reduce the proportion of stem cells from mixed cell preparations during 
differentiation.  
In summary, these findings suggest that the mTOR complex-2 may play an 
unrecognised role in proliferation via interaction with the cytoskeleton during 
mitosis. Furthermore, as stem cells differentiate, the regulation of mTOR signalling 
may be altered, affecting both proliferation and survival responses. This supports the 
notion that targeting the mTOR pathway may have differential effects in pluripotent 
and differentiated cells.  
The data presented and discussed here offers a strategy to enhance the expansion of 
embryonic stem cells by stimulating the mTOR pathway. Furthermore inhibiting the 
mTOR pathway during early differentiation may improve the purity of differentiated 
cell populations by preferentially inhibiting pluripotent stem cell proliferation and 
attachment. The mTOR pathway is an ideal candidate for cost-effective bioprocess 
optimisation as it is both sensitive to the bioavailability of nutrients and a highly 
conserved global regulator of cellular growth and proliferation. 
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6.6  Future work 
This investigation has highlighted key research questions that uncover novel biology 
regarding mTOR regulation in embryonic stem cells. An important aspect of future 
studies would be to assess the contribution of the respective AKT isoforms to the 
mitotic phosphorylation of AKT ser473. Targeted deletion or inactivation of the 
three AKT genes, both individually and in combination would enable isoform 
specific effects to be identified. This would determine whether the mitotic 
phosphorylation of AKT is essential for cell division in ES cells.  
The second investigation would characterise the respective involvement of the 
integrin linked kinase (ILK) and TORC2 kinase in the phosphorylation of AKT 
during mitosis. The particular emphasis would be to assess whether ILK and TORC2 
exhibit functional redundancy in mediating this phosphorylation event. Targeted 
deletion by RNA interference would enable this question to be answered.  
Finally, the association of mTOR ser2481 with intracellular structures of the 
cytoskeleton and cell membrane would be probed in both compact stem cells and 
spread, differentiated cells.  The relationship between membrane localisation and the 
acquired sensitivity to mTOR inhibitors would be addressed in the context of 
TORC2 and ILK knockdown.  
This work would comprise of three projects that taken together would significantly 
advance the understanding of the relationship between mTOR and AKT activation in 
embryonic stem cells. 
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Modulation of the mTOR pathway as a route to generate bioprocess improvements 
for embryonic stem cell-based therapies would require additional investigation into 
the effect of nutrient supplementation and deprivation at the expansion and 
differentiation stages respectively. In support of this, the relationships between cell 
numbers, proliferation rate, cell morphology and nutrient levels should be addressed. 
The combination of a continuous perfusion system to enable dynamic control of 
nutrient levels coupled with a non-invasive image analysis system as documented in 
this study, this approach would deliver the cost-effective bioprocess advantages 
alluded to in this study. 
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Chapter 8 
Appendix 1: Development and characterisation of image analysis methods 
for the assessment of stem cell expansion from phase contrast images.  
In the laboratory setting, routine assessment of the quality of stem cell cultures is 
made by observations of cell morphology and confluence by light microscopy. 
Extensive cell differentiation or impaired proliferation can be quickly determined by 
this method. Empirical analysis of stem cell pluripotency is performed routinely by 
immunostaining for core pluripotency markers such as OCT4 and nanog or by PCR 
based assessment of gene expression. However, these analytical techniques are 
inapplicable for the routine monitoring of ES cell cultures in a large-scale process
133
. 
Therefore a microscopic method for the assessment of stem cell expansion will be 
explored in this study.   
The principle objective was to accurately measure total cell area coverage and 
colony size distribution from phase-contrast micrographs of mES cultures. The 
validation of such a technique would have two roles. Firstly to enable the 
identification of changes in colony size and growth in response to treatment with 
mTOR inhibitors, and the secondly, to generate an analytical tool to provide rapid 
qualitative and quantitative data for the routine monitoring of stem cell cultures in 
vitro. 
In order to investigate the effect of mTOR inhibition on mES cell colony expansion, 
image analysis tools were developed and optimised using the ImageJ analytical 
software platform.  
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A sequence of inbuilt ImageJ analytical modules were arranged into specific 
workflows and then packaged as macros enabling rapid analysis of individual 
images. 
There is currently no true gold-standard technique for the measurement of stem cell 
colony area from phase-contrast images. The manual selection of confluent areas 
from digital images was considered a valid approach. However, analysis by this 
method was both inefficient and prone to subjective interpretation. Therefore, a 
number of computational methods were developed and test data were analysed and 
visually inspected. Finally, the techniques were compared to highlight the respective 
caveats and strengths of each method. 
8.1 Intensity thresholding for determination of cell confluence from 
phase-contrast images (Method A). 
Method A for the assessment of total mES cell area coverage was developed using 
mouse ES cells expressing green fluorescent protein (GFP) linked to the OCT4 
promoter region (mES E14 OCT4/GFP). In these cells, GFP expression is related to 
the expression of OCT4 enabling the effective monitoring of pluripotent marker 
expression in live cells by fluorescence microscopy. Mouse E14 OCT4/GFP cells 
were cultured in complete growth medium for 48h. Plates were imaged by phase-
contrast and fluorescence microscopy under defined illumination and exposure 
conditions. Captured images at 10x magnification were then used to develop the 
image analysis tool. I acknowledge the work of James Lawrence (Biochemical 
Engineering, UCL) for the initial development of the technique that preceded 
Method A. 
  
235 
 
The process described in Method A was based upon a simple thresholding approach 
with 8-bit greyscale images. The workflow involved three key steps. Firstly, the 
differences in greyscale intensity levels between background areas and cell areas 
were sampled and a threshold level determined. A binary image mask of selected 
area was then generated. Secondly, each contiguous area of cellular material was 
identified. Finally, the selected areas were measured and the total selected area was 
calculated relative to the total image area.  
Intensity level thresholding was achieved by sampling the grey-level intensity of the 
background area by selecting numerous regions of interest (ROI). The mean intensity 
and standard deviation of the background region were then calculated. Regions of 
interest containing mES colonies were selected and the mean intensity and standard 
deviation calculated. Mouse ES OCT4/GFP cells grow in vitro as compact colonies 
that appear phase-bright relative to the background area. The threshold level was 
therefore set to a value greater than the mean plus two standard deviations of the 
background level (intensity>105) and a value lower than the mean minus two 
standard deviations of the cell area level (intensity<133). The image was then 
converted into a binary mask, theoretically enabling measurement of the total 
selected area. In practice, numerous modifications of the binary data were necessary 
to generate useful numerical data. Local intensity levels within the cell areas 
overlapped with the background levels, consequently these areas were incorrectly 
excluded from the threshold.  
A series of functions were then utilised to generate contiguous areas around 
individual colonies. The selected areas were expanded with the ‘Dilate’ function. 
The non-selected areas within the colony were then ‘closed’ and gaps between 
selected areas were filled. Finally, the selected areas were ‘eroded’ back to a 
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representation of the original mask area. To generate numerical data pertaining to the 
total cell area, number of colonies and mean colony size, the packaged ‘Analyze 
Particles’ function was utilised. In order to exclude cellular debris from the area 
calculation, a minimum size rule was included in the analysis protocol. 
Consequently, the binary mask area differs from the actual measured area. 
 Figure 8.1.1 represents images of OCT4/GFP mES cells at subsequent stages of the 
process. Before thresholding (A), after thresholding (B), the binary mask of 
threshold data after processing (C) and composite image of the final mask area (red 
pixels) overlayed onto the original image (greyscale) (D). Tabular data provides a 
summary of the mean intensity level and standard deviation of the background and 
confluent area determined to define the threshold value (E), and the numerical 
measurement of the total cell area (F).  
Figure 8.1.2 is a visual representation of the relationship between the total calculated 
cell area from a test image and the expression of OCT4-GFP in these cells. Images A 
and B are the original phase-contrast image and the binary mask area described by 
Method A. To ensure that the analysis module correctly highlighted areas of mES 
colonies, OCT4/GFP expression was visualised by fluorescence microscopy (C). The 
intensity level of GFP was subjected to a threshold above the background level and a 
binary mask was generated (D). The relationship between the confluent colony area 
and OCT4/GFP positive area is represented in image 8.1.2. (F). In this image, the 
confluent colony area is represented by red pixels and the OCT4+ve area by green 
pixels (overlayed onto the original image). Yellow pixels indicate areas of overlap 
between the Method A binary mask area and the OCT4 binary mask area.  
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Image E represents the relationship between the threshold area defined by Method A 
(red pixels) and the actual cell area (greyscale).Visual inspection of test images 
revealed a close overlap between the measured colony area and actual cell area. 
There appeared to be good concordance between the measured colony area and 
OCT4/GFP-positive areas. However, analysis of test data by Method A resulted in 
some inaccuracy in cell area detection (white triangles; E, F). In some areas, cells 
were identified but did not exhibit high OCT4 expression (blue triangle). It was 
concluded that Method A generated a graphical and numerical description of the 
total area of mES cell coverage from phase-contrast micrographs. However, 
limitations of the method were apparent upon visual examination.  
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Figure 8.1.1 
Method A analysis of confluence of OCT4/GFP mES colonies from phase-
contrast micrographs 
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mean 
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deviation 
background 98.2 3.3 
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   size pixels µm2 
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Figure 8.1.2 
Relationship between the calculated cell area from Method A and OCT4+ve 
cell areas 
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A.            B. 
 
240 
 
Figure Legends 
Fig 8.1.1 
Method A technique for the assessment of E14-OCT4/GFP cell coverage from phase-contrast 
micrographs. Original phase image (Image A) and threshold mask (Image B), final binary mask 
area (Image C) and the final mask area overlayed onto the original phase image (Image D). 
Tabular data (E) defines the threshold cutoff values and numerical results returned by the 
image analysis tool (F). 
 
Fig.8.1.2 
Visual representation of the relationship between Method A technique for identification of 
confluent cell areas and OCT4/GFP expression in E14-OCT4/GFP cells. Original phase image (A) 
and the final threshold mask area (B), OCT4/GFP expression (C) and the binary mask of 
OCT/GFP-positive areas (D). The original phase image (greyscale) is overlayed with the binary 
mask of the total cell area (red pixels) (E). A composite of the original phase image (greyscale), 
the mask area defined by Method A (red pixels) and the OCT4/GFP mask area (green pixels) 
(F). Yellow pixels define areas of overlap between calculated cell area and the OCT4/GFP 
binary mask.  An area of cells that was incorrectly identified by Method A is indicated by a 
white triangle, and an area of OCT4/GFP-negative cell coverage identified by Method A 
indicated by a blue triangle.   
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Having established a basic tool to document the total area of mES cell coverage, the 
effect of rapamycin treatment was investigated. Mouse ES cells (E14 OCT4/GFP) 
were cultured with complete growth medium containing 10% FCS supplemented 
with 10
3
u/ml LIF as previously. Cells were seeded into gelatin-coated Nunc™ brand 
tissue culture-treated T25 flasks and cultured in a humidified atmosphere with 5% 
C02. After an initial attachment period, cultures were treated with DMSO and 10nM 
or 100nM rapamycin for 48h. Triplicate wells were imaged at 10x magnification and 
a minimum of ten fields of view per well were captured for analysis. Data was 
generated with Method A is presented graphically (Figs.8.1.3-5). In these figures, 
Image A is the original phase micrograph, Image B the calculated binary mask area, 
Image C represents a line drawing of the actual measured area and Image D 
represents the mask area overlayed onto the original phase image.  
It was previously established that rapamycin treatment inhibited mES cell 
proliferation in a dose-dependent manner (Figure 3.3.3). Therefore it was 
hypothesized that this inhibition in cell proliferation would manifest as a reduction in 
the total area of cell coverage (confluence). Analysis of imaging data by Method A 
revealed no significant difference in the total cell area coverage following treatment 
with 10nM rapamycin. At the higher concentration of rapamycin (100nM), there was 
a significant reduction in the total area of cell coverage compared with DMSO 
treated control cells (p<0.01). 
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Figure 8.1.3 
Image analysis assessment of mES cell confluence following 48h treatment 
with DMSO (Method A). 
 
 
 
 
 
 
 
 
 
 
Fig.8.1.3 
Method A analysis of E14-OCT4/GFP cells after 48h treatment with DMSO.  Image A represents 
the original phase-contrast micrograph; the binary mask generated from Method A (Image B) 
and a line drawing of the actual measured area (Image C). Image D represents an overlay of 
the binary mask area (red pixels) and the original micrograph (greyscale).  
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A.            B. 
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Figure 8.1.4 
Method A assessment of mES cell confluence following 48h treatment with 
10nM rapamycin. 
 
 
 
 
 
 
 
 
 
 
 
Fig.8.1.4 
Method A analysis of E14-OCT4/GFP cells after 48h treatment with 10nM rapamycin.  Image A 
represents the original phase-contrast micrograph; the binary mask generated from Method A 
(Image B) and a line drawing of the actual measured area (Image C). Image D represents an 
overlay of the binary mask area (red pixels) and the original micrograph (greyscale).  
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Figure 8.1.5 
Method A assessment of mES cell confluence following 48h treatment with 
100nM rapamycin. 
 
 
 
 
 
 
 
 
 
 
Fig 8.1.5 
Panel of representative images of Method A analysis of E14-OCT4/GFP cells after 48h 
treatment with 100nM rapamycin.  Image A represents the original phase-contrast 
micrograph; the binary mask generated from Method A (Image B) and a line d rawing of the 
actual measured area (Image C). Image D represents an overlay of the binary mask area (red 
pixels) and the original micrograph (greyscale).  
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Figure 8.1.6 
Assessment of the effect of rapamycin on cell area coverage by Method A  
analysis of phase-contrast images. 
 
 
Fig.8.1.6 
Method A analysis of total confluent cell area of DMSO and rapamycin treated E14 OCT/GFP 
mES cells. Ten unique fields of view per treatment group imaged at 10x magnification by 
phase-contrast microscopy. Results presented of data from three parallel cultures. Statistical 
analysis by unpaired t-test revealed a difference at the alpha level of p<0.01 (**).  
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8.2 Characterisation of Method A for determination of mES expansion 
from time-course images. 
The aim of this experiment was to measure the expansion of the E14-Tga2 parent 
line over time by processing phase-contrast micrographs with the image analysis tool 
Method A.  
Mouse ES cells exhibit variations in colony morphology depending on the cell line 
and culture conditions. It was noted that the E14-OCT4/GFP cells exhibited a 
clustered three dimensional morphology. In contrast, the E14 parent cell-line 
produced flat monolayer colonies (Figure 3.3.1). Therefore the E14 parent line was 
selected for mES colony area measurements. It was hypothesized that during the 48h 
passage the total area of cell coverage would increase, mean colony size would also 
increase but the total number of colonies would decrease. Therefore it was 
anticipated that analysis of mES cell expansion by Method A would generate data 
that was consistent with these traits. 
Mouse ES cells (E14-Tga2) were seeded into 6-well plates and cultured within a 
proprietary live-cell imaging system (Cell-IQ™). Images were captured at 20x 
magnification over a 48h period. Control data was collected from 3 series of images. 
Micrographs from a biological assay were processed by Method A and the numerical 
data was plotted graphically,  results images were then visually inspected to identify 
potential errors. Prior to analysis of the imaging data, modifications to Method A 
were applied to adjust for differences in the mean background intensity level of the 
imaging data. Additionally, the minimum size rule was modified to account for the 
increased magnification factor of the images. 
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Figure 8.2.1 represents graphical data of the total cell area coverage from triplicate 
fields of view imaged over 48h.  Method A measured a time-dependent increase in 
the total confluent cell area. The rate of increase of the total cell area appeared to 
increase after 24h culture. An image series from a single field of view was then 
plotted and a 2nd order polynomial line was fitted (Figure 8.2.2). The coefficient of 
determination for the fitted line was 0.0997 indicating that the data closely matched a 
two order rate equation.  
Data presented in Figure 8.2.3 indicated that after 48h the total number of colonies 
decreased, however, there was a large variation in the number of colonies at each 
time-point as indicated by large standard deviation values. The measurement of 
colony size over time demonstrated a steady increase in mean colony size (Figure 
8.2.4). However, high standard deviation values precluded significance testing. 
In summary, Method A generated data showing an increase in the total area of cell 
coverage over time. Measurements of colony size and colony number contradicted 
this trend. It was anticipated that the total area of cell coverage would relate to both 
colony size and colony number. Large standard deviations of the data points may 
have masked any trend. The results images from selected data points were then 
subjected to visual inspection to highlight the limitations of the analysis protocol. 
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Figure 8.2.1 
Analysis of mES cell expansion from triplicate fields of view over 48h 
Method A. 
 
 
  
 
 
 
 
 
Fig 8.2.1 
Analysis of mouse E14 cell expansion from triplicate fields of view by over 48h by Method A. 
Cells were seeded into 6 well plates cultured with complete growth medium containing 10% 
serum and 10
3
u/m LIF. The Cell-IQ™ automated imaging platform for cell culture was used to 
capture phase-contrast images from fixed positions of the tissue culture plate over 48h.  
Images captured at 20x magnification. 
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Figure 8.2.2 
Method A analysis of a single field of view describing mES colony 
expansion over 48h. 
 
 
 
 
 
 
 
 
Fig.8.2.2 
Analysis of mouse E14 cell expansion from a single view by over 48h by Method A. Cells were 
seeded into 6 well plates cultured with complete growth medium containing 10% serum and 
10
3
u/m LIF. The Cell-IQ™ automated imaging platform for cell culture was used to capture 
phase-contrast images from fixed positions of the tissue culture plate over 48h.  Images 
captured at 20x magnification and subjected to analysis by Method A. The fitted line revealed 
a close concordance with a two order rate equation, assessed by the coefficient of 
determination statistic.  
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Figure 8.2.3 
The mean number of mES cell colonies measured over 48h by Method A was 
highly variable. 
 
 
 
 
 
 
 
 
Fig.8.2.3 
Analysis of mouse E14 cell expansion from triplicate fields of view over 48h by Method A. Cells 
were cultured and imaged as described in the previous figure. Data expressed as mean and 
standard deviation of the number of colonies at each time point.  
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Figure 8.2.4 
High variance in the mean area of mES cell colonies over 48h calculated by 
Method A. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8.2.4 
Analysis of mouse E14 cell expansion from triplicate fields of view over 48h by Method A. Cells 
were cultured and imaged as described in Figure 8.2.1 figure. Data expressed as mean and 
standard deviation of individual colony area measurements at each time point.  
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Examination of the results images generated by Method A revealed inaccuracies in 
cell area selection. Figures 8.2.5 and 8.2.6 represent a visual analysis of total cell 
area measurements at 4h and 12h respectively.  Image panels consist of the original 
phase contrast image (A), a line drawing of the calculated area of cell coverage (B) 
and an overlay of the measured area (red pixels) and the phase-contrast image (C).  
Areas of false positive and false negative identification of mES cells are indicated by 
yellow triangles and white triangles respectively (Figure 8.2.6). Phase-bright areas of 
dead cells and cellular debris were inadvertently selected and counted as individual 
colonies by Method A, potentially skewing the distribution of colony size 
measurements (size distribution data not shown). 
The principle factor for the determination of cell area by Method A was based upon 
identification of pixels with a grey level intensity greater than that of the 
background. Whereas the morphology of E14 OCT4/GFP mES cells in vitro was 
characterised by compact colonies that appeared phase-bright at 10x magnification. 
The E14-Tga2 parent cell line exhibited a less compact, monolayer morphology. 
Analysis of micrographs of E14 cells at 20x magnification by Method A revealed the 
limitations of this method. Areas of false negative identification were abundant after 
12h culture (white triangles, Figure 8.2.6). 
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Figure 8.2.5 
Images of mES cells in culture 4h after seeding analysed by Method A.  
 
 
 
 
 
 
 
 
 
 
 
Fig.8.2.5 
Visual representation of total cell area measurements at 4h and 12 respectively.  Image panels 
consist of phase contrast image (A), a line drawing of the calculated area of cell coverage (B) 
and an overlay of the measured area (red pixels) and the phase-contrast image (C).  Areas of 
false positive and false negative identification of mES cells are indicated by yellow triangles 
and white triangles respectively 
 
A.                    B. 
 
 
C. 
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Figure 8.2.6 
Representative images of Method A analysis of mES cells in culture 12h 
after seeding. 
 
 
 
 
 
 
 
 
 
 
Fig.8.2.6 
Visual representation of total cell area measurements at 4h and 12 respectively.  Image panels 
consist of phase contrast image (A), a line drawing of the calculated area of cell coverage (B) 
and an overlay of the measured area (red pixels) and the phase-contrast image (C).  Areas of 
false positive and false negative identification of mES cells are indicated by yellow triangles 
and white triangles respectively. Areas of the image incorrectly identified as background 
(white triangles) and non-viable areas and cellular debris identified by Method A Indicated 
(yellow triangles). 
A.                    B. 
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8.3 Development of a dual threshold technique - Method B 
Method A was optimised for analysis of phase-contrast micrographs of E14 
OCT4/GFP cells. However, application to the analysis of phase-contrast micrographs 
of the E14-Tga2 parent line at 20x magnification highlighted the limitations of the 
method. This discrepancy may have arisen from differences between colony 
morphology of the two cell lines, a feature exacerbated by increasing the 
magnification factor at image capture.  
The principle concern with Method A was the false-negative identification of cell-
areas. The grey-level intensity of these areas was measured, it was deduced that the 
intensity level of these regions was equal to or lower than the background level. 
Therefore, in order to develop a more accurate analytical tool, a dual threshold was 
applied to exclude pixels within the range of the background and include both high 
intensity and low intensity pixels. Additional concerns with Method A related to the 
high variability in the measurement of the total number of colonies and the large 
standard deviations resulting from the individual colony size measurements. It was 
observed that dead cells and cellular debris were included in the measurement. These 
individual elements were then measured from control images and a minimum size-
rule was redefined. The impact of this modification will be discussed in section 8.5. 
In order to assess whether Method B improved the measurement of cell area, mean 
colony size and the total number of colonies; time series data presented in the 
previous section (8.2) was reanalysed with Method B and compared with the results 
generated by Method A. Figure 8.3.1 shows a representative phase-contrast image 
after 12h culture (A), the overlay of the result from Method A (B), and the Method B 
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result image (C). Visual inspection of these images revealed an improvement in the 
accuracy of Method B in the positive identification of cell areas. 
 Figure 8.3.2 shows the relationship between the area measurement 
calculation generated from the same data by the two methods. Data is presented as 
the measured area fraction over time. It is clear from this graph that Method B 
returned higher values than Method A at all time points. Plotting this data as a scatter 
graph revealed that there was a close correlation in the in the area calculation 
between the two methods (R
2
=0.985). This analytical technique can highlight trends 
between two data sets independently of absolute values. However, as both data sets 
were based upon the same input data, a close correlation was to be expected. 
Consequently, this analysis does not effectively represent differences between the 
two methods. Therefore, the total cell area values were plotted against the difference 
between values generated by each method (Figure 8.3.3). Concordant data sets 
would align at the zero value at all data points. Examination of this chart revealed 
that when the area measurement was low, the difference between the methods was 
also low. As the measured cell area increased, the difference between the values 
generated by Method A and Method B also increased. In conclusion Method B 
provided a more accurate description of total cell area coverage than Method A. 
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Figure 8.3.1 
Visual inspection of selected binary mask area from Method A and Method B 
for analysis of mES cell colony area in phase-contrast images 12h post-
seeding 
 
 
 
 
 
 
 
 
 
 
 
 
  
A.                     
 
. 
 
B. 
 
 
 
C. 
 
Fig.8.3.1 
Panel of representative 
phase contrast images of 
mES cells after 12h in 
culture (image A) and results 
images from Method A 
(image B) and Method B 
(image C). Images reveal 
that Method B provides a 
more accurate description of 
total cell area. 
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Figure 8.3.2 
Comparison between positive threshold analysis (Method A) and dual 
threshold analysis (Method B) for total cell area measurement from phase -
contrast micrographs. 
 
 
 
 
 
 
 
 
Fig.8.3.2 
Total cell area measurement from phase contrast micrographs of mES cells in culture over 48h.  
A single field of view was analysed by Method A (open triangles) and Method B (open squares).  
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Figure 8.3.3 
Correlation between the total cell area measurement calculated by two 
methods (A and B).  
 
 
 
 
 
 
 
 
Fig. 8.3.3 
Data from Fig.8.3.2 presented as a scatter plot to highlight the relationship between Method A 
and Method B calculation of total cell area (area fraction). Linear regression revealed a high 
correlation coefficient of distribution (R
2
) between the two methods. 
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Figure 8.3.4 
Relationship between total cell area measurements by two methods    
(A and B). 
 
 
 
 
 
 
 
Fig. 8.3.4 
The relationship between results generated from Method A and Method B from the same 
input data. Results are plotted as a scatter graph of total area measurement versus the 
difference between values at each data point. A polynomial regression line is included to 
highlight trends. 
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8.4 Characterisation of a robust, local contrast variation - Method C.  
A prerequisite for the analysis of mES cell confluence from phase-contrast 
micrographs by Method A or B was a precisely defined background intensity level. 
However, analysis of images captured at different exposure settings may result in a 
reduction in the power of the technique to correctly identify areas of cell coverage. 
Analysis of images acquired over more than one imaging session therefore requires 
strictly controlled illumination and image capture settings. Alternatively, threshold 
calculations must be re-established from control images at each imaging session. 
Consequently, a more robust image analysis technique was developed. This 
alternative method functions on the basis of local variations in the contrast between 
adjacent pixels. This approach provided advantages over the threshold-based 
analysis as it was less susceptible to ‘between image’ variations in background 
intensity.  
A principle feature of the background area (non-cell area) of a phase-contrast 
micrograph is the uniform distribution of pixel intensity levels (low local contrast). 
Conversely, areas of cell coverage exhibit high variability in pixel intensity. 
Therefore, the primary discriminator for selecting cell areas was based upon this 
local contrast variation. Areas of high local contrast variability were identified and a 
binary mask of the selected area was created as described for the previous methods. 
This process was termed Method C. Measurements of the total cell area, total 
number of colonies and mean colony size were compared with results generated by 
Methods A and B.   
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Figure 8.4.1 shows a panel of representative images of the results generated by 
Methods A, B and C. The same phase contrast image was analysed by each method 
and displayed as an overlay of the binary mask and original phase-contrast image 
(A) and a line drawing of the actual measured area (B). Inspection of these images 
revealed that Method C returned a similar result to Method B and accurately 
described total cell area. This was confirmed by the analysis of time-series data from 
a single field of view imaged over 48h (Figure 8.4.2). Mouse ES cells were cultured 
as previously described in the Cell-IQ™ imaging platform. Images of cells in culture 
were taken at 4h intervals and analysed using each method, data was presented as the 
total cell area over time.   
The area fraction measurement at each time point was plotted against the difference 
between the results returned by each method. This data is presented in Figure 8.4.3. 
When Method C was compared with Method A, it was observed that the difference 
between values increased as cell area increased (i). This was not observed when 
Method C was compared with Method B (ii). Comparisons between these two 
methods revealed a linear relationship that remained close to the zero value (no 
difference between values). These findings, when taken together, show that Method 
C was equivalent to Method B and an improvement over Method A in the 
description of confluent cell area.    
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Figure 8.4.1 
Visual representation of total cell area measurements of mES cells at 24h in 
culture by Methods A, B and C. 
     A                B 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8.4.1 
Binary mask result (A) generated from a representative phase contrast image analysed by 
Method A (red), Method B (green) and Method C (blue). Line drawings of actual measured area 
are also presented (B). 
 Method A           Method A 
 
 
 
Method B            Method B 
 
 
 
Method C           Method C 
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Figure 8.4.2 
Total cell area measurement by Methods A, B and C 
 
 
 
 
 
 
 
Fig.8.4.2 
Total cell area measurement from phase contrast micrographs of mES cells in culture over 48h.  
A single field of view was analysed by Method A (open triangles), Method B (open squares) and 
Method C (open diamonds). Data shows that Method B generates similar results to Method B 
but not Method A. 
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Figure 8.4.3 
 Cell area measurements by Method C closely align with Method B but not 
Method A. 
i. 
 
 
 
 
 
 
ii. 
 
 
 
 
 
 
 
Fig. 8.3.4 
The relationship between total area measurements generated by Method A and Method C(i), 
and Method B and Method C (ii). Results are plotted as a scatter graph of total area 
measurement versus the difference between values at each data point. Regression lines 
highlight the relationship between the methods. This data shows that Method C aligns closely 
with Method B but not Method A. 
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8.5 The relationship between mean colony area measurements and total 
number of colonies by the three methods.  
During routine culture of E14 mES cells in vitro, it was observed that as cells 
reached confluence, individual colonies merged into large monolayers. Therefore, it 
was hypothesised that as the mean colony size increased, the total number of 
colonies would decrease. Moreover, a concordance between these parameters should 
be evident upon computational analysis.  
To assess whether the image analysis methods described here, identified this 
concordance, the mean colony area measurements of mES cells in culture over 48h 
were plotted against the total number of colonies. This data is presented in Figures 
8.5.1 (Method A), Figure 8.5.2 (Method B) and Figure 8.5.3 (Method C). 
Concordance was not found by Method A analysis.  However, Method B and 
Method C exhibited a statistically significant concordance between the colony area 
and the number of colonies. The data from these two methods were described by a 
two-order polynomial equation with a coefficient of determination (R
2
) of 0.994 and 
0.963 for Method B and Method C respectively.   
In summary, these findings demonstrate that Method B and Method C describe the in 
vitro expansion of mouse ES cell in accordance with the stated hypothesis. Method 
C operates independently of image capture settings and can therefore be applied 
post-hoc to imaging data. Consequently it was concluded that Method C provides a 
robust measurement of cell area, colony size and the total number of colonies and is 
therefore applicable for monitoring the expansion of embryonic stem cell cultures in 
vitro in the laboratory setting.  
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Fig 8.5.1 
Relationship between mean colony size and the total number of colonies by 
Method A. 
i. 
 
 
 
 
ii)  
 
 
 
 
 
Fig. 8.5.1 
Graphical representation of the number of colonies/field of view and mean colony size (µm
2
) 
at each time-point over 48h (i) and the relationship between mean colony area and number of 
colonies (ii) from Method A. Linear regression analysis revealed no statistical concordance 
between the parameters,  
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Figure 8.5.2 
Relationship between mean colony size and the total number of colonies by 
Method B. 
i. 
 
 
 
 
ii) 
 
 
 
 
 
Fig. 8.5.2 
Graphical representation of the mean colony area (µm
2
) and number of colonies/field of view 
and at each time-point over 48h (i) and the relationship between mean colony area and 
number of colonies (ii) from Method B. A two-order polynomial equation described the 
relationship between values with a coefficient of distribution of 0.994 (R
2
). Strong 
concordance between values was observed with Method B.  
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Figure 8.5.3 
Concordance between the mean colony size and total number of mES cell 
colonies by Method C. 
i. 
 
 
 
 
ii) 
 
 
 
 
 
 
 
 
Fig. 8.5.3 
Graphical representation of the mean colony area (µm
2
) and number of colonies/field of view 
and at each time-point over 48h (i) and the relationship between mean colony area and 
number of colonies (ii) from Method C. A two-order polynomial equation described the 
relationship between values with a coefficient of distribution of 0.963 (R
2
). Strong 
concordance between values was observed with Method C.   
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8.6 Characterisation of mES cell phase and morphology from phase-
contrast micrographs by Method 2. 
The methods presented in the previous sections describe the total cell area coverage, 
colony number and size distribution from phase contrast micrographs. The principle 
by which Method B operates is the identification of pixels with an intensity value 
that is either greater than or lower than the background level. The mode of action of 
Method C is by detecting local contrast variations differences in adjacent pixels. This 
enables areas of an image containing cells to be discriminated from the background. 
However, there are limitations in the scope of these methods as they are not sensitive 
to differences in cell morphology. Embryonic stem cells undergo morphological 
changes during differentiation, this can often be observed visually by light 
microscopy. The following section describes the development of an image analysis 
protocol that describes stem cell morphology utilising commercially available 
machine-vision software. 
Pluripotent mouse ES cells also exist in numerous cell phases that exhibit discrete 
morphologies. Shortly after seeding into tissue-culture flasks, cells settle and begin 
to adhere to the substrate. At this stage cells appear compact with a phase-bright 
morphology observed by light microscopy. Twelve hours after seeding, small 
colonies exhibit a classical stem cell morphology containing cells with a large 
nuclear to cytoplasmic ratio. Proliferating stem cells undergo successive rounds of 
division, microscopically this can be observed as presents as circular phase-bright 
areas that form two-adjacent spheres which separate before returning into the colony. 
After 48h in culture numerous apoptotic and necrotic cells can be observed. Non-
viable cells appear as small phase bright or phase-dark spheres. Thereafter, cellular 
debris forms which presents as small, phase-dark particles. Thus, pluripotent mouse 
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ES cells may be observed to exist with distinct morphological features that relate to 
the stage of their life-cycle. 
The morphological identification of embryonic stem cells in vitro is complicated by 
their capacity to differentiate into lineage-specific progeny. Differentiated cells may 
present with an array of morphologies depending upon the lineage and stage of 
development. Morphological characterisation is therefore not an accurate predictor 
of cell phenotype. However, the initial stages of embryonic stem cell differentiation 
can be observed as an area of cell spreading, often proceeding from the edge of a 
colony of compact pluripotent cells
132,133
.  
In order to characterise changes in cell phase and morphology in response to 
inhibition of the mTOR pathway, proprietary software incorporating a machine-
learning algorithm was utilised. The use of this software in biological systems has 
been well established but analysis of stem cell morphology has not been published in 
peer-reviewed publications.  
 A series of test images of mES cells in culture were captured and specific cell phase 
distinctions were identified visually.  An analysis protocol was then generated by 
‘training’ the software to recognise specific examples of distinct cell phases. Test 
data was then analysed and results visually inspected. Distinct cell morphologies 
were introduced into the protocol to provide a final iteration that included 
discrimination of cell phase (viable, non-viable, debris) and morphology (compact, 
spread, dividing). At least 100 samples for each group were visually identified and 
categorised according to cell phase and morphology. An analysis protocol was built 
based upon the sample library and this model (Method 2) was then tested with 
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imaging data described in sections 8.4 and 8.5. Data generated from Method 2 was 
compared with the total colony area data generated by Method B and Method C.  
Figure 8.6.1 shows the sample library for cell phase distinction generated from test 
images and Figure 8.6.2 shows the sample library for cell morphology distinction. 
Findings from Method B and Method C were then compared with Method 2. Figure 
8.6.3 shows representative phase contrast and results images for cell phase and 
morphology calculations generated by Method 2. Coloured regions indicate cell 
phase and morphology. Viable (compact) area indicated by blue pixels, viable 
(spread) by green pixels, viable (dividing) by yellow pixels and non-viable (dead) 
cells indicated by red pixels. Cellular debris and background represented by grey 
pixels. Total viable cell area calculations (compact, spread and dividing) were then 
combined to give a total confluent area measurement to enable comparison with data 
generated from Methods B and C. 
Figure 8.6.4 shows the total cell area calculations (confluence) from the three 
methods. This data reveals that the increase in cell confluence with time was 
accurately described by Method 2 as similar results were generated by each of the 
three methods. In order to assess the differences in the area calculations generated by 
these methods, the values returned by Method B and C were subtracted from values 
generated by Method 2. This data was plotted as a scatter graph of the total area 
value (confluence) versus the difference between the values at each data point 
(Figure 8.6.5). It is evident from this analysis that at low cell confluency, Method 2 
returned a higher value than Methods B or C. As cell confluence increased beyond 
40%, Method C returned a lower confluence estimate that Methods A and B. This 
occurred after 30-35 hours in culture.  
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Figure 8.6.5 shows that at this time point the total cell area measurement returned by 
Method 2 diverges from that of Methods B and C. When the relationship between 
measurements by Method 2 and Methods B and C were plotted, a two order 
polynomial rate equation was deemed appropriate to describe the concordance 
between the values (Figure 8.2.6). This was justified as Method 2 discriminated the 
viable cell area from the non-viable cell area the total cell area coverage 
measurements generated by Methods B and C may have included these non-viable 
cells. 
The cell phase distinctions (viable, non-viable) for the area calculation generated by 
Method 2 were plotted individually in Figure 8.6.8. The total area of viable cells 
(compact, spread, dividing) and non-viable cells over 48h are shown in Figure 
8.6.8.A. This chart indicated that the percentage coverage of non-viable cells 
increased with time. This was apparent after 30h in culture, from this time onwards 
there was also a decrease in the rate of colony expansion. Thus, the decline in the 
rate of mES cell expansion was associated with an increase in non-viable cells.  Thus 
the differences between the area measurements described in Figure 8.6.5 and 8.6.6 
can be explained by this increase in non-viable cell area.  
Finally, the change in area coverage of compact cells and spread cells over 48h is 
plotted in Figure 8.6.8.B. Whereas the area covered by compact cells increased with 
time, the total area of spread cells remained constant. As mES cells will retain 
pluirpotency over extended passaging when supplemented with LIF and serum, an 
increase in the total area covered by spread cells in this assay was not expected. 
In summary, Method 2 generated clear description of the total area of mES cell 
coverage from phase-contrast micrographs. Moreover, this method provided 
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distinction between viable and non-viable cell phases and may further enable 
morphological changes that occur during early differentiation to be monitored in a 
non-invasive manner.  
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Figure 8.6.1 
Representative sample library of mES cell phase distinction.  
 
 
 
 
 
 
 
Fig.8.6.1 
Generation of analysis protocol utilising the Cell-IQ Analyser Pro-Write™ v.2.0.1 software. 
Mouse ES cells were cultured within the Cell-IQ Analyser™ for 48h as previously described. 
Test images were visually inspected and cells exhibiting specific cell phase distinctions were 
identified and selected. At least 100 instances of each cell phase were included and a sample 
library was created. Cell phase distinctions include background recognition (358 samples); live 
cell phase (291 samples); non-viable cell phase (dead, 109 samples) and debris (227 samples). 
The analysis protocol was built with a recognition complexity factor of 1.4.  
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Figure 8.6.2 
Representative sample library of mES cell morphology distinction.  
 
 
Fig.8.6.2 
Generation of analysis protocol utilising the Cell-IQ Analyser Pro-Write™ v.2.0.1 software. 
Mouse ES cells were cultured within the Cell-IQ Analyser™ for 48h as previously described. 
Test images were visually inspected and cells exhibiting specific morphologies were identified 
and selected. At least 100 instances of each cell phase were included and a sample library was 
created. Cell phase distinctions include background recognition (358 samples); viable cell 
phase; compact mES cells (291 samples); dividing mES cells (124 samples) and differentiating 
cells (312 samples). The analysis protocol was built with a recognition complexity factor of 1.4.  
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Figure 8.6.3 
Representative phase-contrast and results images of mES cells after 24h and 
48h in culture by Method 2.  
 
 
 
 
 
 
 
 
 
Fig. 8.6.3  
Panel of representative images of mES cells in culture and results returned by the Cell -IQ 
analysis protocol (Method 2). Phase contrast images of mES cells after 24 (A.i) and 48h (B.ii) 
and corresponding results images at 24h (B.i) and 48h (B.ii). Automated image capture was 
undertaken at 20x magnification. Coloured regions indicate cell phase and morphology. Viable 
(compact) area indicated by blue pixels, viable (spread) by green pixels, viable (dividing) by 
yellow pixels and non-viable (dead) cells indicated by red pixels. Cellular debris and 
background represented by grey pixels.  
 
  
A.i. 24h         B.i 48h 
 
 
A.ii          B.ii 
278 
 
Figure 8.6.4 
Comparison of three computational methods to document mES cell 
confluence from phase-contrast images over 48h. 
 
 
 
 
 
 
 
 
Fig.8.6.4 
Total cell confluence was assessed by Method B (open diamonds), Method  C (open squares) 
and Method 2 (red circles). A series of phase-contrast images of mES cells over 48h in culture 
were analysed by each method. The percentage cell area from each time-point was calculated 
and presented. Dashed line indicates the point at which rate of cell expansion measured by 
Method 2 declines. 
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Figure 8.6.5 
The difference between cell area calculations by Method 2 and Methods B 
and C increases with cell confluence.  
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Fig. 8.6.5 
The cell area measurements calculated by Method B and Method C were subtracted from the 
measurements calculated by Method 2 to highlight the difference between methods. This data 
was plotted as a scatter graph and shows that as the measured cell area increases beyond 45% 
the difference between the methods changes (pink shading). 
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Figure 8.6.6 
The relationship between Method 2 and Methods B and C for the analysis of 
mES cell confluence from phase-contrast images. 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Fig.8.6.6 
Total cell area calculations generated by Method 2 were compared with Methods B (chart A) 
and Method C (chart B). Data fitted a two order polynomial rate equation indicated by a fitted 
regression line and the coefficients of determination for the area calculation by Method 2 
versus Method B (R
2
=0.9843) and Method 2 versus Method C (R
2
=0.9816).  
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Figure 8.6.7 
Characterisation of mES cell morphology and phase by Method 2 image 
analysis technique. 
A 
 
 
 
 
B 
 
 
 
 
 
 
 
Fig.8.6.7 
Method 2 analysis of mES cell expansion over 48h from phase contrast micrographs. 
Assessment of viable and non-viable cell area (i) and compact and spread cell morphology (ii).  
0 
10 
20 
30 
40 
50 
60 
0 5 10 15 20 25 30 35 40 45 50 55 
ce
ll 
ar
ea
 (
%
) 
time (h) 
viable 
non-viable 
0 
5 
10 
15 
20 
25 
30 
35 
40 
0 5 10 15 20 25 30 35 40 45 50 55 
ce
ll 
ar
ea
 (
%
) 
time (h) 
compact 
spread 
282 
 
8.7  Summary of findings. 
The principle objective of this work was to generate an image analysis tool to 
analyse stem cell confluence from phase contrast micrographs. To achieve this, the 
ImageJ software platform was utilised. This program was developed and made 
available by the US National Institute of Health. The advantage of using ImageJ for 
this purpose was that it is an open source software with an extensive library of image 
analysis tools (macros). Thus, it is possible to develop new analytical routines that 
meet specific needs. The workflows developed here do not represent novel 
developments in the field of computational image analysis. Rather, they are 
arrangements of pre-existing macros that have been created by others and made 
freely available to the research community.  
The approach presented in this chapter is a step-wise development of an analysis 
protocol for the assessment of mES cell confluence. The limitations of the protocol 
were assessed visually by comparing results images with the original phase contrast 
images. Modifications were then made to the protocols and images were reanalysed 
and inspected. Numerical data generated by the modified protocol was then plotted 
graphically against the original data to enable a statistical description of the iterative 
modifications. Successful enhancements were then incorporated into the next 
generation of the protocol.  
Other parameters were also described by these image analysis methods. The total 
number of colonies was determined and the area of individual colonies was 
calculated. Consequently, the mean colony area measurement and corresponding 
standard deviations could be calculated for each image.  
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Method A was developed for the analysis of E14 OCT4/GFP cells, subsequently the 
effect of rapamycin of mES colony expansion was assessed. It was observed that 
rapamycin inhibited colony expansion after 48h. This was anticipated as rapamycin 
was also shown to inhibit mES cell numbers under these conditions. Therefore, 
Method A was determined to qualitatively document changes mES colony 
expansion. 
This protocol was based upon a simple grey-level thresholding approach. When 
Method A was applied to images of the parent E14 cell line it was noted that some 
areas of cell coverage were not measured. Therefore, the protocol was modified to 
incorporate a dual threshold. This protocol, Method B was then compared with 
Method A by analysis time-course data from select fields of view over 48h. These 
results were inspected and limitations were identified. It was observed that Method B 
provided a better description of cell confluence than Method A as false-negative 
areas of cell identification were not apparent.  
The limitations of the threshold-based approach arose from differences in the 
brightness and contrast of captured images during different imaging sessions. The 
images analysed in this aspect of the study were uniform in brightness and contrast 
as they were generated using an automated cell culture and image capture system.  
However, application of image analysis methods in the laboratory setting would 
necessitate a tool that was not sensitive to the image capture settings. To address the 
limitations of this method, a third iteration of the protocol was developed. This new 
technique, Method C was based upon local contrast variations that distinguished 
cellular material from the uniform background. This tool was then compared with 
previous iterations and was shown to be equivalent to Method B and an 
improvement to Method A in the assessment of cell confluence.  
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The final modification to the protocol defined a minimum size rule to exclude 
cellular debris. This modification was validated by testing a hypothesis that was 
determined from the observation of colony expansion over time. It is evident by 
observing cells in culture that as small colonies expand they join to form large 
colonies. Thus, an image analysis method should describe this as an inverse 
relationship between colony number and colony size. Method B and Method C both 
showed this correlation whereas Method A did not. Therefore, it was concluded that 
Method B and C effectively described individual colony area and the total number of 
colonies of mES cells from phase-contrast images. 
Finally, these methods were compared with an alternative approach to image 
analysis. Commercially available machine learning software for cellular analysis 
enabled the discrimination of morphological parameters of cells in culture. This 
software was ‘trained’ with specific examples of cell morphology that included 
distinctions between viable and non-viable cells, and between compact cells and 
spread cells. This protocol, Method 2 effectively described cell confluence. 
Furthermore, it enabled distinction between areas of viable, non-viable, compact and 
spread cells. The major drawback of this technique related to the analysis time for 
each image. Whereas the ImageJ based methods generated numerical and graphical 
data from an image within 1 second, Method 2 processed each image within 4 
minutes. 
In conclusion, Methods B and C enabled the assessment of embryonic stem cell 
colony expansion. These techniques accurately described cell confluence, colony 
numbers and the individual and mean area of colonies. Method 2 described total cell 
area coverage and further, provided morphological distinction of mES cells. 
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8.8  Appendix 2. 
Cytoskeletal α-tubulin and nuclei in spread and compact cells from mES 
cultures. 
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8.9 Appendix 3. 
Total AKT protein staining in mES cells  
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